

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

Year ended 31 December 2022

Contents

| | | |
|-----|---|----|
| | Summary | |
| A | Business and Performance | 4 |
| B | System of Governance | 11 |
| C | Risk Profile | 21 |
| D | Valuation for Solvency Purposes | 32 |
| E | Capital Management | 55 |
| F | Appendices | 64 |
| F.0 | Cautionary statement | 65 |
| F.1 | Public disclosure quantitative reporting templates | 66 |
| | <i>S.02.01 Balance Sheet</i> | 67 |
| | <i>S.05.01 Premium claims and expenses by line of business [life]</i> | 68 |
| | <i>S.12.01 Technical Provisions [life]</i> | 69 |
| | <i>S.22.01 Impact of transitional measures</i> | 71 |
| | <i>S.23.01 Own Funds</i> | 72 |
| | <i>S.25.02 Solvency Capital Requirement</i> | 73 |
| | <i>S.28.01 Minimum Capital Requirement</i> | 74 |
| F.2 | Glossary of abbreviations and definitions | 75 |
| F.3 | Approvals and determinations | 75 |
| F.4 | Directors' statement | 75 |
| F.5 | Audit opinion | 77 |

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

Summary

The purpose of the Solvency and Financial Condition Report ("SFCR") is to provide information required by the Solvency II regulatory framework, in particular the capital position at 31 December 2022 of Aviva Life & Pensions UK Limited ("the Company"). This report sets out different aspects of the Company's business and performance, system of governance, risk profile, valuation methods used for solvency purposes and its capital management practices.

Business and Performance

The Company is a limited company incorporated under the laws of England and Wales, which transacts life and pension insurance business. The Company has both Non-profit and With-profits funds and offers a market leading range of propositions to individual and corporate customers covering their savings, retirement, insurance and protection needs. The Company also purchases equity release business written by its wholly owned subsidiary Aviva Equity Release UK Limited. The Company predominantly carries out its business in the UK.

The Company reports to its chief operating decision makers using an alternative financial performance measure referred to as 'adjusted operating profit'. The Company regards adjusted operating profit as an appropriate measure of underwriting performance. Adjusted operating profit for the Company in 2022 was £1,186 million (2021: £888 million). The adjusted operating profit is shown after the impacts of quota share reinsurance arrangements with a fellow Group company, Aviva International Insurance Limited ("All"). Under the quota share reinsurance arrangements, 30% of the Company's Non-profit business is reinsured to All. The adjusted operating profit has increased compared to 2021.

Section A of this report sets out further details about the Company's business structure, key operations, market position and financial performance over the reporting period, split by underwriting performance and investment performance.

System of Governance

The Board's role is to be collectively responsible for promoting the long-term success of the Company. It sets the Company's risk appetite and satisfies itself that financial controls and risk management systems are robust, whilst ensuring the Company is adequately resourced. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of customers and shareholders whilst in compliance with regulations.

Roles and responsibilities for risk management in Aviva are based around the 'three lines of defence model' where ownership for risk is taken at all levels in Aviva plc Group ("the Group").

During the year, the Company's Board and Board Committee responsibilities and arrangements, and the fundamental approach to the system of governance, have not materially changed.

Section B of this report describes the system of governance in place throughout the Company by which the operations of the Company are overseen, directed, managed and controlled, and explains how it complies with the requirements of Solvency II. It describes the following key features:

- The roles and responsibilities of the Board, its sub-committees and key management committees, and delegation of authority to senior management;
- The remuneration policy, skills requirements and procedures for assessing fitness and propriety for senior management and key function holders;

- The Company's Risk Management Framework ("RMF") and its codification through risk policies and business standards, which set out the risk strategy, appetite and framework and minimum requirements for the Company's operations. This includes the Company's approach to its Own Risk and Solvency Assessment ("ORSA") and governance over its internal capital model for Solvency II;
- How the Company's business standards set out mandated control objectives and controls that mitigate operational risks faced by the Company, collectively providing the Company's framework of internal control;
- The role and responsibilities of the four key control functions – Risk, Actuarial, Compliance and Internal Audit – and how they are implemented within the Company; and
- The Company's outsourcing policy and information on important outsourced operational functions.

Risk Profile

As a long-term insurer, the Company accepts the risks inherent to its core business line of life insurance. Risks are diversified through the Company's scale, the variety of the products and services offered and the channels through which they are sold.

The Company receives premiums which are invested in order to maximise risk-adjusted returns, so that the Company can fulfil its promises to customers while providing a return to its shareholders. In doing so, the Company has a preference for retaining those risks which it believes it is capable of managing to generate a higher return.

The types of risk to which the Company is exposed have not changed significantly over the year and remain credit, market, underwriting, liquidity and operational risks.

Section C of this report further describes the risks to which the Company is exposed and how it identifies, measures, manages and monitors these risks, including any changes in the year to the Company's risk exposures and specific risk mitigation actions taken.

On 24 February 2022, on-going tensions between Russia and Ukraine developed into full-scale armed conflict between the two countries. The Company has minimal direct investment exposure to Russia and Ukraine, and no exposure to Belarus.

Valuation for Solvency Purposes

Assets, technical provisions and other liabilities are valued in the Company's Solvency II Balance Sheet according to the Solvency II regulations. Assets and liabilities are valued at an amount for which they could be exchanged, transferred or settled by knowledgeable and willing third parties in an arms-length transaction.

The value of technical provisions under Solvency II is equal to the sum of a best estimate liability and a risk margin. Under Solvency II, the Company applies the transitional deduction to technical provisions. The transitional deduction has been approved by the Prudential Regulation Authority ("PRA").

The Company also applies a matching adjustment ("MA") when calculating the liabilities for certain business. The MA is an increase to the discount rate, in excess of risk-free, used to value insurance liabilities where the cash flows are relatively fixed (e.g. no future premiums or surrender risk) and are well matched to assets that are intended to be held to maturity and have cash flows that are also relatively fixed. The intention is that, if held to maturity, the business can earn the additional yield on these assets that relate to illiquidity risk.

At 31 December 2022, the Company's excess of assets over liabilities was £11,675 million (2021: £11,748 million) on a Solvency II basis, with the decrease primarily driven by the impact of increased interest rates and the payment of dividends during the year, offset by profits emerging on existing business and the impact of demographic assumption changes. The excess of assets over liabilities is £5,236 million higher (2021: £5,206 million higher) on a Solvency II basis than the value under International Financial Reporting Standards ("IFRS"). The difference is primarily driven by the different approaches used to value technical provisions.

Section D of this report provides further description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset/liability class. In addition, it also provides an explanation of the material differences between the IFRS and Solvency II bases of valuation.

Capital Management

The Company manages Own Funds in conjunction with solvency capital requirements. In the calculation of the Solvency Capital Requirement ("SCR") the Company has chosen to implement a Partial Internal Model, defined as using a combination of Internal Model and Standard Formula approaches to calculate solvency capital requirements for different components of its business.

In managing capital, the Company seeks on a consistent basis to:

- Match the profile of its assets and liabilities, taking into account the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength in accordance with risk appetite, to support new business growth and satisfy the requirements of the Company's regulators and other stakeholders giving the Company's customers assurance of its financial strength;
- Retain financial flexibility by maintaining strong liquidity; and
- Allocate capital rigorously to support value adding growth and repatriate excess capital where appropriate.

At 31 December 2022, the total eligible Own Funds to meet the SCR were £10,068 million (2021: £11,417 million), consisting of excess of assets over liabilities of £11,675 million (2021: £11,748 million), adjusted to add back allowable subordinated liabilities of £nil (2021: £696 million), offset by a restriction in respect of the Company's ring-fenced funds ("RFFs") of £1,607 million (2021: £1,027 million).

The Company's eligible Own Funds continue to be primarily represented by unrestricted Tier 1 capital (97%) (2021: (85%)) with the remaining Own Funds represented by Tier 3 capital.

The Company's SCR, at 31 December 2022 was £5,619 million (2021: £7,820 million). The overall surplus position was £4,449 million (2021: £3,597 million) which translates to a regulatory cover ratio of 179% (2021: 146%). The minimum capital requirement ("MCR") decreased during the year to £1,663 million (2021: £2,236 million).

Section E of this report further describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR, including information about the Company's Internal Model.

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

A. Business and Performance

In this Chapter

| | | |
|-----|--------------------------|---|
| A.1 | Business | 5 |
| A.2 | Underwriting performance | 6 |
| A.3 | Investment performance | 8 |

The 'Business and Performance' section of the report sets out the Company's business structure, key operations and financial performance over the reporting period.

A.1 Business

A.1.1 Business overview

The Company, a limited company incorporated and domiciled in the UK, transacts life assurance and long-term savings business. The Company has both Non-profit and With-profits funds and writes primarily pensions, annuities, bonds, protection and investment products. The Company also purchases equity release business written by its wholly owned subsidiary Aviva Equity Release UK Limited. The Company carries out its business in the UK.

A.1.2 Organisational structure

The following chart shows, in simplified form, the position of the Company within the legal organisational structure of the Aviva plc Group ("the Group") as at 31 December 2022. Aviva plc is the holding company of the Group and is the ultimate parent undertaking of the Company. The immediate parent undertaking of the Company is Aviva Life Holdings UK Limited ("UKLH"), a company incorporated in England.



A complete list of participations in subsidiary undertakings and other related undertakings of the Company is disclosed in note 47 of the Company's financial statements.

A.1.3 Significant events in the reporting period

The company's financial results are affected by a number of external factors, including demographic trends, general economic and market conditions, government policy and legislation and exchange rate fluctuations. In addition, our 2022 financial performance includes the impact of corporate actions taken aimed at achieving our stated strategy. The impact of these events on IFRS performance and Solvency II may differ due to their different measurement and recognition criteria.

The following significant events impacted our business during the year.

During the year a number of changes were made to the capital structure of the Company as part of managing its balance sheet. The net impact of the changes across the year is:

- Capital contributions of £1,200m from Aviva Life Holdings UK Limited (UKLH).
- The Company reduced its share capital by cancelling and extinguishing 340,000,000 ordinary shares of £1 each, with the amount from such reduction being credited to a distributable reserve of the Company.
- The Company allotted 469,866,387 ordinary shares of £1 each to UKLH for a consideration of £470m in August 2022, which was subsequently cancelled and extinguished in October 2022.
- Inter-group capital instruments totalling £965m were repaid.
- Inter-group subordinated debt totalling £700m were repaid.

The Company approved the merger of the FLC Old With-Profits Sub-Fund and the FLC New With-Profits Sub-Fund.

A number of actions were taken during the year to optimise the Company's liquidity position. This included establishing a short-term loan facility from AGH of £500 million which could be drawn upon to meet collateral demands, which remains undrawn as at 31 December 2022 and a loan from the New With-Profits Sub-Fund to the Non-Profit Sub-Fund for £200 million for a three-year term.

A.1.4 Other information

Qualifying holdings

Qualifying holdings in the Company are held by UKLH, a limited company incorporated and domiciled in the UK, which holds 100% of the Company's share capital.

Supervisor

The Group's and Company's Supervisor is the Prudential Regulation Authority ("PRA"), which is part of the Bank of England. Contact details for the PRA are as follows:

| | |
|------------------|-------------------------------|
| Address | 20 Moorgate, London, EC2R 6DA |
| Telephone number | +44 (0) 20 7601 4444 |

External auditor

The Company's external auditors are PricewaterhouseCoopers LLP. Contact details are as follows:

| | |
|------------------|--|
| Address | 7 More London Riverside, London, SE1 2RT |
| Telephone number | +44 (0) 20 7583 5000 |

Rounding convention

The SFCR is presented in pound sterling rounded to the nearest million which is consistent with the presentation in the IFRS financial statements. The quantitative reporting templates ("QRTs") are presented in pound sterling rounded to the nearest thousand. Rounding differences of +/- one unit can occur.

A.2 Underwriting Performance

Adjusted operating profit - measurement of performance from underwriting and other activities

The Company manages the business gross of the All reinsurance treaty. The Group reports to its chief operating decision makers using a financial performance measure referred to as 'adjusted operating profit'. The Group and the Company regard adjusted operating profit as an appropriate measure of underwriting performance.

Adjusted operating profit is defined across the Group as IFRS profit before income taxes, excluding the following items:

- Investment return variances and economic assumption changes on long-term business (included within non-operating costs in the table in section A.2.1);
- Impairment of goodwill, associates, and joint ventures;
- Amortisation and impairment of acquired value of in-force business;
- Amortisation and impairment of other intangibles (excluding internally generated);
- Profit or loss on the disposal and remeasurement of subsidiaries, joint ventures and associates;
- Interest payable/receivable on intra-group lending;
- Certain pension costs; and
- Integration and restructuring costs and other items.

While these excluded items are significant components in understanding and assessing the Company's financial performance, presentation of adjusted operating profit enhances the understanding and comparability of the underlying performance of the business by highlighting net income attributable to ongoing operations. Adjusted operating profit is not a substitute for profit before income taxes or net income as determined in accordance with IFRS. The Company's definition of adjusted operating profit may differ from similar measures used by other companies, and may change over time.

Section A.2.1 shows a reconciliation of the adjusted operating profit to the income statement included in the Company's financial statements.

A.2.1 Performance from underwriting and other activities

The table below presents the adjusted operating profit for the Company for the year ended 31 December 2022, as well as the reconciliation of adjusted operating profit to IFRS profit before tax as included in the Company's financial statements.

| | 2022 £m | 2021 £m |
|--|-----------------|---------------|
| Income | | |
| Gross written premiums | 8,294 | 9,806 |
| Premiums ceded to reinsurers | (4,193) | (5,413) |
| Net earned premiums | 4,101 | 4,393 |
| Fee and commission income | 787 | 848 |
| Net investment income | (35,255) | 15,709 |
| Total income | (30,367) | 20,950 |
| Expenses | | |
| Claims and benefits paid, net of recoveries from reinsurers | (6,425) | (6,648) |
| Change in insurance liabilities, net of reinsurance | 13,635 | 6,064 |
| Expenses attributed to investment contract provisions | 14,562 | (14,081) |
| Change in unallocated divisible surplus | (23) | (222) |
| Fee and commission expense | (731) | (572) |
| Other expenses | (566) | (400) |
| Finance costs | 8,892 | (4,377) |
| IFRS (Loss) / Profit before tax | (1,023) | 714 |
| Tax attributable to policyholders' returns | 768 | (242) |
| IFRS (Loss) / Profit before tax attributable to shareholders | (255) | 472 |
| Adjusted for non-operating items: | | |
| Investment return variances and economic assumption changes | 1,464 | 431 |
| Other non-operating costs | (23) | (15) |
| Adjusted operating profit before tax attributable to shareholders | 1,186 | 888 |

Adjusted operating profit for the Company is based on expected investment returns on financial investments backing shareholder and policyholder funds over the period, with consistent allowance for the corresponding expected movements in liabilities. The expected rate of return is determined having regard to long-term economic and market forecasts of investment return and asset classification.

Adjusted operating profit includes the effect of variances in experience for non-economic items, such as mortality, persistency, expenses, and the effect of changes in non-economic assumptions. Changes due to economic items, such as market value movement and interest rate changes which give rise to variances between actual and expected investment returns, and the impact of changes in economic assumptions on liabilities, are disclosed as non-operating items.

The Company's adjusted operating profit has increased by £298million (34%) compared to 2021. This increase is driven by higher retirement profits. Additionally, non-trade profits have benefitted from favourable longevity assumption changes and lower product governance costs, offset by a reduction in deferred acquisition costs ("DAC") driven by interest rate rises.

The £1,464 million of investment return variances and economic assumption changes in 2022 is materially driven by negative impacts emerging from an increase in interest rate yields, offset in part by positive inflation impacts. Other non-operating costs are small in 2022.

A.2.2 Solvency II lines of business and product

Detailed information on premiums, claims, expenses and changes in technical provisions by Solvency II line of business is presented in the QRT S.05.01.02 (included in the Appendices in Section F.1). A summary of the information presented in this QRT is shown in the following table.

| | Health insurance | Insurance with profit participation | Index-linked and unit-linked insurance | Other life insurance | Life Reinsurance | 2022 Total |
|---------------------------------------|---------------------|---|--|-------------------------|---------------------|---------------|
| | £m | £m | £m | £m | £m | £m |
| Gross premiums written | 419 | 62 | 12,557 | 7,287 | 54 | 20,379 |
| Premiums ceded to reinsurers | (146) | (7) | (4,310) | (3,141) | — | (7,604) |
| Net premiums written | 273 | 55 | 8,247 | 4,146 | 54 | 12,775 |
| Net claims incurred | (105) | (3,099) | (7,165) | (2,320) | (83) | (12,772) |
| Changes in other technical provisions | 184 | 7,167 | 8,033 | 11,369 | 354 | 27,107 |
| Direct expenses incurred | (180) | (160) | (658) | (1,500) | — | (2,498) |

| | Health insurance | Insurance with profit participation | Index-linked and unit-linked insurance | Other life insurance | Life Reinsurance | 2021 Total |
|---------------------------------------|---------------------|---|--|-------------------------|---------------------|---------------|
| | £m | £m | £m | £m | £m | £m |
| Gross premiums written | 338 | 215 | 12,363 | 8,873 | 59 | 21,848 |
| Premiums ceded to reinsurers | (121) | (6) | (3,988) | (4,087) | — | (8,202) |
| Net premiums written | 217 | 209 | 8,375 | 4,786 | 59 | 13,646 |
| Net claims incurred | (95) | (2,948) | (7,947) | (2,341) | (103) | (13,434) |
| Changes in other technical provisions | 9 | 1,546 | (10,631) | 310 | 157 | (8,609) |
| Direct expenses incurred | (84) | (137) | (825) | (1,812) | — | (2,858) |

As instructed by the European Insurance and Occupational Pensions Authority ("EIOPA"), the analysis presented in S.05.01.02 includes all insurance contracts regardless of accounting classification between investment and insurance. This contrasts with the IFRS financial statements including the extract presented in section A.2.1, where non-participating investment business is deposit accounted and net premiums and claims are not recognised in the income statement.

The Company sells a diverse range of products through its business. The principal products sold include pensions, annuities, bonds, protection and investment products. The Company also purchases equity release business written by its wholly owned subsidiary Aviva Equity Release UK Limited. Some of the Company's insurance and investments products contain a discretionary participation feature, which is a contractual right to receive additional benefits as a supplement to guaranteed benefits. These are referred to as 'participating' contracts.

Material assumption changes

During the year there have been three material assumption changes on technical provisions relating to annuitant mortality, persistency and expenses. A description of each is included in section D.2.2.5.

A.3 Investment performance

A.3.1 Measurement of investment performance

Net investment income, as disclosed in the Company's financial statements, represents the Company's overall investment performance for both policyholders and shareholders. Net investment income consists of dividends, interest and rents receivable for the year, realised gains and losses and unrealised gains and losses on investments held at fair value.

The Company's exposure to investment return varies according to the characteristics of the liability that the assets are held to support. For many types of long-term business, including unit-linked and participating funds, net investment income is broadly offset by corresponding changes in liabilities, limiting the net impact on profit. Therefore, returns on policyholder, participating funds and shareholder investments are distinguished from one another:

- Policyholder assets are connected to unit-linked business, where the policyholder bears the investment risk on the assets in the unit-linked funds. Shareholder exposure loss on policyholder assets is limited to the extent that income arising from asset management charges is based on the value of assets in the funds.
- Participating fund assets relate to a subset of insurance and investment contracts which contain a discretionary participation feature, which is a contractual right to receive additional benefits as a supplement to guaranteed benefits. Shareholder exposure to investment losses on participating funds is generally limited to the shareholder's participation in the fund.
- Shareholder assets are other assets held within the Company's business that are not backing unit-linked liabilities or participating funds.

Adjusted operating profit includes an expected investment return on financial investments backing shareholder funds and policyholder funds, with a consistent allowance for the corresponding expected movements in liabilities.

Assets are invested in order to generate a return for both policyholders and shareholders. The financial strength of the Company and both current and future operating results and financial performance are, therefore, in part dependent on the quality and performance of the investment portfolios held by the Company.

The aim is to match appropriate investments to the nature of the underlying liabilities, whilst at the same time considering regulatory requirements, the level of risk inherent within different investments, and the desire to generate superior investment returns, where compatible with the stated strategy and risk appetite.

A.3.2 Investment performance by asset class

The following section summarises the Company's net investment income and provides an analysis of net investment income by asset class:

| | Debt securities | Equity securities | Loans | Other financial investment | Investment property | 2022 Total |
|--------------------------------------|-----------------|-------------------|----------------|----------------------------|---------------------|-----------------|
| | £m | £m | £m | £m | £m | £m |
| Net Investment Income - Total | | | | | | |
| Dividends | — | 1,635 | — | 1,028 | — | 2,663 |
| Interest | 1,292 | — | 909 | 574 | — | 2,775 |
| Net realised gains/(losses) | (1,411) | 1,387 | (21) | 1,122 | (1) | 1,076 |
| Net unrealised gains/(losses) | (10,938) | (3,486) | (6,353) | (20,292) | (896) | (41,965) |
| Rental income less expenses | — | — | — | — | 200 | 200 |
| Other income less management charges | — | — | — | (4) | — | (4) |
| Total | (11,057) | (464) | (5,465) | (17,572) | (697) | (35,255) |

| | Debt securities | Equity securities | Loans | Other financial investment | Investment property | 2021 Total |
|--------------------------------------|-----------------|-------------------|--------------|----------------------------|---------------------|---------------|
| | £m | £m | £m | £m | £m | £m |
| Net Investment Income - Total | | | | | | |
| Dividends | — | 1,409 | — | 1,515 | — | 2,924 |
| Interest | 1,428 | — | 937 | 283 | — | 2,648 |
| Net realised gains/(losses) | (4,682) | 2,182 | (13) | 2,967 | (61) | 393 |
| Net unrealised gains/(losses) | 2,550 | 2,284 | (1,036) | 5,067 | 948 | 9,813 |
| Rental income less expenses | — | — | — | — | 191 | 191 |
| Other income less management charges | — | — | — | (260) | — | (260) |
| Total | (704) | 5,875 | (112) | 9,572 | 1,078 | 15,709 |

The Company's expense for the year in respect of investment management fees amounted to £281 million (2021: £286 million).

The following table provides an analysis of the Company's net investment income by policyholder, participating and shareholder exposures:

| | Debt securities £m | Equity securities £m | Loans £m | Other financial investment £m | Investment property £m | 2022 Total £m |
|--------------------------------------|-----------------------|-------------------------|----------------|-------------------------------------|------------------------------|---------------------|
| Net Investment Income – Total | | | | | | |
| Policyholder assets | (1,106) | (529) | (253) | (10,724) | (487) | (13,099) |
| Participating assets | (777) | 6 | (43) | (4,170) | (207) | (5,191) |
| Shareholder assets | (9,174) | 59 | (5,169) | (2,678) | (3) | (16,965) |
| Total | (11,057) | (464) | (5,465) | (17,572) | (697) | (35,255) |

| | Debt securities £m | Equity securities £m | Loans £m | Other financial investment £m | Investment property £m | 2021 Total £m |
|--------------------------------------|--------------------------|-------------------------|--------------|-------------------------------------|------------------------------|---------------------|
| Net Investment Income – Total | | | | | | |
| Policyholder assets | (134) | 5,363 | (1) | 9,482 | 668 | 15,378 |
| Participating assets | (112) | 487 | (6) | 670 | 391 | 1,430 |
| Shareholder assets | (458) | 25 | (105) | (580) | 19 | (1,099) |
| Total | (704) | 5,875 | (112) | 9,572 | 1,078 | 15,709 |

Net investment income primarily consists of a mix of realised and unrealised gains across debt securities, equity securities, derivatives and unit trusts (included within other financial investments), loans, and investment properties.

- Losses on debt securities reflect the returns on underlying indices (Government all stock indices of (25.4)% (2021: (7.0)%) and Corporate bond indices of (20.7)% (2021: (6.0)%).
- Losses on equity securities reflect the returns on underlying indices (FTSE all share indices of (3.2)% (2021: 14.6%), S&P Europe indices of (9.6)% (2021: 14.6%) and S&P World indices of (9.2)% (2021: 19.8%).
- Losses on investment properties reflect the movement in the relevant indices - the change in the UK IPD Total Return (MI) All Property Index during the year was (10.1)% (2021: 19.9%).
- Unit trusts are primarily invested in debt and equity funds. Consequently, gains on unit trusts reflect the returns on both debt and equity assets.

A.3.3 Investment performance: other information – investments in securitisations

Securitisation means a transaction or scheme, whereby the credit risk associated with an exposure or pool of exposures is tranching, having both of the following characteristics:

- payments in the transaction or scheme are dependent upon the performance of the exposure or pool of exposures; and
- the subordination of tranches determines the distribution of losses during the ongoing life of the transaction or scheme.

The Company holds investments in securitisation vehicles that are not originated by the Company in the form of debt securities. These securities consist of residential mortgage backed securities, commercial mortgage backed securities, asset backed securities, wrapped credit securities and collateralised loan obligation securities.

Net investment income in the Company for the year in respect of these securitisations was £53 million (2021: £58 million).

The key risks the Company's securitisations are exposed to are market risk and credit risk. The Company's risk management procedures in respect of market risk and credit risk are described in sections C.2.2 and C.3.2.

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

B. System of Governance

In this Chapter

| | | |
|-----|---|----|
| B.1 | General information on the system of governance | 11 |
| B.2 | Fit and Proper policy | 14 |
| B.3 | Risk management system including the own risk and solvency assessment | 15 |
| B.4 | Internal control system | 17 |
| B.5 | Internal Audit function | 18 |
| B.6 | Actuarial function | 18 |
| B.7 | Outsourcing | 18 |
| B.8 | Any other information | 19 |

This section of the report sets out information regarding the ‘System of Governance’ in place within the Company.

Details of the structure of the Company’s “administrative, management or supervisory body” (defined as including the Board, subsidiary boards and Board sub-committees) are provided. The roles, responsibilities and governance of key control functions (defined as the Risk, Compliance, Internal Audit and Actuarial functions) are also provided. Other components of the system of governance are also outlined, including the risk management system and internal control system implemented across the business.

B.1 General information on the system of governance

B.1.1 Overview of the Company’s system of governance

Role and responsibilities of the Board

The Board’s role is to be collectively responsible for promoting the long-term success of the Company and for setting the strategy, against which management’s performance is monitored. It sets the risk appetite and satisfies itself that financial controls and risk management systems are robust, whilst ensuring the business is adequately resourced. The Board is also responsible for setting the values and supporting the culture of the Company, and ensures appropriate dialogue with shareholders on strategy and remuneration.

The Board’s responsibility includes ensuring that an appropriate system of governance is in place. To discharge this responsibility, the Board has established frameworks for risk management and internal control using a ‘three lines of defence’ model.


A strong system of governance aids effective decision-making and supports the achievement of business objectives for the benefit of customers, shareholders and regulators.

The Board comprises the Chairman, Chief Executive Officer, Chief Financial Officer and Independent Non-Executive Directors (“NEDs”). The Board’s policy is to appoint and retain NEDs, who can apply their wider business knowledge and experiences to their oversight of the Company, and to review and refresh regularly the skills on the Board.

The Board has established and delegated responsibilities to various committees to assist in its oversight of risk management and the approach to internal controls. There is alignment and communication between these committees and there is regular reporting to the Board.

The full duties of the Board and of each of its committees are set out in each respective Terms of Reference. The Terms of Reference list both those items that are specifically reserved for decision by the Board and those matters that must be reported to the Board.

The diagram illustrates the governance structure and a brief description of the main roles and responsibilities of each committee follows:



The *Risk Committee* is responsible for oversight of risk, reviewing the Company’s risk appetite and risk profile, reviewing the effectiveness of the Company’s risk management framework including the effectiveness of the Company’s risks and controls other than financial reporting.

It is also responsible for reviewing the methodology used in determining the Company’s capital requirements, stress testing, ensuring due diligence appraisals are carried out on strategic or significant transactions, and monitoring the Company’s regulatory requirements in relation to prudential matters, as appropriate.

The *Conduct Committee* is responsible for assisting the Board in its oversight of conduct issues. This includes oversight of the Company’s conduct framework including product design, selling practices, claims practices, conduct oversight of third parties, the achievement of an appropriate conduct focused culture and the management of good and influential relationships with the regulators in relation to conduct matters. It also sets and reviews the conduct and financial crime risk profile and ensures that the reputational risk is consistent with the risk preference approved by the Risk Committee.

The *Investment Committee* is responsible for assessing and approving investment strategy consistent with the risk preferences approved by the Risk Committee; considering investment matters that require Board approval (for example the investment into a new asset class); overseeing the relationship between the Company and its investment managers and monitoring investment performance.

The *Audit Committee* is responsible for reviewing the effectiveness of the Company’s systems and controls for financial reporting and receives regular updates on the work of the internal audit function and from external auditors. The Board also receives reports from the CFO at each board meeting. The Company’s financial statements are currently externally audited by PricewaterhouseCoopers LLP (PwC) on an annual basis.

There are also two other committees with specific purposes:

- *With-Profits Committee* provides independent oversight and challenge to ensure that fairness and With-profits customers' interests are appropriately considered in governance structures and decision-making processes; and
- *Independent Governance Committee* provides independent challenge in respect of the interests of relevant scheme members of workplace pensions.

An effective delegated authority framework is an important part of good business governance. A set of transaction categories provide a comprehensive framework for assigning financial authorities to certain individuals consistently across the Company, with limits within each category to ensure they support effective and appropriate decision making.

The 'three lines of defence model', and roles and responsibilities of key functions

Roles and responsibilities for risk management are based around the 'three lines of defence model' where employees are involved in the management and mitigation of risk. The roles of the three lines of defence each contribute to embedded risk management.

The first line: management monitoring

Management are responsible for the application of the Risk Management Framework ("RMF") including running the identify, measure, manage, monitor and report ("IMMMR") process, for implementing and monitoring the operation of the system of internal control and for providing assurance to the Risk, Conduct, Investment and Audit Committees, and the Board.

The second line: Risk, Compliance and Actuarial functions(*)

The Risk function is accountable for developing the RMF and for the quantitative and qualitative oversight and challenge of the IMMMR process. As the business responds to changing market conditions and customer needs, the Risk function regularly monitors the appropriateness of the Company's risk policies and the RMF to ensure they remain up to date.

The Compliance function supports and advises the business on the identification, measurement and management of its regulatory, financial crime and conduct risks. It is also accountable for monitoring and reporting on the compliance risk profile.

The Actuarial function is accountable for actuarial methodology, reporting to the relevant governing body on the adequacy of reserves and capital requirements, as well as underwriting and reinsurance arrangements. (*)Following a similar restructure at Aviva Group level, the UK Life Chief Actuary and Actuarial Function activities transferred to Finance (reporting to the Chief Finance Officer) with effect from 1st January 2023. The aim of this transfer was to strengthen the links between actuarial and capital management processes, while preserving the strong risk and actuarial control environment.

Refer to sections B.3.2, B.4.2 and B.6 for further details on the roles, responsibilities, authority, resources, independence and reporting lines of the Risk, Compliance and Actuarial functions respectively, and how their independence is ensured.

The third line: Internal Audit

This function provides independent and objective assessment on the robustness of the RMF and the appropriateness and effectiveness of internal control to the Audit, Conduct, Risk and Investment Committees, and the Board.

Refer to section B.5 of this report for details on the roles, responsibilities, authority, resources, independence and reporting lines of the Internal Audit function.

Implementation and assessment of adequacy of the system of governance

An assessment of the effectiveness of the Company's governance, internal control and risk management systems was conducted at the end of 2022, and documented in the CEO Governance Declaration 2022. Any material risks not previously identified, control weaknesses or non-compliance with the Company's risk policies and business standards or local delegations of authority are highlighted as part of this process.

The Chief Risk Officer ("CRO") provided an opinion on the CEO declaration, based on a review carried out by the Risk function.

The results of the certification process and details of key failings or weaknesses are reported to the Risk Committee to enable them to carry out an effectiveness assessment. The Risk Committee, on behalf of the Board, reviewed both the CEO and CRO certifications at its February 2023 meeting.

Changes in the system of governance during 2022

The Company's Board and Board Committee responsibilities and arrangements, and the fundamental approach to the system of governance, have not materially changed.

Terms of reference for all Board Committees were refreshed as required, for example to reflect changes of non-executive directors.

B.1.2 Remuneration Policy

Aviva's reward principles and arrangements are designed to incentivise and reward employees for achieving stated business goals in a manner that is consistent with the Group's approach to sound and effective risk management. Aviva's remuneration policy aligns Group strategy and Executive Director (EDs) remuneration. The Remuneration Policy provides market competitive remuneration, and incentivises EDs to achieve the annual business plan and the Group's longer-term strategic objectives. Significant levels of deferral and shareholding requirements align EDs' interests with those of shareholders and aid retention of key personnel. Variable remuneration can be zero if performance thresholds are not met. Remuneration payments to directors can only be made if they are consistent with the approved Policy.

The Aviva plc Annual Report on remuneration contained in the 2022 Annual Report and Accounts sets out how Aviva has implemented its Policy for Executive Directors during the course of 2022. Note 61 of the Aviva plc 2022 Annual Report and Accounts notes that key management personnel of the Company may from time to time purchase insurance, savings, asset management or annuity products marketed by group companies on equivalent terms to those available to all employees in the Group. In 2022, other transactions with key management personnel were not deemed to be significant either by size or in the context of their individual financial positions. Note 61 shows total compensation to those employees classified as key management, being those having authority and responsibility for planning and controlling the activities of the Group, including the executive and non-executive directors.

The Remuneration Policy was approved by shareholders at the Aviva plc AGM on 6 May 2021. The full and definitive Policy is therefore set out in our 2021 Annual Report and Accounts, which can be found on our website at <https://www.aviva.com/investors/reports/>.

B.1.2.1 Basic Salary (Fixed pay)

Basic salary should be set on the principle of equal treatment for individuals performing work that is the same or broadly similar. It should reflect:

- The value of a job to Aviva as determined by its external value in the market (e.g. the market benchmark), and its internal value; as determined by the Aviva global grading structure and underpinned by an appropriate job sizing methodology;
- Individual skills and capabilities, performance and contribution; and
- Minimum salary levels as set through any collective agreements, where applicable.

When fully performing in role, and depending on their performance over time, an individual's basic salary should be positioned within the agreed market-based salary range (where used). A level of basic salary above the upper quartile may exceptionally be justified if warranted by individual performance. Positioning towards the upper end of market practice may also be justified where considered necessary to attract and retain scarce talent. A salary below the market median would generally be expected for those new in role and therefore not yet fully performing, and / or those whose performance needs to improve.

Basic salary progression should be based on the sustained performance level of the individual in the role, internal equity, and the ability for the business to pay and absorb fixed costs.

It is important that all our people enjoy a decent standard of living and we are proud to be a Real Living Wage employer in the UK.

Basic Salary is inclusive of any statutory director's fees which may be payable to an employee under the constitutional documents of any Group subsidiary company or any Group affiliated company for which an employee is appointed a statutory director.

Independent Non-Executive Directors receive a basic annual fee in respect of their Board duties. Further fees are paid for membership and, where appropriate, chairing Board committees. They do not participate in any incentive or performance plans or pension arrangements and do not receive an expense allowance. They are reimbursed for reasonable expenses, and any tax arising on those expenses is settled directly by the Company.

B.1.2.2 Variable Pay Awards

Aviva's short term and long-term incentives are designed to reward the people who have contributed to our growth and role modelled our values and behaviours.

To ensure that variable pay meets these objectives, Aviva operates variable pay within a controlled governance environment to ensure that reward is only delivered when it is deserved and that risk, conduct and compliance are considered throughout the variable pay cycle.

Individuals may be considered for variable pay awards to align the interests of employees and the Company (and its shareholders). This recognises that individual performance against goals and contribution is essential for the success of the business. This includes long-term contribution which is recognised through long-term deferred awards i.e. Long-Term Incentive Awards and any deferred element of the Annual Bonus.

Malus and Clawback can be applied to all Variable Pay paid or awarded to employees or former employees of any company within the Aviva Group.

Fixed and variable pay should be appropriately balanced, with a sufficiently high proportion of fixed pay to avoid dependence on variable pay to meet day-to-day expenses. The proportion of variable pay generally increases with seniority in the organisation.

B.1.2.3 Employee Pensions and Benefits

Benefits offered vary by market and may include a company sponsored retirement provision ("pension"), sick pay, share ownership opportunities, and other items, such as Aviva products and services at discounted rates.

In general, benefits aim to:

- be market competitive as part of total remuneration;
- be compliant with all legal requirements; and,
- provide choice and flexibility to meet individual needs.

Where market practice means that pension provision is appropriate, such provision will be through defined contribution type pension arrangements, or appropriate in-country variations. Aviva does not offer defined benefit type pension arrangements, enhanced pension arrangements or early retirement schemes. Legacy defined benefit pension arrangements have been closed to future accrual and all benefits are now deferred, unless mandated otherwise by local legislation.

B.1.2.4 Material transactions with shareholders and persons exercising significant influence during the period

No material transactions have been identified during the period with persons who exercise a significant influence on the undertaking, or with members of the administrative, management or supervisory body.

Key management personnel may from time to time purchase insurance, savings, asset management or annuity products marketed by Group companies on equivalent terms to all employees of the Group. In 2022 other transactions with key management personnel were not deemed to be significant either by size or in the context of their individual financial positions.

Additional information on the material transactions with the Company's shareholder is included within the 'Related party transactions' note of the Company's financial statements.

B.2 Fit and proper policy

B.2.1 Description of specific requirements concerning skills and knowledge

For persons responsible for running the undertaking subject to regulatory approval/notification, an assessment of fitness and propriety ("F&P") must consider their allocated responsibilities, skills and experience across a skills matrix which covers the following areas as appropriate:

- Insurance and financial markets;
- Business strategy and business models;
- Systems of governance;
- Financial and actuarial analysis where applicable to the role; and
- Regulatory framework and requirements.

The Nomination Committee identifies the skills and experience that it would like to have at Board level. A skills matrix for Board members has been developed and it supports the Committee's discussions during the Board and Committee appointment process. The skills matrix sets out the expertise and experience of each Board member. The Nomination and Governance Committee also monitors the development of the Group Executive Committee to ensure there is a diverse supply of senior executives with the appropriate skills and experience.

B.2.2 Description of policies and processes for assessing fitness and propriety

Aviva has policies in place to ensure that individuals employed within the Group or acting on behalf of the Group are both "fit" and "proper" in line with the PRA and Financial Conduct Authority's ("FCA") fit and proper requirements for individuals subject to the Senior Managers and Certification Regime ("SMCR"), this means:

- Fit – As part of recruitment and employee screening, an individual's career history will be assessed and validated to establish whether an individual's skills and knowledge are appropriately matched to the role.
- Proper – checks are in place to ensure that an individual is honest, of good reputation, has integrity and is financially sound.

At Aviva the governance over the fit F&P of individuals cuts across the employee lifecycle including recruitment, performance management and training. To ensure that Aviva protects itself against employing individuals who potentially could threaten our people, customers, properties, facilities or reputation, the majority of F&P activities take place within recruitment and more specifically in pre-employment screening.

A policy to apply a minimum set of basic screening requirements has been agreed and implemented in order to support the recruitment activity for all staff across Aviva. Additional enhanced screening and ongoing F&P requirements are also applied for individuals who are subject to regulatory approval by the PRA and FCA.

B.3 Risk management system including the ORSA

B.3.1 Overall risk management system: strategies, processes and reporting procedures

The Risk Management Framework (“RMF”) forms an integral part of the management and Board processes and decision-making framework across the Company. The key elements of this framework comprise risk appetite (including risk preferences and risk tolerances); risk governance, including risk policies and business standards; and the processes used to identify, measure, manage, monitor and report risks, including the use of the Company’s risk models and stress and scenario testing.

To promote a consistent and rigorous approach to risk management across all parts of the business, there is a set of risk policies and business standards which set out the requirements for risk strategy, appetite, and minimum requirements for the Company’s operations.

For the purposes of risk identification and measurement, risks are usually grouped by risk type: credit, market, liquidity, underwriting and operational risk. Risks falling within these types may affect a number of metrics including those relating to balance sheet strength, liquidity and profit. They may also affect the performance of the products delivered to customers and the service to customers and distributors, which can be categorised as risks to the brand and reputation or as conduct risk.

A regular top-down risk assessment and reporting process is facilitated by the Risk function. This includes the consideration of emerging risks and is supported by deeper thematic reviews. This, together with the risk and control self assessment (“RCSA”) process, are the main processes used to IMMMR risks. They are run separately but are complementary. The RCSA process is run by the first line, with challenge by the Risk function. It focuses on operational risks, which are recorded on ‘iCARE’, the Company’s risk management system.

Risk models are an important tool in the measurement of risks and are used to support the monitoring of the risk profile and in the consideration of the risk management actions available. A range of stress tests are carried out (where one risk factor, such as equity returns, is assumed to vary) and scenario tests (where combinations of risk factors are assumed to vary) to evaluate their impact on the business and the management actions available to respond to the conditions envisaged.

The Risk function is accountable for quantitative and qualitative oversight and challenge of the IMMMR process and for developing the RMF. Internal Audit provides an independent assessment of the risk framework and internal control processes.

Board oversight of risk and risk management across the Company is maintained on a regular basis through the Risk, Conduct and Investment Committees.

The Board has overall responsibility for determining risk appetite, which is an expression of the risk the business is willing to take. There are risk appetites for solvency, liquidity, operational, conduct and climate risks. Risk preferences are set for each risk type and three risk tolerances (interest rate, longevity and macro-economic) are also set, calculated on the basis of the Solvency II balance sheet. The position against risk appetite and risk tolerances is monitored and reported to the Board Risk Committee on a regular basis.

Risk preferences, being qualitative statements that express the risks that the Company prefers, wishes to avoid or minimize, or accepts exposure to are approved by the Risk Committee. Long-term sustainability depends upon the protection of franchise value and good customer relationships. As such, there is a risk preference that the Company will not accept risks that materially impair its reputation and requires that customers are always treated with integrity.

Reporting of risks is provided to Board Committees and the Board by management, alongside Risk and Audit opinions as required. The Board has set clear expectations that reporting must present a clear and timely picture of existing and emerging issues, risk exposures and risk management activities and provide demonstrable evidence that the Company is managing its risks.

It is recognised that it is important to have an appropriate risk culture (“tone from the top”). An appropriate culture includes the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by employees, and a commitment to integrity, ethical behaviour and compliance.

A risk and control goal is set for senior management as part of the annual bonus plan to help drive and reward effective risk management and a robust control environment. This is assessed on an annual basis, with oversight by the Risk function.

B.3.2 Risk function

The Risk function is responsible for the design and implementation of the risk management system, and the design and independent validation of Solvency II capital models requiring regulatory approval. The Risk function reports to the Board on material risks identified, together with any other specific areas of risk requested by the Board, and assists the board and management in the effective operation of the risk management system through the provision of specialist analysis and quality reviews, an aggregated view of the risk profile, and an assessment of the key risks associated with the business’s strategy, business plans, major projects, strategic investments and other key decisions.

The Risk function has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. The scope of the Risk function’s activities extends to all legal entities, joint ventures, partnerships, outsourcing and reinsurance arrangements.

The Risk function operates as part of the Global Risk function, which also includes the Compliance function, and the Actuarial function (until the end of 2022, after which it moved under Finance, as noted in section B.1.1 above). Further information on the Compliance and Actuarial functions is set out in sections B.4.2 and B.6 respectively.

B.3.3 Integration of risk management into the decision-making processes

Under Solvency II, the Internal Model must be embedded at the heart of risk and capital evaluation and its outputs must be used as a key part of a wide range of business and strategic decisions. As well as being a Solvency II requirement, this makes sense from a business perspective - using a model which reflects the actual risk profile of the business drives more informed decisions. A range of evidence items

(made up of actual business management information and relevant committee / board papers) is collated each year as part of the activity to evidence the use of risk management and Solvency II capital in decision making.

All key decisions must have the support of the Risk function before proceeding and the Chief Risk Officer has the power of veto.

B.3.4 Risk management system: Own risk and solvency assessment (“ORSA”)

The ORSA Report is the outcome of the combined processes and procedures (collectively ORSA processes) in place to manage and assess the risk and solvency position of the Company. The goal of the ORSA process is to provide a continuous and forward-looking assessment of the short-term and long-term risks that the Company faces, or may face, ensuring that solvency requirements are met at all times.

The ORSA processes comprise a number of elements of the RMF which are embedded in the business through the requirements of supporting risk policies and business standards around strategy, planning, capital management, stress and scenario testing and use of Solvency II capital in decision-making.

In combination, these elements create a holistic overview of the elements of risk that may impact the Company, and which should be taken into account by management in day-to-day decision-making, in particular through the use of Solvency II capital, and ensures risk and capital management are connected.

Consistent with the three lines of defence model, first line management is responsible for the implementation of the majority of the underlying ORSA processes.

The ORSA Report articulates the Board’s formal view of the capital the Company needs to hold, given the risks currently faced by the business and how these might evolve over time, in line with delivery of the business strategy. It summarises a high-level description of the key components of the underlying ORSA processes and the key outcomes from these processes.

The Company’s annual ORSA report provides a forward-looking assessment of the risk and solvency needs of the Company over a 3-year time horizon; reflecting the company’s strategy and business plans. The ORSA processes and associated ORSA report play a key role in supporting decision making and strategy development at our boards and risk committees.

Outputs of the underlying ORSA processes are presented to the Board and/or its sub committees throughout the year. The subsequent ORSA report is produced and approved by the Board annually, or in the event that ORSA triggers are met (per its ORSA policy). For example, an out of cycle ORSA update may be triggered (at the discretion of the Board), in the event of:

- An actual or projected material impact on the Company’s Own Funds or diversified SCR compared to Plan;
- The invocation of the Company’s Crisis Action Leadership Team (under the Financial Event Response Plan); or
- More broadly any potentially material change to the Company’s risk profile.

The Chief Risk Officer is responsible for producing the ORSA Report which is reviewed and approved by the Risk Committee and the Board.

For the purpose of the ORSA, the Board has approved that capital resources and requirements are measured on the basis of Solvency II requirements for determining Solvency II Own Funds and SCR.

Solvency II capital (as a risk-based capital measure) is embedded at the heart of the Company’s risk and capital evaluation and is used as a key input to a wide range of business and strategic decisions. Solvency II capital is calculated using the Company’s Partial Internal Model.

The RMF, supported by risk policies and business standards, sets out the areas where businesses are expected to use Solvency II capital management information as part of their decision-making and risk management processes. This ensures that requirements to use Solvency II capital are embedded within the instructions of how the relevant processes (for example asset liability management or strategy and planning) are to be performed.

B.3.5 Governance over the Internal Model

The Solvency II Model Governance and Data Governance business standards and associated guidance, manuals, logs and reports are part of the overall RMF. These combine to ensure that the Company’s businesses operate within a controlled environment when developing methodologies and assumptions, and when running processes and systems.

The appropriateness of the Company’s Internal Model is tested and confirmed by model validation, review and challenge, weakness and limitation management and general change control processes. In aggregate, these tests ensure there is a robust governance framework to support the use of the Internal Model in both a production environment and during model development or change.

The Board is responsible for approving the Internal Model change application before submission to the PRA for approval. It is anticipated that there will be one model change application a year (around June each year). The quarterly model change report and supporting evidence provide the required information to support Board and PRA approval.

The Chief Risk Officer is the ultimate Internal Model Owner. In practice the day-to-day responsibilities are delegated to the Chief Actuary, as he has the accountability to give assurance to the Board that the Internal Model is appropriate for use on an ongoing basis; adequately reflects the business’s risk profile; takes into account new information as it becomes available and works effectively. This enables the Board to conclude whether the Internal Model is fit for purpose whilst also ensuring it is used to provide information for important strategic and business decisions; capital management; business planning; risk mitigation; investment allocation and product development.

The Internal Model Independent Validation Review (refer to the section below for further details) also provides an opinion to the Board on whether the Internal Model is suitably accurate and fit for purpose, and whether or not its approval is recommended.

Validation processes

As a key part of capital assessment and capital management, the Internal Model is rigorously validated using a series of tests. This suite of tests includes both validation of the individual calibrations and methodologies underlying the model, and validation of the model using its results.

The validation tests applied comprise both mathematically defined tests and those based on qualitative judgment, to ensure that the model and its components are both accurate and reflect management opinion. Key tests include back-testing (historic experience is compared against the results produced by the model), sensitivity testing (the analysis of the change in results due to changes in its inputs) and benchmarking (the results of the Internal Model and its components are compared against external benchmarks, at the overall Group level). The validation tests are run, documented and assessed (against criteria set by the Actuarial function), and are designed to draw conclusions on the appropriateness of the Internal Model. The results of this analysis are made available to the Risk Committee and Board.

In addition, separate and independent validation of the Internal Model is performed to give assurance to the Board that the model is appropriate for use on an ongoing basis, adequately reflects the business's risk profile and takes into account new information as it becomes available, and works effectively. This informs whether the Internal Model is fit for purpose, including informing important strategic and business decisions, capital management, business planning, risk mitigation, investment allocation and product development.

The Board approves the scope and approach proposed by the UK Life Enterprise Risk Director (who reports into the Chief Risk Officer) for each independent validation exercise, as required by the Internal Model Independent Validation Business Standard. The UK Life Enterprise Risk Director performs the independent validation and provides an opinion to the Board whether the Internal Model is materially fit for purpose.

B.4 Internal control system

B.4.1 Description of the internal control system

Internal controls facilitate effective and efficient business operations, the development of robust and reliable internal reporting and compliance with laws and regulations.

- The Company sets an appropriate culture, including “tone from the top”. This ensures the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by employees, and a commitment to integrity, ethical behaviour and compliance;
- The Company has an organisational structure that supports the system of internal control. This includes the effective operation of an adequately resourced three lines of defence model, appropriate and proportionate segregation of duties, a clear system of delegated authorities, clearly defined roles and responsibilities for staff, and the consideration of risk management and control responsibilities when setting objectives for and reviewing the performance of all staff;
- The Company has a Risk Management Framework (see section B.3.1);
- The Company has effective controls for each core business process and these are monitored and reported upon regularly; and
- The Company has a risk oversight process that provides adequate challenge to the completeness and openness of internal control and risk assessment. Where a committee structure is put in place to support this work, then all committees have defined terms of reference and appropriate membership, with proceedings adequately recorded and actions followed up.

B.4.2 Compliance function

The primary purpose of the Compliance function is to assess and manage the business's exposure to regulatory risk.

The Compliance function is an integral part of the RMF and constitutes a key part of corporate governance. The function is a critical contributor to the safe and sound operation of the business and underpins the achievement of strategic and business goals. The Compliance function is lead by the Chief Conduct and Compliance Officer, who reports to the Group Compliance and Financial Crime Risk Director and has delegated authority to manage compliance related risk across the business.

Three key processes comprise Aviva's compliance activity:

- Conduct regulatory risk management (including monitoring regulatory developments), performed by the Compliance function and including activities such as;
 - Setting conduct policy framework;
 - Providing advice, support, guidance and challenge on conduct risk; and
 - Managing conduct regulatory engagement.
- Prudential regulatory risk management (including monitoring regulatory developments), performed by the Risk function and including activities such as;
 - Setting prudential regulatory risk policy framework;
 - Providing advice, support, guidance and challenge on prudential regulatory risk; and
 - Managing prudential regulatory engagement.
- Legal developments monitoring, performed by the Legal and Company Secretarial function.

The Compliance function has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

Through these processes the Compliance, Risk and Legal Functions also take responsibility for reporting information to the Board and its committees. The oversight of conduct risk has remained a key focus of the Conduct Committee during 2022. The Committee receives a report from the Chief Conduct & Compliance Officer (CCCO) at each meeting which covers any material concerns regarding conduct risk and the treatment of customers generally, along with details and an assessment of the adequacy of management's response.

The CRO and CCCO have responsibility for prudential and conduct regulatory risk management, whilst the General Counsel is responsible for monitoring legal developments.

B.5 Internal Audit function

B.5.1 Role and responsibilities

Internal Audit's (IA) purpose is to help the Board and Executive Management to protect the assets, reputation and sustainability of Aviva by providing independent and objective assurance designed to add value and improve Aviva's operations.

IA does this by assessing and reporting (to group and business unit audit, risk and governance committees and to management as appropriate) on the effectiveness of the design and operation of the framework of controls, the effectiveness of management actions to address the deficiencies in the framework of controls and whether all significant risks are identified, managed appropriately reported by management to the Board and executive management.

IA undertakes this work in accordance with its IA Charter and in conformance with the Institute of Internal Audit (IIA) Standards and the Chartered Institute of Internal Auditors (CIIA) code for Effective Audit in Financial Services.

B.5.2 Independence and objectivity of the internal audit function

IA must always be independent from management in order to be effective in performing its activities. The arrangements to protect the independence of IA are set out below:

- In accordance with the IA Charter, the IA team is led by the Chief Audit Officer (CAO) who has a direct reporting line into the chairs of business unit Audit Committees.
- All IA directors working in the business units report directly to the CAO and form part of IA (except where IA services are provided by the joint venture partners), and have a dotted reporting line to the local Audit Committee Chair.
- The Chair of the Group Audit Committee ("GAC") is responsible for recommending the appointment and removal of the CAO to the Board. Board Audit Committees for business units have a duty to recommend the appointment or dismissal of the CAO to the respective business unit Board and to participate, jointly with the CAO or designee, in the determination of the objectives of the CAO and the evaluation of their levels of achievement, including consultation with the CEO.
- The Head of Quality Assurance (QA) monitors and evaluates the function's adherence to all relevant Internal Audit standards of practice and Internal Audit methodology and has direct access to the Group Audit Committee Chair. An independent external assessment of the Internal Audit function is performed every three years.
- Independence is confirmed through a declaration form signed annually by all members of IA staff. Staff working in IA have no direct responsibility or authority over any operational activities reviewed and should not relieve others of such responsibilities, and IA manage a staff rotation process to ensure that independence is maintained.
- IA staff who previously worked in Aviva Group, but outside of IA, will not perform or manage reviews in the business area for which they were previously responsible for a period of at least one year after the end of their role within the business. This excludes similar business areas in other legal entities or operating units. Internal auditors on rotation from a business unit will not perform or manage reviews in the business area for which they were previously responsible.

B.5.3 Authority and resources of the internal audits function

IA is authorised to review all areas of the Group and has full, free, and unrestricted access to all activities, records, property, and personnel necessary to complete their work. The scope of IA activities extends to all legal entities, joint ventures and other business partnerships, outsourcing and reinsurance arrangements. The CAO shall propose a budget which ensures that IA has appropriate skills and resources to discharge its responsibilities.

B.6 Actuarial function

The Actuarial function is accountable for actuarial methodology, reporting to the Board on the adequacy of reserves and capital requirements, and on the adequacy of underwriting and reinsurance arrangements.

As noted in section B.1.1 above, the function moved reporting line from Risk to Finance with effect from 1st January 2023.

The Actuarial function has authority to review all areas of the business and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

B.7 Outsourcing

The Group Procurement and Outsourcing Standard is the Company's Outsourcing Policy which is aligned to regulatory expectations and sets out the relevant responsibilities, objectives, process, controls and monitoring arrangements to be applied in cases of outsourcing, all of which shall be consistent with the overall business strategy. The standard applies equally to any externally or internally (intra-group) outsourced activity. The objective of this standard is to ensure that minimum control objectives and controls for supplier related activities are followed by the Company, to ensure that supply risk is managed effectively, suppliers act in accordance with the best interest of our customers, as well as mitigating potential financial, operational, contractual, and brand damage caused by inadequate management. All key outsourcer-related dealings are subject to appropriate commercial terms and conditions. Contracts and agreements are established, incorporating clearly defined performance levels, duties, responsibilities, obligations and rights on both parties. We ensure that appropriate governance structures are established to provide oversight for both individual arrangements and across the aggregated supply landscape. Arrangements are actively and regularly managed to ensure contractual obligations and service levels are achieved. The

Procurement and Outsourcing Standard requires a global Outsourcing Landscape document to be produced bi-annually to capture details of all material, outsourced operational functions and activities.

The standard applies to all staff involved in supplier related activities and provides direction to staff on their roles and responsibilities in effectively managing supplier activity. It provides clarity to businesses on the definition of outsourcing, including where activity is delegated to an intermediary, and whether a function or activity outsourced is material. All staff have a responsibility to comply with this standard if they are involved with supplier related activity.

The Group's Risk Committee approves the control objectives and controls in the standard which cover the following areas:

- Supply Governance - Governance and oversight of sourcing and supply management activities to mitigate risk, protect customer outcomes and meet regulatory expectations.
- Sourcing (including renewals and alterations to existing arrangements) - Ensuring that the relative risk and impact that a sourcing request poses to the business has been considered, and that the appropriate level of rigour is applied based upon the scale, complexity and risks a particular supply poses. Includes the financial, commercial and legal approval of contracts.
- Supply Management - Risk based approach ensuring supply arrangements are being actively and regularly managed to mitigate operational risk, minimise customer impact following any disruption in service or supply in line with operational resilience and recovery requirements, ensuring contractual obligations and service levels are achieved (including Aviva's own obligations).

Material outsourcing will attract the highest level of rigour, including regulatory notification, performance and relationship reviews, risk and control assessments and regulatory compliance reviews. By default, intra-group arrangements will be classified as material.

B.7.1 Outsourced functions and activities

The Group outsources a wide range of operational functions and activities, including the following that are considered material: policy administration, claims handling, customer contact centres, fund management, finance/back office services and IT support services/system development. Service providers for these activities are mostly based in the UK with significant offshore support in India and Sri Lanka.

B.7.2 Material intra-group outsourcing arrangements

Material intra-group outsourcing arrangements for the year ended 31 December 2022 primarily comprise a range of shared support services (including IT, delivery of online customer propositions, finance, procurement, internal model independent validation and employment of staff) outsourced to service companies within the Group. Material intra-group outsourcing arrangements are primarily based in the UK.

The majority of Investment management services are outsourced within the Group in the UK.

B.8 Any other information

The Company has no other information to disclose.

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

C. Risk Profile

In this Chapter

| | | |
|-----|--|----|
| C | Overview of the Company's risk profile | 21 |
| C.1 | Underwriting risk | 22 |
| C.2 | Market risk | 23 |
| C.3 | Credit risk | 25 |
| C.4 | Liquidity risk | 26 |
| C.5 | Operational risk | 27 |
| C.6 | Any other information | 29 |

The 'Risk Profile' section of this report provides information on the key risks encountered by the Company as well as the corresponding processes for monitoring the risk exposures and the techniques in place for mitigating these risks.

Overview of the Company's risk profile

For the purposes of risk identification and measurement, and aligned to the Company's risk policies, risks are usually grouped by the following principal risk types: underwriting risk (including life and long-term health), market, credit, liquidity and operational risk.

An overview of the Company's process for identifying, measuring, managing and monitoring the risks it faces is set out below, with further detail provided in sections C.1 to C.5.

Risk identification

The ultimate parent company, Aviva plc, and its related undertakings comprising the Group (including the Company) operate a risk framework which defines the enterprise-wide approach to managing risk, including how the Group identifies, measures, manages, monitors and reports on the risks to which it is, or could be, exposed. The Group has a variety of tools and processes to support the identification and measurement of the material risks the Group is, or could be, exposed to in the short, medium and long-term. The risk framework has been adopted by the board of this Company.

Primary sources for identifying risks include risk events analysis, external and internal trends analysis and management information, as well as other risk governance processes and input from executive teams and internal committees.

Exposure measurement and monitoring

The primary basis used by the Company to measure and assess risks is the Solvency II SCR, which is calculated as Solvency II Own Funds at risk in a 1-in-200 year loss event over a one year time horizon. Solvency II SCR is the basis on which the Company sets solvency risk appetite and is used to assess the significance of risks and to appropriately direct resources to their management. Refer to section E.2 of this report for details of the methodology and assumptions used in the calculation of the Company's Solvency II SCR.

The primary risk types measured in the Company's Solvency II SCR calculation are:

- Underwriting risk – Life and health risk (refer to section C.1);
- Market risk (refer to section C.2);
- Credit risk (refer to section C.3); and
- Operational risk (refer to section C.5).

Some categories of risk are not managed by holding capital. Principal amongst these risks is liquidity risk, which is measured through the liquidity coverage ratio (see section C.4).

The Company also assesses risks on the basis of their potential impact on the value of the Company's franchise, which is supported by the Company's reputation, brand and good customer relationships. Operational risks, in particular, have the potential to significantly impact the franchise value (see section C.5) compared to other risk types which are relatively more significant measured on the basis of Solvency II SCR.

The Company also measures and assesses risk in terms of its total gross exposure and sum at risk, as well as monitoring risk indicators that might indicate changes in the risk exposure and act as a trigger for management action. These are generally risk type specific and are considered in sections C.1 to C.5.

Changes in the period to risk profile

During 2022 risk free yields have risen significantly. This has resulted in a fall in the value of assets and liabilities. The value of the SCR has fallen, in-line with the reduction in value of assets and liabilities. Sections C.1 to C.5 include details on the key changes to the Company's risk profile in the reporting period.

Risk mitigation

Risks arising across the Group are mitigated through application of elements of the Group's RMF, and in particular business standards in respect of asset liability management and reinsurance. Risk mitigation techniques applied are explained in greater detail by risk type in sections C.1 to C.5.

Monitoring the effectiveness of risk mitigation techniques

Annually the Group Risk function undertakes an assessment, presented to the Group Risk Committee, of the effectiveness of the Group's and business units' overall risk management, including specifically the robustness of their control environments in mitigating operational risk. The Group's major business units have dedicated risk monitoring teams which monitor the effectiveness of risk management in the business including risk mitigation. How the effectiveness of specific risk mitigation techniques is monitored is considered in sections C.1 to C.5.

Risk concentration

The Company writes a diverse mix of business that is subject to similar risks (mortality, persistency, etc.). The Company assesses the relative costs and concentrations of each type of risk through the Internal Model. This analysis enables the Company to assess whether accumulations of risk exceed risk tolerances and capital limits. The main concentrations of risk for the Company are considered by risk type in sections C.1 to C.5.

Sensitivity analyses

The Company performs sensitivity analyses and stress and scenario testing in order to understand the impact that changes would have on the Company's risk profile, capital generation and SCR. Refer to section C.6.1 for details on the methodology employed, the assumptions and limitations in performing these analyses, and the results obtained.

Prudent Person Principle

The Company ensures that its assets are invested in accordance with the prudent person principle as set out in Article 132 (Directive 2009/138/EC), through the collective application of its risk policies and business standards. These ensure the Company invests in assets whose risks it can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs. The Company's Asset Liability Management Business Standard and certain provisions of the Investment Management Business Standard contain mandatory requirements to ensure that the Company develops its own set of key risk indicators and takes into account the risks associated with its investments without relying solely on the risk being adequately captured by the capital requirements. Risk tolerances by risk type are also set and monitored by the Company. Other business standards set requirements for the quality of investment assets (including setting risk limits to control the market and credit risk within a portfolio), matching of assets to liabilities, diversification of invested assets, use of derivatives, assets not admitted for trading and the consistency of investment mandates with the way the investment proposition is described and marketed to customers of unit-linked contracts.

C.1 Underwriting risk

C.1.1 Exposure

Underwriting risk is the risk of loss or adverse change in the value of liabilities arising from inappropriate insurance pricing, inadequate claims reserving assumptions as well as unforeseen fluctuations in the timing, frequency and severity of insured events relative to the expectations at the time of underwriting. The risk excludes operational risk arising from internal processes in the writing of insurance business or settling of claims. The principal life and health underwriting risks that the Company is exposed to are described below:

- Longevity risk: The risk that annuitants may live longer than expected;
- Mortality risk: The risk that more policyholders die earlier than expected, either due to general trends or due to pandemics or other specific events e.g. terrorism. This risk impacts claims on life insurance products;
- Morbidity risk: The risk that either more customers fall sick than expected or customers recover at a slower rate than expected. This risk impacts claims on critical illness and income protection products;
- Persistency risk: The risk of adverse financial impact arising from changes in the level, trend, other changes to the term structure or volatility (i.e. variability due to population size) of the rates of policy lapses, terminations, renewals and surrenders (including partial surrenders, reduction in premiums and Paid Up Policies);
- Expense risk: The risk that the future costs of managing and administering customer policies are higher than expected; and
- Policyholder behaviour: The risk that the number and timing of customers exercising various choices differs from expectations, e.g. paying additional premiums or extending the length of their policy. Also, the exercise of options, guarantees and other embedded product features offer policyholders varying degrees of guaranteed benefits at maturity or on early surrender, along with options to convert their benefits into different products on pre-agreed terms.

The Company chooses to take measured amounts of underwriting risk provided it has the appropriate core skills to assess and price the risk, and adequate returns are available.

Exposure Measurement

The following measurement and analysis of underwriting risks is undertaken by the Company with appropriate frequency to support management and monitoring of risk exposures:

- Analysis of actual experience against expected experience to support ongoing monitoring of the appropriateness of assumptions;
- Capital calculations, consistent with Solvency II SCR methodology, for principal underwriting risk types. The impact of policyholder behaviour linked to the take-up of insurance options and guarantees risk is captured in the capital requirements for underwriting risk. An allowance for basis risk in risk transfer arrangements is included, where appropriate, in the capital requirements for the underlying underwriting risks;
- Standard stresses for mortality, morbidity, longevity, expense, lapse and policyholder behaviour risks. This output is also used to inform liquidity risk analysis; and
- Combined scenarios considering interest rate falls or rises where adverse experience has the potential to increase or decrease the duration of the liability and financial market falls where there is a possibility of significantly higher lapses. This output is also used to inform liquidity risk analysis.

The following analysis is undertaken on an annual basis, or more frequently if required, as part of the planning process to support management and monitoring of risk exposures:

- Stress and scenario tests for assumptions that are identified as critical to the profitability and risk profile of the business based on standard stresses;
- An in-force risk profile analysis to understand the guarantee profile of the business looking at minimum interest rate guarantees and other financial and non-financial guarantees;
- Projected liquidity is compared to risk appetite for the base plan and scenarios; and
- Business mix sensitivities to determine how Solvency II capital requirements would move under different plan scenarios.

At 31 December 2022, the underwriting component of the SCR amounted to £3,237 million before diversification and tax.

Changes to risk profile in the reporting period

The main change in underwriting risk profile during 2022 is a reduction in longevity risk exposure as a consequence of a significant rise in interest rates.

Other drivers of change include new business written during 2022 which has increased exposure to underwriting risk and the impact of policies maturing and claims being paid out which offsets the impact of new business on risk exposures. Higher inflation during 2022 has also increased the size of underwriting risk as the size of current and future index-linked payouts and policy expenses increased. The net impact of these changes is nevertheless smaller than the reduction in underwriting risk due to rising interest rates during 2022 which has the effect of reducing all risk exposures.

C.1.2 Risk mitigation

The individual underwriting risks are mitigated and managed as follows:

- Mortality and morbidity risks are partly mitigated by the use of reinsurance and by the existence of life concentration limits and are monitored against the latest external industry data and emerging trends. The Company selects reinsurers from those approved by the Group, based on local factors, and monitors the aggregation of risk ceded is within credit risk appetite;
- Longevity risk is partly mitigated by the use of reinsurance and is monitored against the latest external industry data, emerging trends and likely or possible future trends. The Company monitors exposure to longevity risk and any associated capital implications for its annuity business;
- Persistency risk is managed through frequent monitoring of Company experience, and benchmarked against local market information. Generally, persistency risk arises from customers lapsing their policies earlier than has been assumed or more customers ceasing to pay regular premiums than has been assumed. The Company also implements specific initiatives to improve the retention of policies which may otherwise lapse; and
- Expense risk is primarily managed through the assessment of profitability and frequent monitoring of expense levels.

Monitoring the effectiveness of risk mitigation techniques

Implementation of the risk mitigation techniques are discussed and then approved via the Company's governance forums (e.g. the Asset and Liability Committee), with ongoing effectiveness being monitored as part of 'business as usual' management information, the Life Insurance Risk Policy attestation process, and periodic Internal Audit reviews, significant findings from which are reported to the Audit Committee.

C.1.3 Risk concentration

The Company's policy on underwriting risks is to avoid concentrations of risk exposure. Underwriting concentration risk is a reflection of too little diversification within or across underwriting risk types. The Company avoids significant concentrations of underwriting risk through its scale, diversity of product lines and concentration risk limits. Risk transfer solutions, primarily through reinsurance, are employed to transfer risks that the Company does not wish to retain due to the presence of single large exposures, accumulations, or limited internal expertise to the external market.

Controls are in place to ensure accumulations of risk can be evaluated properly. Counterparty concentration as a result of underwriting activities and reinsurance arrangements and their management and monitoring are considered in section C.3.3.

C.1.4 Special purpose vehicles

The Company has not transferred underwriting risk to special purpose vehicles, as defined by the Solvency II Directive.

C.2 Market risk

C.2.1 Exposure

Market risk is the risk of adverse financial impact resulting from changes in fair values or future cash flows of financial instruments due to fluctuations in interest rates, equity prices and property prices. Market risk arises within the Company due to fluctuations in the relationship between the values of liabilities and the value of investments held.

The principal market risk types that the Company is exposed to are described below:

- Equity price risk: The Company is subject to equity price risk arising from changes in the market values of its equity securities portfolio. The most material exposures are to policyholder With-profits and Unit-linked funds, which are exposed to a fall in the value of the funds due to increasing costs of policyholder guarantees and falls in the value of annual management charges respectively;
- Equity price volatility risk: The Company is subject to equity price volatility arising from its equity securities portfolio. The most material exposures are within policyholder With-profits funds, for which an increase in the expected future volatility of equity securities increases the costs of policyholder guarantees;
- Property price risk: The Company and its subsidiaries are subject to property price risk directly due to holdings of investment properties and indirectly through property collateral on commercial mortgage and equity release mortgage loans;
- Inflation risk: Inflation risk arises primarily from the Company's exposure to expense inflation and exposure to inflation-linked benefits within its annuity portfolio;
- Interest rate risk: Interest rate risk arises primarily from the Company's nominal and real yield curve exposure within both assets and liabilities. Interest rate risk also exists for policies that carry investment guarantees on early surrender or at maturity, where claim values can become higher than the value of backing assets when interest rates rise or fall;
- Foreign currency exchange rate risk: The Company is subject to currency risk from financial instruments held in currencies other than Sterling;
- Derivative risk: The Company is exposed to market risk through its derivative portfolio. Derivatives are used for efficient investment management and risk hedging purposes including risk mitigation when structuring certain retail savings products; and

- Correlation risk: The Company recognises that lapse behaviour and potential increases in consumer expectations are sensitive to and interdependent with market movements and interest rates. These interdependencies are taken into consideration in the SCR and in scenario analysis.

Measurement

For each of the major components of market risk the Company has put in place additional policies and procedures to set out how each risk should be managed and monitored and the approach to setting appropriate risk limits and tolerances.

The management of market risk is undertaken by the Asset and Liability Management (“ALM”) team, which is responsible for monitoring market risk, including the matching of assets and liabilities. Exposures by individual market risk types are monitored through Solvency II capital modelling, sensitivity testing and stress and scenario testing, as well as specific measures for different risk types (e.g. duration matching for interest rate risk). Derivative investment activity is overseen by the ALM and Risk teams, which monitor exposure levels and approval of large or complex transactions.

The principal basis used to measure the Company’s exposure to market risks is the Solvency II SCR. The sensitivity of the Solvency II balance sheet surplus and coverage ratio are also key measures of exposure, particularly to interest rate movements (as the SCR, risk margin and transitional measures on technical provisions are themselves sensitive to movements in interest rates). In addition, for each risk category, management is responsible for identifying key parameters to be used for risk measurement. For example:

- Shifts in key interest rate/currency-related parameters relevant to market risk profile (e.g. term structure shifts, interest rate volatility, drift and correlation, slope and convexity);
- Changes in price level of individual assets or specific asset classes, for example equity or property;
- Changes in price volatility of individual assets or specific asset classes;
- Changes in realised and/or implied inflation; and
- Portfolio sensitivities, for example duration.

These parameters are monitored regularly and significant changes included in management information reported to the appropriate management committee.

The Company is exposed to the level of the house price inflation and assumptions made about the future growth rate of house price inflation on its equity release mortgage portfolio. The level of house price inflation is monitored and the impact of exposure to adverse movements is regularly reviewed.

At 31 December 2022, the market risk component of the SCR amounted to £4,771 million before diversification and tax, and inclusive of the SCR related to credit risk from corporate and government bond holdings.

Changes to risk profile in the reporting period

There has been a general decrease in market risk arising from the significant increase in interest rates over 2022. In addition, there has been a small increase in equity risk due to a change in appetite resulting in less of the exposure to changes in annual management charges on unit-linked business being hedged.

C.2.2. Risk mitigation

Risk mitigation actions by principal market risk types are described below:

- Equity price risk: Direct equity exposures are limited in line with risk preferences. Investment limits require that the Company holds diversified portfolios of assets thereby reducing exposure to individual entities. The Company actively models the performance of equities through the use of stochastic models, in particular to understand the impact of equity performance on guarantees, options and bonus rates. In the principal With-profits funds, a dynamic hedging strategy is in place which aims to protect the surplus within the funds from adverse changes in asset values, in particular equities. In respect of Unit-linked funds hedging is in place to protect the surplus from falls in equity reducing the value of annual management charges;
- Equity price volatility risk: In the principal With-profits funds derivatives are held to reduce the adverse impact on surplus of an increase in equity price volatility;
- Property price risk: Investment in property is subject to investment limits, liquidity requirements and the expectations of policyholders. The financial impact from changes in property values is examined through stress and scenario analysis. Exposure to property risk on equity release mortgages from sustained underperformance in UK house price inflation is managed by setting suitably low loan to value levels at origination and monitoring levels of business written against agreed credit limits;
- Inflation risk: Exposure to inflation risk is monitored through Solvency II capital modelling, sensitivity testing and stress and scenario testing. The Company typically manages inflation risk through its investment strategy and, in particular, by investing in inflation-linked securities and through a variety of derivative instruments, including inflation-linked swaps;
- Interest rate risk: The Company typically manages interest rate risk by adopting asset liability matching techniques, including the use of a variety of derivative instruments, to minimise the impact of mismatches between the value of assets and liabilities (including capital requirements) from interest rate movements. Any asset-liability mismatch is monitored through Solvency II capital measures and interest rate hedges are used to maintain the sensitivity of the Solvency II balance sheet within risk appetite;
- Foreign currency exchange risk: Currency risk from financial instruments held in currencies other than Sterling is limited as nearly all such holdings are backing either Unit-linked or With-profits contract liabilities or mitigated by matching liabilities in local currency or hedging; and
- Derivatives risk: Collateral is held against derivative transactions. Speculative derivative activity is prohibited. Over the counter (“OTC”) derivative contracts are entered into only with approved counterparties, in accordance with the Company’s policies. The Company applies strict requirements to derivative administration and valuation processes, and has a control framework that is consistent with market and industry practice.

Monitoring the effectiveness of risk mitigation techniques

In accordance with the Group Financial Risk Mitigation Business Standard, the Company assesses and documents the effectiveness of arrangements in place to mitigate market and credit risks (financial risks). This assessment is initially undertaken when structuring arrangements and prior to execution. The assessment considers impacts on key metrics including measures of risk (primarily Solvency II capital) and financial measures, including cash flow, IFRS adjusted operating profit and expenses. Where the initial assessment indicates that the impact on key metrics is material, further assessment is carried out at appropriately regular intervals throughout the life of the arrangement. These assessments typically include stress testing and sensitivity analysis. Transactions aimed at mitigating risk may be considered in aggregate with the relevant risks.

The Company's ALM team is responsible for monitoring the Company's market risk, including the effectiveness of risk mitigation techniques in place. The Company prepares regular management information on hedging arrangements to ensure appropriate oversight.

C.2.3 Risk Concentration

The Company monitors its investment exposures, in aggregate across all classes of financial instruments (debt securities, equities and other investments), to individual issuers, geographies, sectors, and asset classes to ensure the Company is not individually exposed to significant risk concentrations. This includes look-through, where information is available, to the underlying investments held within investment funds. Further information on how the Company manages, monitors and limits investment exposures is included in C.3.3.

C.3 Credit risk

C.3.1 Exposure

Credit risk is the risk of financial loss as a result of the default or failure of third parties to meet their payment obligations to the Company, or variations in market values as a result of changes in expectations related to these risks. Credit risk can provide the returns required to satisfy policyholder liabilities and generate returns for the Company's shareholders. Therefore, the Company is prepared to accept a degree of credit risk based on its credit risk analysis capability and the structural investment advantages conferred to insurers with long-dated, relatively illiquid liabilities.

The principal credit risk categories that the Company is exposed to are as follows:

- Spread risk is the risk that credit spreads over risk-free interest rates change. Credit concerns (improving or worsening) with respect to the issuer and market factors such as risk appetite and liquidity within the market can give rise to a change in credit spread;
- Default risk is the risk that a counterparty is unable or unwilling to meet its financial obligations when they fall due; and
- Rating migration risk is the risk that a change in the external credit rating of a counterparty adversely impacts the Company.

Exposure of the Company to credit risk arises principally through the following asset holdings:

- Debt securities, including investments in sovereign and corporate bonds;
- Loans including policy loans, loans and advances to banks and mortgage loans;
- Reinsurance assets. Where the Company has reinsurance arrangements in place, credit risk arises in relation to the reinsurance counterparties; and
- Other assets. Credit risk arises in relation to other assets, including structured investments, bank deposits and derivative counterparties.

Measurement

The principal basis used to measure the Company's exposure to credit risk is the Solvency II SCR. In addition, the following factors are used by the Company when measuring credit risk exposure:

- Maximum exposure: The Company's maximum exposure to credit risk of financial assets and reinsurance assets, without taking collateral, credit hedges or reinvestment risk into account, is represented by the carrying value of the financial assets and reinsurance assets recognised in the Solvency II balance sheet;
- Credit ratings: Credit ratings (both internal and external) are used as indicators of credit risk to help determine risk management actions, investment decisions and asset allocation; and
- Loan specific factors: The Company uses loan to value, interest and debt service cover, and diversity and quality of the tenant base metrics to monitor exposures to commercial mortgage loans. The risk characteristics of commercial mortgage loans are assessed before acquisition and are monitored thereafter.

The majority of the Company's credit risk arises from corporate and government bond holdings. This credit risk is reported within the market risk component of the SCR. In addition to this, at 31 December 2022, the counterparty default risk component of the SCR amounted to £127 million before diversification and tax.

Changes to risk profile in the reporting period

The main change in the credit risk profile during 2022 is a reduction in exposure to sovereign spread risk as a consequence of selling gilts hedging Solvency II balance sheet interest rate exposure and replacing these with interest rate receiver swaps. Credit risk, including spread risk, measured by undiversified SCR fell in 2022. This fall was primarily due to higher interest rates, which reduce SCR as a result of the higher impact of discounting.

C.3.2. Risk mitigation

The Company's approach to managing credit risk recognises that there is a risk of adverse financial impact resulting from fluctuations in the credit quality of third parties including default, rating transition and credit spread movements. The Company implements credit risk management processes including a limit framework (section C.3.3), operates specific risk management committees, and ensures detailed reporting and monitoring of its exposures against pre-established risk criteria.

The Company may also impose ad-hoc restrictions to control exposures. The Company also uses ad-hoc restrictions to reserve certain counterparties for a particular business activity. For example, direct investment in the securities of principal reinsurance counterparties is restricted.

In addition to the risk mitigation techniques described above, specific credit risk mitigation techniques apply to certain portfolios of assets:

- The Company has significant securities financing operations. The credit risks within this activity are mitigated by over-collateralisation and minimum counterparty credit quality requirements which are designed to minimise residual risk. The Company operates strict standards around counterparty quality, collateral management, margin calls and controls;
- The Company is also exposed to counterparty credit risk through derivative trades. This risk is mitigated through collateralising almost all trades (the exception being certain foreign exchange trades where it has historically been the market norm not to collateralise, exchange traded positions and certain swaps with Private Finance Initiative ("PFI") counterparties). Residual exposures are captured within the Company's credit management framework; and
- For Unit-linked business the policyholder bears the direct market risk and credit risk on investment assets in the unit funds and the shareholders' exposure to credit risk is limited to the extent of the income arising from asset management charges based on the value of assets in the fund. The exception to this is credit risk on certain reinsured Unit-linked business which is borne by the Company.

Monitoring of the effectiveness of risk mitigation techniques

The processes for monitoring the effectiveness of risk mitigation techniques in respect of credit risk and market risk are set out in section C.2.2.

C.3.3. Risk concentration

The Company operates a credit limit framework, which limits investments in individual issuers, geographies, sectors, and asset classes to ensure it is not exposed to significant concentrations of credit risk. Credit concentrations are monitored as part of the regular credit monitoring process and are reported to the Asset and Liability Committee ("ALC").

Credit limit framework

The credit limit framework is based on three different layers (counterparty, sector and country) and is supported by a number of escalation frameworks which seek to ensure larger and/or higher risk transactions and activities are escalated appropriately. Specific escalation frameworks exist for ALM and investment decisions, and for derivative transactions.

The counterparty limit framework aims to avoid concentrations to single counterparties and to encourage issuer diversification within the portfolio. The limits combine to restrict the total exposure to a single counterparty, both in terms of balance sheet exposure and shareholder exposure, and restrict the amount of high risk assets or exposures that can be held.

Concentration risk is further managed by sector concentration limits which are used to mitigate against, or manage, concentrations to specific sectors, and geographical areas to ensure appropriate geographical diversification and appropriate exposure limits depending on the risk profile of the country.

Significant concentrations

The Company holds a diversified portfolio of assets subject to credit risk due to its internal credit limit framework which limits exposure to individual concentrations of risk.

The Company is exposed to concentrations of risk with individual reinsurers, due to the nature of the reinsurance market. The Company places reinsurance with those reinsurers that have acceptable credit ratings. The Company has a significant reinsurance asset as a result of the quota share reinsurance ceded to All, as detailed in the Business and Performance section of the Summary, which is considered to be an acceptable exposure to a fellow group undertaking. The Company operates a policy to manage its reinsurance counterparty exposures and the impact from reinsurer default is measured regularly, in particular through Solvency II stress and scenario testing.

C.4 Liquidity risk

C.4.1 Exposure

Liquidity risk is the risk that financial obligations to policyholders and other relevant external and internal parties cannot be met in a timely and cost-effective manner as they fall due. Liquidity issues may arise from uncertainty in the value and timing of liabilities as well as uncertainty in the ability to realise assets as cash to meet obligations.

Sources of liquidity risk are those activities or external factors that could alter the liquidity needs and liquidity resources in a stress scenario. The Company is responsible for identifying where liquidity risk exists and the factors that may increase the liquidity risks it faces at either the Company or specific fund level when setting risk appetite. Some examples of sources of liquidity risk are:

- Higher than expected claims. An increase in surrenders (for example a mass lapse event for With-profits business) could increase the claims paid in the short term but reduce those in the longer term. In addition, increases in the level of annuity claims (for example through fewer deaths than expected) would also increase the claims paid over the medium term;
- Collateral and margin calls on derivatives following movements in underlying market values; and
- Timing mismatches in cash inflows and outflows including delays in reinsurance settlements and reinsurance defaults, and mismatches between annuity claims and expenses versus investment income and redemption proceeds.

The Non-profit fund is particularly susceptible to spikes in liquidity needs, although these spikes are recognised and actively managed to limit their impact on the Company.

Liquidity risk appetite is expressed and measured through both absolute level targets and the Liquidity Coverage Ratio (“LCR”) which measures the extent to which stressed liquid assets held and stressed inflows are sufficient to meet liquidity requirements over a specified time horizon. The Company has short and long-term risk appetites for legal entities and ring-fenced funds.

Changes to risk profile in the reporting period

Although there were no material changes in the Company’s liquidity risk profile during 2022 the UK financial markets reaction to the mini-budget statement in September 2022 resulted in a significant liquidity strain on the Company. The liquidity held through the risk appetites ensured that the Company could continue to meet all collateral calls throughout this period and management actions were taken to create a further additional liquidity buffer against the crisis continuing.

Sensitivity analysis

Stress and scenario testing, including reverse stress tests, is undertaken by the Company for the purpose of recovery planning and to test the resilience of the business plan. This testing specifically considers impacts on the Company’s liquidity position.

C.4.2 Risk mitigation

The Company manages and mitigates its exposure to liquidity risk as follows:

- A liquidity risk appetite is set which requires that sufficient liquid resources be maintained to cover net outflows in a stress scenario;
- Maintenance of undrawn committed borrowing facilities;
- Asset liability matching methodology which optimises asset portfolio maturity structures to ensure cash flows are sufficient to meet liabilities when they fall due; and
- Limiting stock-lending of assets, and availability of repo arrangements.

In addition, the Company has access to a contingent funding plan that permits limited borrowing from other companies within UK Life, and may also request additional borrowing from other Group companies (subject to relevant approvals). To pre-empt the need to initiate the contingent funding plan, the Company sets liquidity buffers and triggers to enable action to be taken before target levels are breached.

The liquidity risk appetite triggers are calibrated to enable the Company to absorb the impact of stress events. In addition, to mitigate against any potential risk to liquidity, the Company has access to £325 million of external undrawn committed borrowing facilities and additional liquidity management actions are also available.

Monitoring the effectiveness of risk mitigation techniques

In addition to the overall monitoring of the risk mitigation techniques described in the Overview section, the Company monitors the effectiveness of its liquidity risk mitigation as follows:

- Assurance work (e.g. testing) to ensure that controls that enable effective risk management are in place and work effectively; and
- Continual monitoring of actual and projected liquid resources and cash inflows and outflows against liquidity risk appetites and liquidity buffers.

C.4.3 Risk concentration

Concentration of liquidity risk can occur if the Company’s assets are invested in a limited number of issuers, asset classes and sectors and, in the event of an external shock, market liquidity for these investments disappears and the assets can not be realised for cash. The measures taken to avoid such risk concentrations are set out in section C.3.3.

The diversity of sources of liquidity available to the Company helps reduce concentration of liquidity risk.

C.4.4 Additional information on liquidity risk: Expected Profit in Future Premiums (“EPIFP”)

EPIFP is the expected present value of future cash flows which result from the inclusion in technical provisions of premiums relating to existing insurance and reinsurance contracts that are expected to be received in the future. It is calculated as the difference between:

- The net of reinsurance best estimate liabilities of the contract; and
- An alternative scenario for the contract under which no future premiums are paid. Excluding the premiums is likely to have an impact on the benefit to be paid. Relevant benefit and expense cash flows are therefore assumed to be on a paid up or lapse basis. Where ‘unearned’ commission could be clawed back on a paid-up basis, this is also allowed for. However, any penalties on the contract associated with the policyholder making the policy paid up are not taken into account.

The amount of EPIFP was £1,594 million as at 31 December 2022 (2021: £1,472 million).

C.5. Operational risk

C.5.1 Exposure

Operational risk is the risk of loss arising from inadequate or failed internal processes, people and systems, or external events including changes in the regulatory environment. There is a ‘risk limiting’ preference for operational risk and the aim is to reduce this risk as far as is commercially sensible.

Conduct risk is an aspect of operational risk and is the risk that positive customer outcomes are not achieved. It arises throughout the whole product lifecycle from the development of products and the sales process to servicing policies and handling claims.

Reputational risk can result from operational risk. This is the risk that litigation, employee misconduct, operational failures, the outcome of regulatory investigations, media speculation and negative publicity, disclosure of confidential client information, and inadequate services (whether or not founded) could impact the Company’s brands or reputation. The Company’s brands or reputation could also be affected if products or services recommended by it (or any of its intermediaries) do not perform as expected (whether or not the expectations are well founded) or if customers’ expectations for the product change.

Measurement

The RCSA process, as described in section B.3.1, is used to identify operational risks. The process involves the mapping of identified operational risks to operational processes, the identification of mitigating controls and an assessment of the effectiveness of these controls. A residual risk impact and probability assessment is then performed. Residual impact is assessed quantitatively on the basis of financial loss and misstatement, and qualitatively for reputational and conduct considerations.

UKLAP have adopted the overarching Operational Risk and Control Management ("ORCM") framework set by Aviva Group. This framework is designed to enable management and Boards to assess the overall quality of the operational risk environment relative to risk appetite, and where a business unit is outside of appetite, require clear and robust plans to be put in place in order to return to appetite. Metrics have been put into place to underpin the operational risk appetite.

To the extent that operational risks cannot be fully mitigated and in recognition of the risk of control failure (i.e. due to ineffectiveness in design or performance), the Company holds capital to cover these risks within the Solvency II SCR.

At 31 December 2022, the operational risk component of the SCR amounted to £1,583 million (2021: £1,511 million) before diversification and tax.

Changes to risk profile in the reporting period

The Company's continued exposure to risks such as cyber attacks remained high in 2022.

Given the current global economic and political environment, the Company's exposure to the above factors is expected to remain high in the short to medium term. However, steps continue to be taken to improve the control framework and take mitigating actions so as to manage this exposure and related potential impacts. Externally, the cyber crime environment continues to be volatile with a high level of change and increasing sophistication. There is an increasing concern around the emerging risk of cyber espionage and nation state attacks, due to the current geopolitical tensions.

There continues to be a high level of both regulatory and non-regulatory change in the business currently, and the impacts of this on the control framework are being closely monitored. The delivery of Consumer Duty for all open products in 2023 is a high priority for the entire Aviva Group, including Aviva UK Life, and this is being monitored alongside internal strategic change initiatives.

Aviva has committed to being carbon net zero by 2040. In 2021 a new climate risk appetite was introduced to track our progress against our climate ambitions. This is based on five separate risk appetite metrics, which are set at a Group level, with Aviva UK Life influencing the proposals. This risk appetite is actively monitored with escalation pathways to the Executive Risk Committee ("ERC"), Board Risk Committee ("BRC") and the Board should we fall outside of tolerance.

C.5.2 Risk mitigation

Most operational risks are considered preventable and are managed through business controls. The Company's preference is to improve its business processes through reduction of errors and rework, in order to achieve:

- Reduced operational risk and associated losses, hence improving cost to income ratio and lessening variability in financial performance;
- Improved customer outcomes and employee satisfaction;
- Sustained customer confidence; and
- A positive regulatory reputation.

The Group's business standards set out the minimum control objectives and controls that each business area is expected to have in place. Operational risk limits and tolerances act as quantitative boundaries that constrain specific risk-taking activities at an operational level.

The Company records and analyses operational risk events, arising from inadequate or failed processes, people or systems or external events, in order to ensure remedial action is taken, lessons are learnt and, where the event impacts customers, that they are treated fairly. As well as events that result in losses, this includes risk events which do not give rise to a financial loss, such as near misses or fortuitous gains and also reputational and customer impacts. The lessons learned enable business areas to highlight areas for improvement, implement corrective actions to avoid recurrence, and improve the Company's risk assessment and understanding of operational risk, feeding into the RCSA process.

Monitoring of the effectiveness of risk mitigation techniques

All three lines of defence have an important role to play in monitoring the effectiveness of the controls that are in place in respect of operational risk. More details on the three lines of defence are included in section B.1.1.

C.5.3 Risk concentration

Concentrations of operational risk arise when there is dependency on a single supplier to provide a product or service supporting a business-critical function. The Company is required to identify such business-critical outsourced functions and for each have exit and termination plans and business continuity and disaster recovery plans in the event of supplier failure. These plans are required to be reviewed at least annually.

The Company's operations are spread across a number of geographical office locations helping to ensure continuity of service if a catastrophic event results in an office being out of action. Additionally, the Company has a series of business continuity plans in place for critical functions which should ensure continuity of service to its customers without significant interruption. These business continuity plans were tested during the COVID-19 pandemic when homeworking was required across all Aviva and Third Party offices. There were no sustained or critical process or control failures throughout the initial transition to homeworking. No additional material failures have arisen due to the subsequent move to the hybrid of home and office 'smart working' model. Furthermore, additional activity has been undertaken to set tolerance statements around operational resilience within the key business services.

Most of the Company's products are sold under the 'Aviva' brand, enabling the Company to leverage the strength of the brand and supporting delivery of its business strategy. The Company is therefore particularly vulnerable to any operational failures that could adversely impact public perception of the 'Aviva' brand.

C.6 Any other information

C.6.1 Sensitivity analyses

As set out in the Risk Profile Overview section, the primary basis used by the Company to measure risks is the Solvency II SCR. The Company performs sensitivity analysis and stress and scenario testing in order to understand the impact that changes in underlying risk calibrations (and correlations of those risks) would have on the Company's risk profile and Solvency II coverage ratio. This section describes the sensitivity analyses performed, and section C.6.2 describes the Company's stress and scenario testing.

The sensitivity analyses performed by the Company include consideration of the sensitivity of the Company's Solvency II coverage ratio to a range of economic and non-economic assumptions as follows:

Economic assumptions

- 50 and 100 basis point increases and 50 and 100 basis point decreases in the risk-free rate, including all consequential changes (including assumed investment returns for all asset classes, market values of fixed interest assets and risk discount rates);
- 50 and 100 basis point increases and 50 basis point decrease in credit spreads for corporate bonds with credit rating A at 10-year duration, with the other ratings and durations stressed by the same proportion relative to a stressed capital requirement;
- an immediate full letter downgrade on 20% of bonds in the Matching Adjustment Portfolio ("MAP") (e.g. from AAA to AA, from AA to A);
- 10% and 25% increases and 10% and 25% decreases in market values of equity assets;
- 20% increase and 20% decrease in the market values of commercial property assets; and
- 20% increase and 20% decrease in the market values of residential property assets.

Non-Economic assumptions

- 10% increase in maintenance and investment expenses (a 10% sensitivity on a base expense assumption of £10 p.a. would represent an expense assumption of £11 p.a.);
- 10% increase in lapse rates (a 10% sensitivity on a base lapse assumption of 5% p.a. would represent a lapse rate of 5.5% p.a.);
- 5% increase in both mortality and morbidity rates for life assurance; and
- 5% decrease in mortality rates for annuity business.

All other assumptions remain unchanged for each sensitivity, except where these are directly affected by the revised economic conditions or where a management action that is allowed for in the SCR calculation is applicable for that sensitivity. For example, future bonus rates on With-profits policies are typically adjusted to reflect changes to future investment returns.

Transitional Measures on Technical Provisions ("TMTP") is assumed to be recalculated in all sensitivities where its impact would be material.

The table below shows the absolute change in cover ratio under each sensitivity at 31 December 2022:

| Sensitivities (net of tax and gross of non-controlling interests) | | Impact on Regulatory Surplus as at 31 December 2022 £m | Impact on regulatory cover ratio 31 December 2022 (%) |
|---|---|---|---|
| Changes in economic assumptions | | | |
| | 50 bps increase in interest rate | (81) | 1 % |
| | 100 bps increase in interest rate | (155) | 1 % |
| | 50 bps decrease in interest rate | 32 | (2)% |
| | 100 bps decrease in interest rate | 80 | (4)% |
| | 50 bps increase in corporate bond spread | (3) | 2 % |
| | 100 bps increase in corporate bond spread | 13 | 4 % |
| | 50 bps decrease in corporate bond spread | (65) | (2)% |
| | 20% of MA bond assets downgraded by 1 letter rating | (262) | (6)% |
| | 10% increase in market value of equity | (20) | (2)% |
| | 25% increase in market value of equity | (38) | (4)% |
| | 10% decrease in market value of equity | (23) | 1 % |
| | 25% decrease in market value of equity | (48) | 3 % |
| | 20% increase in value of commercial property | 221 | 6 % |
| | 20% decrease in value of commercial property | (360) | (8)% |
| | 20% increase in value of residential property | 291 | 6 % |
| | 20% decrease in value of residential property | (445) | (10)% |
| Changes in non-economic assumptions | | | |
| | 10% increase in maintenance and investment expenses | (386) | (8)% |
| | 10% increase in lapse rates | (185) | (4)% |
| | 5% increase in mortality/morbidity rates - Life assurance | (86) | (2)% |
| | 5% decrease in mortality rates - annuity business | (503) | (10)% |

Limitations of sensitivity analysis

The table above demonstrates the effect of a change in a key assumption while other assumptions remain unchanged. In reality, there is a correlation between the assumptions and other factors. It should also be noted that these sensitivities are non-linear, and larger or smaller impacts should not be interpolated or extrapolated from these results.

The sensitivity analysis does not take into consideration that the Company's assets and liabilities are actively managed. Additionally, the Solvency II position of the Company may vary at the time that any actual market movement occurs. For example, the Company's financial risk management strategy aims to manage the exposure to market fluctuations.

As investment markets move past various trigger levels, management actions could include selling investments, changing investment portfolio allocation, adjusting bonuses credited to policyholders, and taking other protective action. Other limitations in the above sensitivity analysis include the use of hypothetical market movements to demonstrate potential risk that only represent the Company's view of possible near-term market changes that cannot be predicted with any certainty, and the assumption that all interest rates move in identical fashion.

C.6.2 Stress and scenario testing

Stress and scenario testing (including reverse stress testing) is used to test the resilience of business plans and strategic projects (including material portfolio changes such as those related to products, customers and distributors) and inform decision-making. A series of stress tests are performed to analyse their impact on the Company's solvency and liquidity. These tests include the Company 1-in-X reference stresses driven by the Company's risk profile as well as several scenarios as part of the Company's Recovery Planning and Liquidity Risk management planning processes.

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

D. Valuation for Solvency Purposes

In this Chapter

| | | |
|-----|----------------------------------|----|
| D.1 | Assets | 34 |
| D.2 | Technical provisions | 35 |
| D.3 | Other liabilities | 48 |
| D.4 | Alternative methods of valuation | 50 |
| D.5 | Any other information | 53 |

The 'Valuation for Solvency Purposes' section of the report provides a description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset and liability class.

Assets and liabilities under Solvency II are valued in accordance with the Company's accounting policies under international accounting standards in conformity with the requirements of the Companies Act 2006 (IFRS), unless stated otherwise in sections D.1 'Assets', D.2 'Technical provisions' and D.3 'Other liabilities'. A summary of the Company's accounting policies can be found in the accounting policies note of the Company's 2022 financial statements.

The table below sets out a summarised balance sheet as at 31 December 2022. It compares assets and liabilities as reported in the financial statements (column a) to the Solvency II balance sheet (column d).

Where differences are present either in respect of the classification or measurement of assets or liabilities between IFRS and Solvency II, they have been presented in the table below, in columns (b) and (c), and a qualitative description provided for all material items in sections D.1 'Assets', D.2 'Technical provisions' or D.3 'Other liabilities'.

Balance Sheet – IFRS and Solvency II As at 31 December 2022

| IFRS balance sheet headings | Note from financial statements | IFRS (a) £m | Reclassification (b) £m | SII valuation adjustments (c) £m | Solvency II (d) £m | Solvency II balance sheet headings | S.02.01.02 Appendix F.1 Reference | SFCR Note |
|--|--------------------------------|----------------|-------------------------|----------------------------------|--------------------|--|-----------------------------------|-----------|
| Assets | | | | | | | | |
| Acquired value in-force business and intangible assets | O,9 | 27 | — | (27) | — | Intangible assets | R0030 | D.1.1 |
| Deferred tax asset | AE,31 | 340 | 1 | — | 341 | Deferred tax assets | R0040 | D.3.2 |
| Deferred acquisition costs | AA,20 | 1,137 | — | (1,137) | — | Deferred acquisition costs | - | D.1.2 |
| Property & equipment | P,12 | 20 | — | 25 | 45 | Property, plant & equipment held for own use | R0060 | D.1.3 |
| Investment property | Q,13 | 4,416 | (3,139) | — | 1,277 | Investment property | R0080 | D.1.4 |
| Investment in subsidiaries, joint ventures and associates | C, D, 10, 11 | 3,056 | 24,608 | 82 | 27,746 | Participations | R0090 | D.1.5 |
| | | | | | 2,164 | Equities | R0100 | |
| | | | | | 44,957 | Bonds | R0130 | |
| Financial Investments | T,18 | 185,003 | (131,791) | — | 457 | Collective investment undertakings | R0180 | D.1.6 |
| | | | | | 3,104 | Derivatives | R0190 | |
| | | | | | 2,530 | Deposits other than cash and cash equivalents | R0200 | |
| | | | 138,745 | — | 138,745 | Assets held for index-linked and unit-linked funds | R0220 | D.1.7 |
| Loans | Y,16 | 23,817 | (6,470) | (86) | 17,261 | Loans and Mortgages | R0230 | D.1.8 |
| Reinsurance assets | N,28 | 66,714 | (90) | (1,905) | 64,719 | Reinsurance recoverables | R0270 | D.1.9 |
| Cash and cash equivalents | | 21,311 | (20,301) | — | 1,010 | Cash and cash equivalents | R0410 | D.1.10 |
| Receivables | U,AE,19,31 | 2,541 | (1,891) | — | 650 | Receivables (insurance, reinsurance and intermediaries) | R0360 | D.1.11 |
| | | | | | | Other assets (including prepayments and accrued income) | R0370 | |
| Prepayment and accrued income | 20 | 1,761 | (522) | — | 1,239 | | R0380, R0420 | D.1.12 |
| Total assets | | 310,143 | (850) | (3,048) | 306,245 | | | |
| Liabilities | | | | | | | | |
| Gross insurance liabilities | L,24 | 80,031 | | | 81,664 | Technical provisions – life (excluding index-linked and unit-linked) | R0600 | D.2.1 |
| Gross liabilities for investment contracts | L,M,26 | 150,635 | (1,287) | (6,916) | 140,799 | Technical provisions – index-linked and unit-linked | R0690 | D.2.1 |
| Unallocated divisible surplus | L,30 | 1,849 | — | (1,849) | — | - | - | D.3.6 |
| Deferred tax liabilities | AE,31 | 101 | 1 | 550 | 652 | Deferred tax liabilities | R0780 | D.3.2 |
| Derivatives financial liabilities | 35 | 8,167 | (360) | — | 7,807 | Derivatives | R0790 | D.3.3 |
| Debts owed to credit institutions | 35 | — | 204 | — | 204 | Debts owed to credit institutions | R0800 | D.3.4 |
| Financial liabilities other than debts owed to credit institutions | 35 | 2,040 | 755 | — | 2,795 | Financial liabilities other than debts owed to credit institutions | R0810 | D.3.4 |
| Payables arising out of direct insurance | 31, 35 | 843 | 1,199 | — | 2,042 | Insurance and intermediaries payables | R0820 | D.3.4 |
| Deposit received from reinsurers | 35 | 57,602 | — | (14) | 57,588 | Deposits from reinsurers | R0770 | D.3.5 |
| Payables arising out of reinsurance operations | 35 | 102 | — | 1 | 103 | Reinsurance payables | R0830 | D.3.5 |
| Other financial liabilities | 35 | 1,622 | (862) | — | 760 | Payables (trade, not insurance) | R0840 | D.3.4 |
| Loans from parent/group undertakings | AF, 34 | — | — | — | — | Subordinated liabilities | R0850 | D.3.4 |
| Other liabilities | 36 | 547 | (485) | (56) | 6 | Other liabilities | R0880 | D.3.6 |
| Provisions | AD,32 | 165 | (15) | — | 150 | Provisions other than technical provisions | R0750 | D.3.1 |
| Total liabilities | | 303,704 | (850) | (8,284) | 294,570 | | | |
| Excess of assets over liabilities | | 6,439 | — | 5,236 | 11,675 | | | |

There are a number of classification differences between the presentation of the balance sheet in the financial statements and the Solvency II balance sheet which have no material net asset impact and therefore no impact on Solvency II measurement. The impact of these changes is shown in column (b) above. The key reclassifications are as follows:

- Reclassification of £138.7 billion of assets backing unit-linked and index-linked contracts to the assets held for index-linked and unit-linked funds category. This includes £129.3 billion shown as financial investments, £6.3 billion classified as cash and cash equivalents and £3.1 billion classified as investment property in the financial statements; and
- Reclassification into participations (where the criteria described in section D.1.5 are met) of liquidity funds classified within cash and cash equivalents and financial investments in the financial statements of £24.6 billion.
- Reclassification of outstanding claims payable of £1.2 billion from Insurance liabilities to payables arising out of direct insurance.
- The majority of the loans reclassification consists of equity release securitised mortgages of £6.9bn from Loans to Financial Investment - Bonds to reflect the securitised notes issued in place of the underlying mortgages.
- The majority of the the receivables reclassification relates to the reclassification of accrued interest of £1.5 billion to financial investments.

A number of valuation differences exist in respect of the assets and liabilities reported in the Company balance sheet under Solvency II compared to IFRS as at 31 December 2022. The nature of the material differences is set out in section D.1 'Assets', D.2 'Technical provisions' and D.3 'Other liabilities'. The net impact of these differences is an increase in net assets of £5,236 million. This primarily reflects the differences in assumptions and reserving methodology used to value technical provisions under Solvency II compared to IFRS.

D.1 Assets

Assets have been valued according to the requirements of the Solvency II Directive and related guidance; the basis of the Solvency II valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction.

A description of the basis of valuation under Solvency II along with valuation differences between the Solvency II bases and the IFRS financial statements, by asset class, is provided below.

The Company considers markets to be active where transactions take place with sufficient frequency and volume for pricing information to be available on an ongoing basis. Where the Company has concluded that markets are not active, alternative methods for valuation are used. Refer to section D.4 for further details on alternative methods for valuation.

D.1.1 Intangible assets

Intangible assets recognised in accordance with IFRS include software intangibles and acquired value-in-force ("AVIF").

For Solvency II purposes software intangibles are restated at their fair value. The fair value of intangible assets is required to be based on a valuation methodology that uses market observable inputs. If market observable inputs for an intangible asset are not available it has nil value under Solvency II. The Company's software intangibles are valued at nil in accordance with the Solvency II valuation methodology described above, as no market observable inputs are available.

AVIF is also set to nil in the Solvency II balance sheet and instead the associated cash flows are included in the measurement of Solvency II technical provisions.

D.1.2 Deferred acquisition costs

Deferred acquisition costs valued at £1,137 million for IFRS purposes are set to nil in the Solvency II balance sheet and instead the associated future profit cash flows supporting the deferred acquisition costs are included in the measurement of Solvency II technical provisions.

D.1.3 Property, plant and equipment (own use)

Under IFRS 16, lessees are required to recognise lease assets and liabilities on the statement of financial position for all leases, with the exception of short-term and low-value leases. Where the Company is the lessee, a lease liability equal to the present value of outstanding lease payments and a corresponding right-of-use equal to the costs are initially recognised. The right-of-use asset is subsequently measured at amortised cost and depreciated on a straight-line basis over the length of the lease term. Depreciation on lease assets and interest on liabilities is recognised in the income statement.

Under Solvency II, the leased asset is held at fair value. Where the lease is not impaired this is deemed to be equal to the related lease liability as the best proxy for fair value. Where the lease asset is deemed to be impaired it is held at a value equal to its IFRS carrying value.

D.1.4 Investment property

Investment property is measured at fair value for both Solvency II and IFRS purposes. The fair values are assessed by qualified external valuation specialists or by qualified staff and reflect rental income and other assumptions that market participants would use when pricing the investment property under current market conditions. Further information on the valuation of investment properties is included in section D.4.4.

D.1.5 Participations

A participation is a Solvency II term for a holding, direct or by way of control, of 20% or more of the voting rights of an undertaking. It can therefore be a subsidiary, an associate or a joint venture.

The Company's participations in related undertakings are valued in the Solvency II balance sheet at the Company's proportionate equity share of the excess of assets over liabilities (valued on a Solvency II basis) of each related undertaking. Liquidity funds (classified within cash and cash equivalents under IFRS) and collective investment schemes (held within financial investments under IFRS) are reclassified into participations under Solvency II.

Under IFRS, investments in subsidiaries, associates and joint ventures which are held to back policyholder liabilities and are managed on a fair value basis are stated at their fair values, estimated using applicable valuation models underpinned by the quoted market valuations of comparable listed entities; other investments in subsidiaries are recognised at cost less impairment.

D.1.6 Financial investments

All financial investments, primarily consisting of debt securities, equity securities and unit trusts, are measured at fair value for both Solvency II and IFRS purposes. Fair value is obtained from quoted market prices or, if these are not available, by using relevant valuation techniques. Further information on financial investments valued using an alternative method to either a quoted market price or a quoted market price for a similar asset is included in section D.4.

Listed equity securities, bonds and exchange traded derivatives in the IFRS financial statements are fair valued using quoted market prices. This methodology is consistent with Solvency II. Unlisted equities are fair valued using a range of techniques details of which are outlined in Section D.4. Collective investment undertakings are carried at fair value using quoted unit prices which is consistent with Solvency II. The Solvency II valuation of deposits other than cash equivalents is in line with the IFRS treatment.

D.1.7 Assets held for index-linked and unit-linked funds

Assets held to cover index-linked and unit-linked funds are measured at fair value for both Solvency II and IFRS purposes. These assets are predominately financial investments which are valued as described in section D.1.5.

Assets held to cover index-linked and unit-linked funds are classified within their respective individual asset categories in the IFRS balance sheet and combined together as a single total in the Solvency II balance sheet. These balances are therefore reclassified from the individual asset lines to this category for Solvency II reporting purposes.

D.1.8 Loans and mortgages

Loans and mortgages (primarily consisting of mortgage loans including commercial mortgages, loans to credit institutions, Private Finance Initiative ("PFI") loans and infrastructure loans), are measured at fair value under Solvency II. The valuation technique used is an income approach, which reflects the present value of cash flows the loan is expected to generate calibrated as far as possible to market observable parameters.

Under IFRS the majority of loans are recognised at their fair values. Section D.4 describes alternative methods of valuation applicable to assets in this category.

D.1.9 Reinsurance recoverables

Reinsurance recoverables are calculated as a probability-weighted average of discounted future cash flows relating to reinsurance contracts, adjusted for the expected losses due to counterparty default. Only reinsurance cash flows that relate to cash flows included in the best estimate liability are included. The reinsurance recoverable is calculated consistently with the boundary of the underlying contract to which the recoveries relate. The difference in value under Solvency II compared with IFRS is driven by the differences in valuation methodology for technical provisions (refer to section D.2.4). All internal reinsurance is valued in the same way as external reinsurance. There is no business reinsured with an external special purpose vehicle ("SPV").

D.1.10 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, deposits held at call with banks, treasury bills and other short term highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value. Such investments are those with less than three months' maturity from the date of acquisition, or which are redeemable on demand only with an insignificant change in their fair values. Deposits other than cash equivalents and unit-linked or index linked investments are reclassified to the appropriate category under Solvency II. Under Solvency II cash is valued in accordance with IFRS principles.

D.1.11 Receivables (insurance, reinsurance and intermediaries)

Under Solvency II, receivables are held at fair value, being the amount for which they could be exchanged between knowledgeable parties in an arm's length transaction. All the Company's receivables are due within one year. Where receivables are expected to be recovered within one year, the Solvency II fair value is equal to the IFRS carrying value.

D.1.12 Other assets

Other assets consist of prepayments and accrued income which are held at cost less impairment under both Solvency II and IFRS.

D.2 Technical provisions

This section provides a definition of Solvency II technical provisions, the methodology and main assumptions used in the valuation of the Solvency II technical provisions, the total value of Solvency II technical provisions split by material lines of business, a comparison of the valuation of Solvency II technical provisions with IFRS technical provisions and a description of the level of uncertainty in technical provisions.

D.2.1 Definition of Technical Provisions

The value of technical provisions under Solvency II is equal to the sum of a best estimate liability and a risk margin (unaudited) less the transitional measure on technical provisions (unaudited).

The best estimate liability is defined as the probability-weighted average of the present value of future cash flows on a market consistent basis, using the relevant risk-free interest rate term structure after making allowance for the volatility adjustment ("VA") or matching adjustment ("MA") as required (described in section D.2.2.2).

The risk margin is an allowance for the amount, in addition to the best estimate liability, that a third party (buyer) would expect to receive in order to take over the insurance obligations of an existing entity. It is calculated as the present value of a cost of capital each year in respect of non-hedgeable risks.

Technical provisions also include the transitional measure on technical provisions ("TMTP") (unaudited) which allows firms to transition from the Solvency I liabilities to the Solvency II technical provisions over a period of 16 years from 1 January 2016. This is described in more detail in section D.2.2.1(c).

The following general principles apply to technical provisions valuation:

- The calculation of technical provisions is performed on a going concern basis. This means a proportion of expected future costs (such as general overheads) will be covered by future new business; and
- The definition of a "best estimate" assumption is one that represents the expected outcome from the range of possible outcomes for future experience of that assumption and is reasonable and realistic with no deliberate margins for prudence included.

The process and overall methodology for setting assumptions and technical provisions is consistent between funds. The material changes to assumptions during the year are detailed in the section D.2.2.5.

D.2.2 Technical provisions methodology and assumptions

Technical provisions are calculated in accordance with the Solvency II Directive, Delegated Regulations and regulator guidance. This section describes how the rules and guidance have been applied to the Company. Unless otherwise stated the methodology and assumptions apply to all types of business.

D.2.2.1 Methodology

(a) Valuation methodology

Cash flow modelling

A deterministic valuation approach producing point estimates, based on best estimate assumptions and all relevant future cash flows required to settle the life insurance liabilities, is used for most of the business. The exception is for contracts with embedded options and guarantees, in particular With-profits participation business, where a more sophisticated stochastic approach based on the average of a number of scenarios is used. The best estimate liability is calculated separately for cash flows in different currencies. Reinsurance cash flows are modelled as well as cash flows gross of reinsurance.

Future investment returns are also projected in order to determine the value of such items as annual management charges, investment expenses and the value of investment guarantees on With-profits participation business.

Policy grouping

The cash flow projections used in the calculation of the best estimate liability for life insurance business are made separately for each policy with the exception of some participation business where policies are grouped and group protection business where the modelling is done at a scheme level with multiple members of an employer being part of the scheme.

Minimum technical provision per policy

Technical provisions for insurance contracts are allowed to be negative where future cash in-flows are expected to exceed future cash out-flows.

The technical provisions of an insurance or reinsurance contract may be lower than the surrender value available to the policyholder of the underlying contract.

Contract boundaries

The calculation of the best estimate liability allows for any boundaries of the insurance contract. A boundary exists where the insurance undertaking has a unilateral right to: terminate the contract; reject premiums payable under the contract; or amend the premiums or benefits payable under the contract at a future date in such a way that the premiums fully reflect the risks. Any obligations which relate to insurance services which may be provided after that date do not belong to the contract, unless the undertaking can compel the policyholder to pay the premium for those obligations.

An immediate contract boundary applies to unit-linked regular premium savings and pensions policies which do not have material risk benefits or guarantees.

Unit-linked policies invested in charge capped funds are treated as having an extended contract boundary which includes expected future premiums. As a consequence, auto-enrolment default funds, stakeholder pensions and products with voluntary charge caps (set at a similar level to stakeholder pensions) are considered to have an extended contract boundary. This also applies to some classes of unitised With-profits business.

Where contract boundaries are applied, these contracts are treated as paid-up at the valuation date. The expense and lapse assumptions are reviewed to ensure that they are appropriate to the restricted contract boundary.

Group Protection policies have a contract boundary applied at the end of the current contract term (which typically ranges from 2 to 3 years), as at the end of this term Aviva can reprice the policy to reflect the revised view of the risk.

Within some Term Assurance business, a Global Treatment rider is offered with a limited term independent of the term of the policy. This Global Treatment rider is modelled with the contract boundary ending at the rider term, but the rest of the policy continues to be modelled till end of policy term.

Financial options and guarantees

Where options and guarantees are contract features, a stochastic approach to valuation is used, unless the risk is immaterial or there is insufficient data to calibrate the model. There are a small number of guarantees not modelled within the stochastic model for which the expected cost of guarantees is based on the results for similar products where guarantees are modelled. For some relatively small blocks of business with guaranteed annuity options that are not modelled stochastically, it is assumed that a high proportion of the guarantee is taken up. Where policy guarantees (e.g. unit-linked Guaranteed Fund investment guarantees) mean that persistency is likely to be higher, a lower assumed lapse rate is used to reflect this, and an additional reserve is determined stochastically to reflect the time value of the investment guarantee. A small additional reserve is held to cover options to renew/convert existing protection policies at normal premium rates.

Management actions

As part of the best estimate assumptions, the actuarial and statistical methods used to calculate the technical provisions for participating business take account of future management actions. These actions reflect what management would reasonably expect to carry out in the circumstances of each scenario over the duration of the projection.

A wide range of future management actions is incorporated into the technical provisions. The types of future management actions are not restricted provided they meet the objective, realistic and verifiable standards in Solvency II.

Management actions are typically limited to:

- Changes in asset allocation;
- Changes in regular and final bonus rates;
- Changes to market value reduction factors and surrender bases;
- Changes to the target payout ratio; and
- Changes in assumed distributions from the fund.

The impact of any assumed management actions on other assumptions is taken into account within a certain valuation scenario. In particular, the effects of management actions on policyholder behaviour or on the related expenses are taken into account. Future management actions allow for relevant legal or regulatory constraints.

The Company produces, at least annually, a future management action plan, which is updated and signed off by the Board. This action plan covers a number of areas including:

- The identification of actions that are relevant to the valuation of the technical provisions;
- The identification of specific circumstances in which the actions would or would not be able to be carried out;
- The order in which the actions would be carried out, and the applicable governance requirements;
- Ongoing work required to ensure that the undertaking is in a position to carry out the actions;
- Description of how the actions have been reflected in the calculation of the best estimate liability including a quantitative impact on the best estimate liability; and
- Description of the applicable internal reporting procedures for the actions implemented in the calculation of the best estimate liability.

Basis, methods and assumptions applicable to particular classes of business

Unit-linked business

Unit-linked business is valued as the face value of the units at market bid price, together with allowance for non-unit cash flows, including mortality and other claim benefits, future expenses and policy charges. Allowances are included where appropriate for loyalty bonus and for waiver of premium benefits, permanent health benefits, permanent total disability benefits and guaranteed insurability options.

Non-unit reserves are calculated by projecting cash flows on a monthly basis for each month that the policy is expected to remain in force. Explicit allowance is made for future commission where appropriate. Allowance is also made for the promise that the Company made to policyholders that the charges on certain pensions policies will not exceed 1% p.a. in any future year.

A non-unit reserve is determined along similar lines for unitised With-profits business where the investment liability arises in a With-profits fund, but other policy benefits, charges and expenses arise in the Non-profit funds.

On 7 December 2017 the PRA issued feedback to life insurers expressing a preference for unit liabilities included within technical provisions to be reported within technical provisions as a whole on the Solvency II Balance Sheet. This was not a mandated approach and has no impact on the measurement of Own Funds or of technical provisions. The Company has continued to present the unit liabilities within best estimate liabilities in line with the approach adopted in previous years.

Participating business

The best estimate liability for participating business is the sum of the “With-Profits Benefit Reserve” (“WPBR”) and “Future Policy Related Liabilities” (“FPRL”). Shareholder transfers do not form part of the technical provisions but are required to determine the amount of restricted Own Funds for ring fenced funds (see section E.1.7).

For the majority of participating business, the WPBR is an “asset share” calculated on an individual policy (or increment) basis. The asset share is generally calculated on a retrospective basis and represents an accumulation of premiums plus investment return less charges, claims, and other sources of profit or loss in line with the fund’s rules.

For a small proportion of business, where asset shares are not currently calculated, or where they are unreliable as a starting point for deriving future bonuses, a prospective method is used, such as the bonus reserve valuation (“BRV”). BRVs are the discounted value of future expected benefits and expenses, using risk-free earned and discount rates along with best-estimate assumptions for other basis items such as lapses and mortality.

The present value of the expected costs of any payments in excess of the WPBR is referred to as the FPRL. For the purposes of valuing the FPRL, a stochastic simulation approach is adopted. This covers all guarantee types in the With-profits funds, including:

- Maturity guarantees;
- Guarantees on surrender, including no-MVR guarantees and guarantees linked to inflation;
- Guaranteed annuity options;
- Guaranteed minimum pension (“GMP”) underpin on Section 32 transfers; and
- Expected payments under the Mortgage Endowment Promise.

The same best estimate liability of participating business described above can also be expressed as the sum of the guaranteed benefits plus discretionary benefits. The value of guaranteed benefits represents the value of the minimum benefits that have to be paid out on a contract, whereas the discretionary benefits represent the value of any anticipated future non-guaranteed bonus or final bonus.

Group Protection

For group protection, the total best estimate liability is calculated based on projected cashflows of premiums, benefits and expenses. In addition, the following 3 components are reserved for:

- Premium deficiency reserve
- Pandemic reserve
- Outstanding claims reserve (consisting of 'incurred but not reported' and 'reported but not paid' reserves)

A premium deficiency reserve is recognised when the premium reserve is insufficient to cover the risks associated with the unexpired policies.

A pandemic reserve is set up to represent the asymmetric nature of the pandemic risk.

The incurred but not reported reserve is the claims that have been incurred at the reporting date but have not yet been reported to the insurer. The size of this reserve is estimated based on the past history of claim reporting delays in the portfolio.

The reported but not paid reserve is the claims that have been reported at the reporting date but not yet been paid by the insurer.

The liability for current group income protection claims in payment is the discounted value of future claim payments, with any benefit escalation explicitly allowed for. In addition, claim expenses are valued explicitly for all group income protection contracts.

Ring fenced funds ("RFFs")

The treatment of cash flows between RFFs (e.g. With-profits funds) and other funds is also taken into account. For example:

- Where there is an expense charging arrangement between a With-profits fund and a Non-profit fund the technical provisions in the With-profits fund are on a fees basis and a technical provision in relation to the excess of fees over expenses (typically negative) is held outside the With-profits fund in the Non-profit fund;
- Where With-profits business is written on 100:0 basis and the shareholder is exposed to annual management charges less expenses ("C-E") on this business, the C-E cash flows are reflected in the Non-profit fund and all other cash flows are reflected in the With-profits fund; and
- Where internal reinsurance exists on With-profits policies, which allocate pre-defined sources of surplus between a With-profits fund and a Non-profit fund, the cash flows modelled in each fund will follow the pre-defined formula as defined in the With-profits scheme rules.

The technical provisions take into account all payments to policyholders (and beneficiaries) including future discretionary bonuses consistent with paying out the asset share of the policies, whether or not those payments are contractually guaranteed.

Future cash flows are split into guaranteed and discretionary benefits because the loss absorbing capacity of technical provisions is limited by the technical provisions relating to the future discretionary benefits.

In line with Solvency II requirements, technical provisions exclude payments representing surplus funds. As a consequence, for With-profits business, in line with guidance received from the PRA, only future benefits arising from enhancements that are regarded as Permanent have been assumed in the calculation of the technical provisions.

Reinsurance accepted

Reinsurance accepted is valued in the same way as direct written business using a discounted cash flow approach.

(b) Valuation components**Cash flows in scope**

For life insurance obligations (lines of business 29-32), all cash flows (including any charges related to embedded options) required to settle the insurance liabilities over their lifetime are taken into account.

The table below summarises the main cash flows that are modelled:

| Gross cash in-flows | Gross cash out-flows |
|--|--|
| Future premiums (gross of commissions and policyholder tax). Annual management (and other) charges in unit-linked business. | Benefits including: Claims payments, Maturity benefits, Death and critical illness benefits, Disability benefits, Surrender benefits, Annuity payments, Income protection benefits, Profit sharing bonuses. |
| | Expenses including: Administrative expenses, Investment management expenses, Claims management expenses (direct and indirect), Acquisition expenses including commissions which are expected to be incurred in the future, Renewal commission. Other items which are charged to policyholders (or required to settle the obligations): Taxation |
| Reinsurance cash in-flows | Reinsurance cash out-flows |
| Reinsurance recoveries in respect of gross claims/benefit payments. Reinsurance commissions including profit commissions. | Future reinsurance premiums (including adjustment premiums and reinstatement premiums). Commission. Reinsurance refunds. |
| Floating leg payments in respect of longevity swaps. | Fixed leg payments in respect of longevity swaps. |

Future premiums

Future premiums are projected using persistency assumptions and contract boundaries appropriate to each class of business. Premium levels will also reflect the impact of other decrements such as mortality.

Death and other claim benefits

Death and other claims benefits are projected using decrements appropriate to each class of business, including persistency, mortality and morbidity.

For deferred annuity products, the value of any benefit payable on death during the deferred period is added to the value of the deferred annuity. For deferred annuities continued beyond the normal pension age, the cash available at the normal pension age is accumulated in line with policy conditions.

For contracts which have fixed benefit increases the valuation provides for these increases within the discounted cash flow method.

For group protection, the main insured benefit value, due to mortality or morbidity, is modelled based on the underwriting view i.e., the underwriting claims ratio x the premium. This approach has been adopted given that the modelling is done at a scheme level where standard decrement assumptions like mortality rate or morbidity rate cannot be applied.

Income protection benefits

In individual income protection, the benefit inceptions and terminations are explicitly modelled.

In group income protection, the active members are modelled at a scheme level with the total benefit value being modelled, based on the underwriting view i.e., the underwriting claims ratio x the premium. The members who are already 'in claim' are modelled at a member level and have the termination decrements applied explicitly in benefit cash flow projections.

Annuity payments

The conventional immediate and deferred annuity business is valued by discounting future benefit payments with an allowance for mortality, including future improvements in mortality. Where the benefits are linked to inflation, a market implied inflation curve is used in projecting the future annuity payments, applied in line with policy terms and conditions.

Tax

The best estimate liability includes tax payments charged to policyholders or those which are required to settle the insurance liabilities. This includes the Basic Life Assurance and General Annuity Business ("BLAGAB") tax on investment income less expenses ("I-E") but tax on company profits is not included. Policyholder tax is modelled as a separate cash flow rather than implicitly.

For most lines of business, future tax on I-E is based on a deterministic model. For the With-profits participation business, where a stochastic liability model is used, the tax calculation is based on the average I-E over a range of scenarios.

Reserves are established (or credit is taken) for charges to funds reflecting tax on unrealised gains (or losses) for unit-linked and with-profits business as part of the unit-linked and with-profits liabilities.

Options and guarantees

The most material options and guarantees are in the Company's With-profits funds. The valuation methodology for these is covered in section (a) above.

Reinsurance cash flows

The valuation of reinsurance cash flows is not a component of technical provisions. However, the value is included within Reinsurance Recoverables in the balance sheet (see section D.1.9).

(c) Transitional arrangements (unaudited)

Insurers need to hold capital to ensure that they can pay claims and their obligations in extreme scenarios. At the end of 2015 the regulations governing this changed from the previous Solvency I capital regulations to new Solvency II capital regulations. In order to avoid unnecessary disruption to insurers from 'transitioning' between these two capital regimes, a number of transitional arrangements were created, including the TMTP. The unrestricted TMTP applies to all shareholder business within UKLAP written pre 1 January 2016. The Company has approval to exclude the contribution of homogeneous risk groups of With-profits funds that have a negative contribution to the legal entity's TMTP.

The TMTP is applied as a reduction to the Solvency II technical provisions and applies over a period of 16 years starting from 1 January 2016, with its use requiring approval from the PRA. A mandatory recalculation of the TMTP is required at least every two years, the last of which was at 31 December 2021. In the absence of any non-mandatory recalculations the TMTP would then run-off linearly between the mandatory recalculation dates, based on an end date of 31 December 2031. The TMTP is also expected to be recalculated if there is a material change in risk profile. There was a material change in risk profile during the first half of 2022 due to movements in risk free rates leading to a recalculation of the TMTP at 30 June 2022. The TMTP value included in the 31 December 2022 Technical Provisions is based on the value recalculated at 30 June 2022 run-off by 6 months.

A further recalculation has occurred at 31 December 2022, due to movements in risk free rates during the second half of 2022, which is expected to be included in the 31 March 2023 Technical Provisions.

The calculation is done in two parts:

1. An unrestricted TMTP is derived for business written prior to 1 January 2016 as the difference in the following two amounts:
 - The technical provisions on a Solvency II basis, including the impact of the MA and VA where applicable, and after deduction of amounts recoverable from reinsurance at the valuation date; and
 - The Solvency I Pillar 2 Individual Capital Assessments ("ICA") technical provisions, after deduction of the amounts recoverable from reinsurance.
2. If necessary the TMTP is restricted to ensure that the Solvency II financial resources (defined as the sum of the Solvency II technical provisions and other non-technical liabilities after application of the unrestricted TMTP and the SCR) are no lower than the most onerous of the Solvency I Pillar 1 financial resources and Solvency 1 Pillar 2 financial resources (defined as the sum of the technical provisions, other non- technical liabilities and SCR).

The restriction in part 2 above does not apply following the recalculation of the TMTP at 30 June 2022 and 31 December 2022.

The impact of removing the TMTP is set out below:

| 31 December 2022 (£m) | Including TMTP (A) | Setting TMTP to zero (B) | Impact of removing TMTP (C) = (B) - (A) |
|--------------------------------|-----------------------|--------------------------------|---|
| Technical Provisions | 222,463 | 224,531 | 2,067 |
| Basic Own Funds | 10,068 | 8,502 | (1,565) |
| Eligible Own Funds to meet SCR | 10,068 | 8,502 | (1,565) |
| SCR | 5,619 | 6,121 | 502 |
| Eligible Own funds to meet MCR | 9,727 | 8,161 | (1,565) |
| MCR | 1,663 | 1,670 | 6 |

The impact from the TMTP on SCR arises because the TMTP reduces liabilities, which generates a corresponding deferred tax liability. The SCR represents a 1-in-200 loss scenario, and may be reduced by the deferred tax asset created by the loss to the extent that there are sufficient liabilities to offset the loss. The TMTP deferred tax liability can increase the tax relief on the SCR, and therefore removal of the TMTP may increase the SCR.

Within technical provisions, the TMTP is applied to the risk margin first. Where the total TMTP exceeds the total risk margin, the excess is allocated to the best estimate liability in proportion to the contribution of each line of business to the total deduction, as was the case at 31 December 2022.

D.2.2.2 Assumptions

The definition of a "best estimate" assumption is one that represents the expected outcome from the range of possible outcomes for future experience of that assumption and is reasonable and realistic with no deliberate margins for prudence included. The table below summarises the main assumptions used in the calculation of the best estimate liability:

| Economic assumptions | Non-economic assumptions |
|--|---|
| Risk-free rates | Assured mortality |
| Matching adjustment | Critical illness (morbidity) rates |
| Volatility adjustment | Annuitant mortality |
| Reinsurance counterparty default allowances | Persistency |
| Expense inflation | Guaranteed annuity option take-up rates |
| Tax | Expenses |
| Asset volatility and correlations (With-profits business only) | Income protection inception and termination rates |
| Benefit inflation | |

Economic assumptions are reviewed quarterly while non-economic assumptions are reviewed at least on an annual basis to ensure that these remain appropriate, relevant and realistic. The choice of assumptions is validated through experience analyses and, where available and appropriate, benchmarked against external sources.

Approximations are employed where credible data is unavailable, predominantly for small blocks of business or assumptions considered to be relatively immaterial.

(a) Economic assumptions

The technical provisions are valued using the basic risk-free rate curve applicable for the currency of the liabilities. The basic risk-free rate curve incorporates a "credit risk adjustment" (CRA) for non-GBP currencies. A CRA deduction is no longer made for the GBP currency following the move to a SONIA based swap curve. The discount rate is then increased by a VA or MA for some categories of business. The MA calculation requires assumptions for fundamental spreads which are published by the PRA.

Risk free discount rates

The GBP and EUR risk-free rates at key durations, used to value the technical provisions at full year 2022 are stated in the table below. The figures shown below allow for a CRA of 10bps on EUR.

| Risk-free rates (bps) | 1 year | 5 years | 10 years | 15 years | 20 years | 40 years |
|-----------------------|--------|---------|----------|----------|----------|----------|
| GBP | 446 | 406 | 371 | 362 | 354 | 315 |
| EUR | 318 | 313 | 309 | 302 | 276 | 285 |

Where swaps do not exist, or are not sufficiently liquid or reliable from a certain point, the basic risk-free interest rate is extrapolated in a smooth progression. EIOPA has prescribed by currency the entry points for extrapolation, the duration to convergence and the ultimate forward rate, as shown in the table below.

| Currency | Entry point for extrapolation of risk-free rates (years) | Duration to convergence to ultimate forward rate (years) | Ultimate forward rate pa |
|----------|--|--|--------------------------|
| GBP | 50 | 90 | 3.45 % |
| EUR | 20 | 60 | 3.45 % |

Volatility adjustment

The VA is intended to reflect temporary distortions in spreads caused by illiquidity in the market or extreme widening of credit spreads. The VA reduces technical provisions by increasing the discount rate used to calculate the best estimate liability. VAs are prescribed by the PRA on a currency and country basis.

The PRA has approved the application for the VA to be applied in the Company. The VA is applied to all those liabilities where a MA is not applied, with the exception of unit-linked business and business originally written in the FLP heritage company, where no application was made.

The VAs used at 31 December 2022 are shown in the table below.

| Volatility adjustment (bps) | 31 December 2022 |
|-----------------------------|------------------|
| GBP | 29 |
| EUR | 19 |

The impact of Long-Term Guarantees and Transitional measures is disclosed in QRT S.22.01.04 using a step-by-step approach. The impact of setting the VA to zero is set out below:

| 31 December 2022 (£m) | Including volatility adjustment (A) | With volatility adjustment set to zero (B) | Impact of removing volatility adjustment (C) = (B) - (A) |
|----------------------------------|-------------------------------------|--|--|
| Technical Provisions (unaudited) | 222,463 | 222,796 | 333 |
| Basic Own Funds | 10,068 | 10,065 | (3) |
| Eligible Own Funds to meet SCR | 10,068 | 10,065 | (3) |
| SCR (unaudited) | 5,619 | 5,753 | 134 |
| Eligible Own Funds to meet MCR | 9,727 | 9,724 | (3) |
| MCR | 1,663 | 1,666 | 3 |

Note that the quantification of the impact of setting the VA to zero includes the MA but is after the removal of the TMTPs.

Matching adjustment

The MA is an increase applied to the risk-free rate used to value insurance liabilities where the cash flows are relatively fixed (e.g. no future premiums or surrender risk) and are well matched to assets that are intended to be held to maturity and have cash flows that are also

relatively fixed. The intention is that, if held to maturity, the business can earn the additional yield on these assets that relates to illiquidity risk.

The MA used for 31 December 2022 is shown in the table below. The MA shown below applies to technical provisions net of external reinsurance retained in the MA portfolio.

| Matching adjustment (bps) | UKA |
|---------------------------|-----|
| Bps | 115 |

The MA is broadly derived from the spread over risk-free on the assigned portfolio of assets, net of an allowance for default and downgrade (known as the fundamental spread). The fundamental spreads applied are prescribed by the PRA.

The table below shows the asset classes that are considered to be eligible for the MA portfolio, with the market value of those assets that are used to back liabilities that are valued with a Matching Adjustment. This includes both 'Component A' and 'Component B' assets. Only Component A assets are used in the derivation of the MA, however Component B assets are required to cover the additional liability that arises due to the allowance for downgrade risk of the Component A assets. The table below includes the deposit withheld assets in respect of the All reinsurance arrangement.

| 31 December 2022 Market Value (£m) | Total eligible assets UKA |
|---|------------------------------|
| UK Government bonds | 5,528 |
| Overseas Government & Supranational bonds | 1,874 |
| Corporate bonds | 18,577 |
| Commercial Mortgages | 6,169 |
| PFI loans & Infrastructure | 7,154 |
| Equity release fixed rate note | 7,130 |
| Other | 404 |
| Total | 46,836 |

Equity release mortgage assets meet the criteria for inclusion within the MA when they are securitised into an internal SPV, which then issues a fixed coupon note (equity release fixed rate note) secured by those assets to the MA portfolio of the Company. The equity release mortgage assets that have been restructured in this way do not meet the IFRS de-recognition criteria and are therefore still presented on the IFRS balance sheet (with the securitised notes not recognised under IFRS).

Commercial and healthcare mortgages, PFI infrastructure loans and the equity release fixed rate notes eligible for inclusion within the MA are assigned a fundamental spread based on an internal credit rating set in accordance with the internal rating methodology framework.

The impact of Long-Term Guarantees and Transitional measures is disclosed in QRT S.22.01.04 using a step-by-step approach. The quantification of setting the MA to zero is set out below:

| 31 December 2022 (£m) | Including matching adjustment (A) | With matching adjustment set to zero (B) | Impact of removing matching adjustment (C) = (B) - (A) |
|----------------------------------|--------------------------------------|--|--|
| Technical Provisions (unaudited) | 222,463 | 226,064 | 3,601 |
| Basic Own Funds | 10,068 | 6,555 | (3,513) |
| Eligible Own Funds to meet SCR | 10,068 | 6,555 | (3,513) |
| SCR (unaudited) | 5,619 | 8,851 | 3,232 |
| Eligible Own Funds to meet MCR | 9,727 | 6,214 | (3,513) |
| MCR | 1,663 | 2,363 | 699 |

Note that the quantification of the impact of setting the MA to zero is after the removal of TMTPs and the setting of the VA to zero. In practice the impact may be lower if the Company were able to apply the VA in place of the MA should the latter no longer be available. Additionally the impact of removing the MA quoted above is smaller than on a Aviva Group basis due to the impact of internal reinsurance.

Reinsurance counterparty default allowances

Reinsurance counterparty default risk for both internal and external counterparties is allowed for in calculating the best estimate liability. Reinsurance counterparty default in the best estimate liability depends on:

- the probability of default based on the credit rating of the counterparty and the year of projection; and
- the recovery rate, which is a constant over time, but varies by reinsurer.

Expense inflation

Future expense inflation is based on a future inflation RPI curve. Expenses are generally assumed to increase in line with RPI.

Investment management expenses are assumed to vary in line with the projected change in funds under management.

Tax

The tax assumptions used at 31 December 2022 are shown in the table below.

| Parameter | 31 December 2022 |
|----------------------------------|---------------------|
| Corporation tax (current year) | 19 % |
| Corporation tax (future profits) | 25 % |
| Policyholder tax | 20 % |

For BLAGAB business only, allowance is made for policyholder taxation, applying a rate of taxation of 20% to relevant cashflows within the BEL. The corporation tax rate for future shareholder transfers is set at 25% at 31 December 2022 (25% at 31 December 2021).

Asset volatility and correlations

The following volatility assumptions are required to value the With-profits participation business in the stochastic model:

- Equity volatility - Equity volatility is calibrated to equity implied volatility. The approach to calibration is to capture the volatility of the longest available option term;
- Bond volatility - The model allows for the extra volatility in corporate bonds compared to that in Government bonds as a result of credit risk; and
- Property volatility - Property is modelled as an equity type asset using a constant volatility model.

Correlations between asset returns are targeted to best estimate assumptions. These targets have been derived by considering historical behaviour.

(b) Non-economic assumptions

Mortality/morbidity assumptions

The mortality and morbidity assumptions define the proportion of policyholders expected to die or experience a critical illness each year. Assumptions comprise:

- A percentage of base table mortality rates which define the probability of policyholders claiming over the one-year period following the start of the model projection; and
- Projection factors which determine the change in base rates in future years of the projection. For mortality, this is generally a reduction in future years.

For Accelerated Critical Illness ("ACI") models, a single assumptions set is used for claims due to critical illness or death. For Stand Alone Critical Illness ("SACI"), the assumption is for claims due to critical illness only. For both ACI and SACI a future deterioration factor (rather than an improvement factor) is currently used.

The primary source of data for setting base assumptions is analysis of the Company's own experience. Publicly available data from the Continuous Mortality Investigation ("CMI") on mortality experience across the industry is also considered. The experience analysis compares actual claims over the investigation period with those predicted by the assumptions that applied for that period. The analysis is carried out for sub-divisions of the business and is supplemented by the inclusion of exposure figures to indicate the credibility of the results.

The base tables used are typically the industry standard Txx16 (2021: Txx08) tables for life protection policies, ACxx16 (2021: ACxx08) tables for critical illness protection policies, ELT15 tables for funeral plans and Axx00 tables for savings policies (unchanged from 2021). Different tables apply to males and females and to smokers and non-smokers for products where the smoker status is known.

For Group Protection business mortality and morbidity assumptions reflect scheme underwriting.

Annuitant mortality

Recent mortality experience is regularly reviewed in order to set assumptions. The investigations carried out cover the majority of the Company's annuity business and are performed on both a lives and an amounts basis. Base mortality has been set based on 2015-2019 experience inclusive. 2020 and 2021 experience has been ignored due to distortions caused by Covid-19.

Annuitant mortality assumptions are required for both deferred annuity and in-payment annuity business and fall into three main categories:

- base tables;
- adjustments to base tables; and
- future improvements.

Base tables describe the current levels of mortality. The base tables are different for males and females and may include an adjustment for anti-selection that varies by individual year of entry.

For most individual annuities in payment these are expressed as a percentage of the 2016 Series of pension tables published by the CMI. Unlike the previous "08" series, the CMI has published different tables for the "16" Series for various sources of business. For the largest portfolio of pensions annuity business the tables used are PMA16_IND and PFA16_IND, which include experience from all individual annuities (internal and external), consistent with this business arising from both internally vesting annuities and external annuities. For most other blocks of business the tables used are PMA16_IND_INT and PFA16_IND_INT, consistent with the majority of this business being derived from internally vesting annuities and with these tables providing a better overall fit to the experience of this business than the "IND" tables.

Adjustments to base tables include allowances for policyholder specific factors.

For the largest portfolio of pensions annuity business transferred from, the underlying mortality assumptions for Males are 104.1% of PMA16_IND with base year 2016 (unchanged from 2021) ; for Females the underlying mortality assumptions are 100.3% of PFA16_IND with base year 2016 (unchanged from 2021).

For all the main portfolios of annuities, improvements are based on 'CMI_2021 (S=7.25) Advanced with adjustments' (2021: 'CMI_2019 (S=7.25) Advanced with adjustments') with a long-term improvement rate of 1.5% (2021: 1.5%) for males and 1.5% (2021: 1.5%) for females. An allowance has been made to allow for greater mortality improvements in the annuitant population relative to the general population on which CMI_2021 is based using "Parameter A", which is set to 0.15% for males and 0.20% for females (unchanged from 2021). The long-term improvement rates are assumed to taper to zero between ages 85 and 110 (2021: taper between ages 90 and 115). Some further

adjustments have been made to the CMI_21 tables for YE22 but these have a small impact in aggregate (adjustments unchanged from 2021).

For the largerst portfolio of pension annuity business, year-specific adjustments are made to allow for potential selection effects due to the development of the Enhanced Annuity market and covering possible selection effects from pension freedom reforms.

The portfolio also includes some enhanced annuities. For this business, allowance is also made for higher mortality on impaired lives (based on reinsurer loadings and with an assumption for run-off).

For the largest portfolio of BPA business, the mortality assumptions are derived from internally generated tables produced from 'Club Vita' data. The 'Club Vita' data covers a wide variety of occupational pension schemes in the public and private sector. The assumptions include adjustments to the base tables for factors such as financial usage, council tax band, region, size of pension and early retirement factors.

Persistency assumptions

Recent persistency experience is reviewed annually to assist with setting assumptions for the continuation of premiums being paid by policyholders and for the number of policies remaining in force. In addition, consideration is given to factors that may cause future experience to differ from past experience, such as changes to pensions regulations.

Assumptions are set by product, and may vary by duration, age, sales channel and size of policy.

Lapse rate assumptions for unit-linked pensions business combine transfers and retirements.

Guaranteed annuity option take-up rates

The guaranteed annuity option ("GAO") take-up rates define the proportion of policyholders expected to exercise the guaranteed annuity option at maturity. The take-up rates are set based on current experience and are assumed not to change in the light of future economic conditions, as the guarantees are significantly in the money already.

Expense assumptions

The best estimate liability for future expenses is a combination of the following elements:

- Administrative expenses;
- Claims management expenses/handling expenses;
- Acquisition expenses, but only to the extent that they are incurred on existing business after the valuation date;
- Commissions which are expected to be incurred in the future;
- Reserves for certain exceptional and project costs; and
- Investment management expenses, which are expressed as a percentage of funds under management.

These allowances cover all expenses arising within the Company and from the Company's management services company: UK Life Services Limited ("UKLS"), and also in respect of the outsourcing agreements on certain business between the management services company and the outsourcing companies, and the investment management agreements with Aviva Investors.

It is assumed that the full cost incurred by the service company in managing the policies will be charged to the Company, so the best estimate expenses is based on an estimate of the underlying costs to the service company.

For With-profits policies, it is assumed that a defined charge in line with a Management Services Agreement is charged to the With-profits fund, and the difference between the defined charge and the underlying cost is charged to the Non-profit fund.

Other assumptions

Individual Income Protection

Income protection is modelled using claim inception rates based on CMI12 and IP11 tables (2021:CMI12 and IP06). Recovery rates are based CMIR 12 (2021: CMIR 12). Inception and recovery rates have adjustments based on the historical experience of the portfolio for appropriate rating factors.

Events not in data ("ENID")

The term ENID refers to any events not deemed to be captured by the data, which need to be allowed for within the best estimate calculation to allow for the uncertainty in the future cash flows. ENIDs are considered both at line of business level, and at portfolio level with allocations to lines of business, depending on the scenario being considered.

The Company considers ENID through either adjusting the best estimate assumptions to ensure the likely impact of the event is included or using a scenario approach where they are expected to be material. Expert judgement is applied to determine the expected impact on future experience. For annuity business, it was concluded that no adjustment to best estimate assumptions was required. Climate change was also considered for annuities but no adjustment was made as it was considered that doing so may be spurious given the uncertainties in the improvement basis as a whole.

(c) Consistency of assumptions

The calculation of the best estimate liability requires a number of projection assumptions to be used. These assumptions are consistently reflected in both the valuation of technical provisions and the calculation of the SCR where necessary.

There are also a number of modelling dimensions across which consistency is ensured. These include using the same asset and liability data for both the SCR calculation and the technical provision valuation and ensuring that the calibrations and calculations used are consistent across the Internal Model. There are a number of specific areas of consistency:

- Insurance risk factor calibrations are often based on estimates of uncertainty, for example predicting future mortality rates for longevity risk. The same methodology is used to calibrate this uncertainty as is used to calculate the best estimate of liabilities – i.e. reflecting the base mortality levels and future mortality improvement factors; and
- In order to value the reinsurance recoverables for technical provisions, assumptions are set for the rate of external reinsurer counterparty default. These assumptions are aligned with the counterparty default rates used in the credit portfolio model to calculate the probability of default for credit risk exposures.

D.2.2.3 Risk margin methodology (unaudited)

The risk margin is calculated for the Company using a Cost of Capital (“CoC”) approach allowing for diversification between lines of business and is on a net-of-reinsurance basis. The CoC rate is the cost in excess of the risk-free rate, to a third party taking over the liabilities, of raising and holding capital to support the non-hedgeable risks over the lifetime of the business. The same CoC rate is used for all insurance companies and is prescribed by the PRA at 6% per annum.

The risk margin is underpinned by the non-hedgeable SCR (“nhSCR”). This takes into account the following risks:

- Life underwriting risk;
- Health underwriting risk;
- Counterparty default risk with respect to reinsurance contracts, arrangements with debtors and any other material exposures which are closely related to the insurance obligations; and
- Operational risk.

The Company has no material non-hedgeable market risk to include.

The rate used to discount the projected nhSCR is the basic risk-free rate with no allowance for volatility adjustment or matching adjustment.

Projection of the SCR

The Company adopts a mix of approaches to non-hedgeable risk projections. For some risks the projected run-off is exact and no approximation is made. For others the Company makes use of risk carriers, where a suitable statistic is chosen which can be readily projected and used as a proxy.

The projected risks are then aggregated using a correlation matrix approach at each future time period to derive the nhSCR. Adjustments are made to reflect the differences between the correlation matrix approach and the Internal Model.

Diversification

The risk margin allows for diversification as follows:

- Diversification is taken into account at the Company level;
- No diversification is assumed between RFFs and the rest of the business; and
- Diversification between the MA portfolio and the rest of the non-MA business within that fund is permitted.

Loss absorbing capacity

The loss absorbing capacity of technical provisions assumed in the calculation of the nhSCR is consistent with the loss absorbing capacity of technical provisions assumed in the calculation of the SCR. No allowance for the loss absorbency of deferred taxes is included in the risk margin.

Allocation of the risk margin to Solvency II lines of business

The risk margin is allocated to line of business using an approximate approach.

D.2.2.4 Simplified methods

Simplified methods are used only where it would be disproportionate to apply an accurate method and where the impact on the technical provisions is not material. Examples of where simplifications have been applied are:

- For options and guarantees that are considered to be immaterial, alternative methods such as closed form approaches or a series of deterministic projections are used to calculate the liability. This is based on the results for similar products where guarantees are modelled stochastically and is a proportionate approach given materiality considerations;
- For some older products, subsidiary benefits are ignored where they are not likely to increase the liability, e.g. rider benefits paid for by mortality charging, where the mortality charge exceeds the expected cost, even in a stress scenario; and
- Manual adjustments to results calculated by the main valuation systems often involve approximations. Manual adjustments are usually made where a product or product feature is difficult to model, or where there is a data deficiency.

Other simplifications have already been mentioned, e.g. grouping of data to value With-profits guarantees.

D.2.2.5 Material changes in assumptions

This section highlights the most material changes to assumptions made in the calculation of technical provisions compared to the previous reporting period.

Annuitant Mortality

The impact of mortality for annuitant contracts on long-term business relates primarily to the UK. In 2022, there has been a reduction in BEL due to longevity assumptions arising from:

- Updates to the rate of mortality improvements for a change to the long-term-rate rate used to taper improvements;

- Updates to mortality improvements moving onto the latest CMI_2021 model; and
- Updates to base mortality to reflect methodology and process refinements on BPA business.

Of these, the change to the taper was most significant. In total, these changes reduced the best estimate liability, net of reinsurance recoverables, by £361 million.

Persistence

Persistence assumptions have been updated based on current experience, as described in section D.2.2.2.

These changes reduced the best estimate liability, net of reinsurance recoverables, by £44 million.

Expenses

There has been a reduction in reserves for maintenance expenses arising from:

- Actual maintenance costs in 2022 have increased by much less than the assumed inflation rates.

This is offset by an increase in the provision for future company costs to exceed the assumed per policy allowances in the valuation models. This provision allows for the effects of recent high inflation which have not yet fully fed into the per policy expense assumptions (which are based on 2022 costs).

The overall impact of expense assumption changes is a reduction in best estimate liability of £99m.

D.2.3 Value of technical provisions by line of business

The following table sets out the technical provisions for the Company, split by Solvency II lines of business, as detailed in Annex I to the Level 2 Delegated Acts. Note that Solvency II line of business numbers 1 to 28 refer to non-life insurance business and are not applicable to the Company. The best estimate liability and the risk margin are provided separately. These figures are gross of reinsurance and after the impact of transitional measures (included in the risk margin) on technical provisions.

| # | Line of Business (YE2022 £m) | Technical provisions | Best Estimate ¹ | Risk Margin ¹ |
|----------|-------------------------------------|----------------------|----------------------------|--------------------------|
| 29 | Health insurance | 622 | 622 | — |
| 30 | Ins with profit participation | 27,088 | 26,834 | 255 |
| 31 | Index-linked and unit-linked | 140,023 | 139,857 | 167 |
| 32 | Other life insurance | 52,912 | 52,835 | 77 |
| 34 | PPOs not health | 76 | 76 | — |
| D | Life insurance obligations | 220,721 | 220,222 | 498 |
| 35 | Health reinsurance | 3 | 3 | — |
| 36 | Life reinsurance | 1,740 | 1,739 | 2 |
| E | Life reinsurance obligations | 1,743 | 1,741 | 2 |
| | Total | 222,463 | 221,964 | 500 |

1. Risk margin and the reduction in best estimate liabilities relating to the transitional measures on technical provisions as set out in D.2.2.1 are unaudited.

The methodology and assumptions used to calculate the technical provisions are set out in section D.2.2 above.

D.2.4 Comparison of Solvency II technical provisions to IFRS technical provisions

Solvency II technical provisions are comprised of two components – the best estimate liability and the risk margin. By contrast, the IFRS provisions are a single calculation of liabilities, with appropriate margins for risk included within the assumptions and/or methodology. There is also a different approach to discounting.

There are specific differences in the methods used relating to the risk margin, contract boundaries, non-unit reserves and Unallocated Divisible Surplus (“UDS”). The material differences between the assumptions used relate to discount rates, mortality rates, lapse rates and expense assumptions. These differences are outlined in this section.

The following table summarises the Company's gross technical provisions split by Solvency II line of business. The Solvency II technical provisions are shown gross of reinsurance and include the impact of any transitional measures.

| # | Insurance liability | Best Estimate Liability ¹ | Risk Margin (RM) ¹ | Solvency II | IFRS | Difference |
|-------------------------|-------------------------------------|--------------------------------------|-------------------------------|----------------------|----------------------|----------------|
| As at 31. December 2022 | | (BEL) | | technical provisions | technical provisions | |
| | | £m | £m | £m | £m | £m |
| 29 | Health insurance | 622 | — | 622 | 1,151 | (530) |
| 30 | Insurance with profit participation | 26,834 | 255 | 27,088 | 28,576 | (1,487) |
| 31 | Index-linked and unit-linked | 139,855 | 167 | 140,022 | 143,648 | (3,625) |
| 32 | Other life insurance | 52,835 | 77 | 52,912 | 54,169 | (1,258) |
| 33 | PPOs not health | 76 | — | 76 | 79 | (3) |
| D | Life insurance obligations | 220,222 | 498 | 220,719 | 227,623 | (6,903) |
| 34 | Health reinsurance | 3 | — | 3 | 5 | (2) |
| 35 | Life reinsurance | 1,739 | 2 | 1,741 | 1,723 | 18 |
| E | Life reinsurance obligations | 1,742 | 2 | 1,744 | 1,727 | 15 |
| | | | | | | |
| | Total | 221,964 | 500 | 222,463 | 229,351 | (6,887) |

¹ Risk margin and the reduction in best estimate liabilities relating to the transitional measures on technical provisions as set out in D.2.2.1 are unaudited.

Key areas of difference between the methods used to calculate Solvency II technical provisions and the methods used to calculate IFRS technical provisions are:

IFRS margins

Under IFRS, explicit margins for uncertainty are added to various best estimate assumptions including discount rates, mortality rates, lapse rates, expense assumptions and reinsurance counterparty default rates. The key exception is participating business. Margins for uncertainty are not included in the Solvency II best estimate liability. This results in a decrease in Solvency II best estimate liabilities relative to IFRS technical provisions in respect of this adjustment.

Treatment of With-profits business

Under IFRS, assets in excess of liabilities of a With-profits fund are held as a separate liability called the UDS, which is not classified as part of IFRS technical provisions. Under Solvency II, a proportion of the UDS is implicitly included within the best estimate liability. This results in an increase in Solvency II best estimate liabilities relative to IFRS technical provisions in respect of this adjustment.

Under IFRS, enhancements to asset shares that the Company expects to pay in order to treat policyholders fairly are included in liabilities, together with consequent impacts on guarantee costs, irrespective of whether the enhancement is classified as 'permanent' under Solvency II. Neither IFRS nor Solvency II liabilities include the value of future shareholder transfers. This results in a decrease in Solvency II best estimate liabilities relative to IFRS technical provisions in respect of this adjustment.

These differences are most relevant to line of business 30 (Insurance with profit participation).

Treatment of unit-linked business

Under IFRS, the technical provisions for unit-linked business are based on current unit value, plus an allowance for non-unit cash flows, but only where this would increase the technical provisions. Under Solvency II, the technical provisions are lower than the unit value reflecting the profits expected to emerge in respect of future management charges expected to be earned from existing business. This results in a decrease in Solvency II best estimate liabilities relative to IFRS technical provisions in respect of this adjustment.

This is most relevant to line of business 31 (index-linked and unit-linked).

Discount rates

The Solvency II best estimate liability is valued using a risk-free rate curve with an allowance for an MA or VA where applicable.

Following guidance from the PRA, the Solvency II best estimate liabilities for reinsured business in matching adjustment portfolios are discounted at a risk free rate. This increases gross of reinsurance best estimate liabilities, with an equal increase to the reinsurance asset, thus have no impact on best estimate liabilities net of reinsurance.

For non-participating life insurance contracts, IFRS technical provisions are valued using a valuation interest rate which reflects the yields available on the underlying assets, with an allowance for credit risk based on internal analysis and an additional margin for adverse deviation.

No distinction is made for reinsured business in the IFRS valuation interest rate. This results in an increase in gross Solvency II best estimate liabilities relative to gross IFRS technical provisions in respect of this adjustment.

Contract boundaries

Solvency II technical provisions are subject to contract boundaries for certain product types, such as unit-linked savings contracts with no (or limited) insurance risk or material financial guarantee. This means that future premiums are ignored for regular premium unit-linked contracts where contract boundary conditions are applied and there is no obligation for the policyholder to pay future premiums. IFRS

technical provisions are not subject to the same restrictions. This results in an increase in Solvency II best estimate liabilities relative to IFRS technical provisions in respect of this adjustment.

This is most relevant to line of business 31 (Index-linked and unit-linked).

Risk margin

In addition to the best estimate liability, Solvency II technical provisions include a risk margin. This is analogous to the additional margins held under IFRS to cover uncertainty.

D.2.5 Level of uncertainty in value

Set out below are the main areas of uncertainty over the calculation of liabilities.

Life insurance technical provisions

The best estimate liability corresponds to the probability-weighted average of future cash flows, taking account of the time value of money using the relevant risk-free interest rate term structure, and is derived using policyholder data, cash flow models and a set of assumptions.

All estimates are based on management's knowledge of current facts and circumstances; assumptions based on that knowledge; and their predictions of future events and actions. Actual results may differ from those estimates, possibly significantly. The list below sets out the estimates and assumptions that are considered particularly susceptible to valuation uncertainty:

- Fluctuation in the amount and/or timing of claims events, e.g. when estimating the length of time for which an annuity will be paid. This requires a projection of annuitant mortality rates in excess of 20 years into the future which cannot be done with certainty;
- Changes in the value of an index/market values used to determine claims amounts, e.g. estimating future market values of the assets backing the With-profits asset share liabilities; and
- Uncertainty in policyholder behaviour, e.g. for estimating lapse rates for different policy types and for different durations of a policy.

The best estimate liability assumptions are governed by a rigorous process, underpinned by actuarial judgement and peer review. The scope of assumption review papers includes a consideration of the degree of uncertainty inherent in the assumptions being reviewed.

Data governance and model governance standards are in place, which help to ensure that the cash flow models used to calculate technical provisions, and the data which is used within that calculation, are fit for purpose and are managed under appropriate change control processes.

The cash flow projection models which are used to determine the best estimate liability are subject to an ongoing program of baselining, to reproduce the model's results from first principles, taking into account any information obtained from policy documents and operational procedures.

Guarantees on long-term savings products

As a normal part of operating activities, the Company has written contracts that provide guarantees and options for policyholders, including interest rate and inflation protection guarantees, in respect of certain long-term insurance and investment products. In providing these guarantees and options, the Company's capital position is sensitive to fluctuations in financial variables including interest rates, inflation, property values and equity prices. Interest rate guaranteed returns, such as those available on guaranteed annuity options, are sensitive to interest rates falling below the guaranteed level, should they currently be above that level. Other guarantees, such as maturity value guarantees and guarantees in relation to minimum rates of return, are sensitive to fluctuations in the investment return below the level assumed when the guarantee was made.

Regulatory compliance

The Company's insurance business is subject to dual local regulation, directly authorised by both the PRA (for prudential regulation) and the FCA (for conduct regulation). Between them, the PRA and FCA have broad powers including the authority to grant, vary the terms of, or cancel a regulated firm's authorisation; to investigate marketing and sales practices; and to require the maintenance of adequate financial resources.

The Company has compliance resources to respond to regulatory enquiries in a constructive way, and take corrective action when warranted. However, all regulated financial services companies face the risk that their regulator could find that they have failed to comply with applicable regulations or have not undertaken corrective action as required.

The impact of any such finding could have a negative impact on the Company's reported results.

D.3 Other liabilities

Liabilities have been valued according to the requirements of the Solvency II directive and related guidance. The basis of the Solvency II valuation principle is the amount for which the liabilities could be transferred or settled between knowledgeable willing parties in an arm's length transaction.

A description of the basis of valuation under Solvency II along with valuation differences between the Solvency II bases and the IFRS financial statements, by liability class, is provided below.

D.3.1 Provisions other than technical provisions

Under Solvency II and IFRS, provisions are valued using expected cash flows discounted, where the effect of the time value of money is material, using a pre-tax discount rate (or rates) that reflects current market assessments of the time value of money and those risks specific to the liability that have not been reflected in the best estimate cash flows.

D.3.2 Deferred tax asset and liabilities

Deferred tax for Solvency II valuation purposes is determined in accordance with IAS 12 principles (as adapted for Solvency II by the EU Directive, Delegated Regulation and Guidance, and the PRA Supervisory Statement SS2/14). Deferred tax is calculated on 'temporary differences' between the economic value of assets or liabilities on the Solvency II balance sheet and their tax base.

Deferred tax assets may be recognised separately on the Solvency II balance sheet in cases where there are net deferred tax assets after offset against corresponding deferred tax liabilities, or where deferred tax assets cannot be so offset. This is subject to the deferred tax assets meeting the criteria for recognition, in accordance with IAS 12 principles (adapted as described above).

At 31 December 2022 the Company had deferred tax assets of £341million (£nil at 31 December 2021) which cannot be offset against deferred tax liabilities.

Deferred tax balances in the Solvency II balance sheet differ from those recognised in the IFRS balance sheet as a result of:

- Differences between the IFRS and Solvency II balance sheet valuation basis (as described in section D.1, section D.2 and the remainder of section D.3) and consequential impact on recognition of deferred tax assets and liabilities, the largest impact being as a result of the revaluation of technical provisions; and
- IFRS assets and liabilities with an associated deferred tax balance treated as having no economic value under Solvency II.

Unused tax losses and credits

The Company has unrecognised tax losses of £131 million at 31 December 2022. The £131 million consists of £102 million of non-trade tax losses in IFRS and a Solvency II adjustment of £29 million relating to the revaluation of debt with fellow Aviva Group undertaking Aviva Group Holdings Limited to fair value.

D.3.3 Derivatives

Under Solvency II, derivative liabilities are measured at fair value in accordance with IFRS, excluding any adjustments for changes in own credit standing of the Company since issuance. Fair values are obtained from quoted market prices, or if these are not available, by using valuation techniques such as discounted cash flow models or option pricing models. All derivatives are classified as assets when their fair values are positive and as liabilities when their fair values are negative.

D.3.4 Financial liabilities (including payables)

Financial liabilities (including payables) consist of the following headings listed in the Solvency II balance sheet QRT:

- Debts owed to credit institutions;
- Financial liabilities other than debts owed to credit institutions;
- Insurance and intermediaries payables;
- Lease liabilities;
- Payables (trade, not insurance); and
- Subordinated liabilities.

Deposits received from reinsurers are described in section D.3.5.

Each of these categories is valued according to the methodology described below.

Financial liabilities expected to be paid within one year are valued on the Solvency II and IFRS balance sheets at the amounts expected to be paid.

Under Solvency II, non-current financial liabilities are measured at fair value, adjusted to eliminate movements in fair value due to changes in the own credit standing of the Company. This is achieved by determining the timing and monetary amount of expected outflows of cash or other resources and discounting the projected cash flows using a current risk free rate adjusted for the credit spread at initial recognition of the liability. Under IFRS, non-current financial liabilities are either carried at amortised cost or fair value under the fair value option.

IFRS financial liabilities other than amounts owed to credit institutions include financial reinsurance liabilities of £98 million. For the purposes of Solvency II reporting, amounts owed in respect of financial reinsurance are included within the BEL calculation and classified within technical provisions rather than financial liabilities, as they are under IFRS.

Leasing arrangements are detailed in section D.1.3, with further information provided in note 14 of the Company's financial statements.

Under Solvency II subordinated liabilities are valued on a fair value basis, adjusted to eliminate the impact of changes in the own credit standing of the Company, with reference to the market value of similar group issued instruments which are externally listed. These items are included within Own Funds for Solvency II and more detail on the instruments can be found in section E.

D.3.5 Deposits received from reinsurers and reinsurance payables

Deposits received from reinsurers represent funds withheld by the Company under the terms of a 30% quota share reinsurance arrangement entered into with All. Further information on this arrangement is provided in section A.1.3 of this report and in note 35 of the Company's financial statements. Reinsurance payables are valued in a manner consistent with the method used for financial liabilities described in section D.3.4.

D.3.6 Other liabilities

Other liabilities expected to be paid within one year are valued on the Solvency II and IFRS balance sheets at the amounts expected to be paid.

The IFRS balance sheet includes £1,849 million within other liabilities in respect of the UDS. In certain participating long-term insurance and investment business, the nature of the policy benefits is such that the division between shareholder reserves and policyholder

liabilities is uncertain. Amounts whose allocation either to policyholders or shareholders has not been determined by the end of the year are held within liabilities as a UDS. If the aggregate carrying value of liabilities for a particular participating business fund is in excess of the aggregate carrying value of its assets, the difference is held as a negative UDS balance, subject to recoverability from margins in that fund's participating business. Under Solvency II a proportion of the UDS is implicitly included within best estimate liabilities, particularly unrealised gains and losses on participating business as these are considered part of the policyholder share of assets.

Amounts related to deferred income have no value under Solvency II as they are not separable, and their economic value cannot be realised through a disposal.

Provisions are recognised in line with IFRS. Additional information on the provisions, which includes amounts relating to customer redress, is included in note 32 of the UKLAP Annual Report and financial statements which are publicly available.

D.3.7 Contingent liabilities

Under Solvency II reporting, material contingent liabilities are required to be recognised in the balance sheet. The Company has no material contingent liabilities under Solvency II.

D.4 Alternative methods of valuation

D.4.1 Company approach to valuation

The Company applies the Group Asset Valuation Business Standard to the valuation of its assets. This sets out a control framework in respect of valuation, including assets valued under alternative methods of valuation. This standard defines the following control objectives:

- Primary valuation – Parties responsible for primary valuations must ensure that appropriate valuation techniques are selected and justified;
- Independent price verification – A party independent of the primary valuation process must have sufficient controls in place to ensure valuations of all asset classes are reasonable. Controls should be commensurate with the materiality of the assets;
- Valuation uncertainty – The extent of uncertainty within valuations must be understood, quantified and reported to senior management;
- Reporting bases – IFRS permits an amortised cost valuation basis to be applied. There should be no differences between fair value determined under IFRS and Solvency II; and
- Client supplied prices – Client supplied prices should be identified, and sufficient independent price verification ("IPV") controls exercised to provide assurance over the quality of the valuation.

D.4.2 Assets and liabilities to which an alternative valuation approach applies

For the financial year ending 31 December 2022, the following classes of assets and liabilities were subject to valuation under alternative valuation methods:

- Commercial mortgages, commercial real estate loans and healthcare mortgages;
- Equity release securitised notes and mortgages;
- Investment property and property partnerships;
- Over the Counter ("OTC") derivatives;
- PFI and private infrastructure lending;
- Privately placed debt securities;
- Privately placed debt securities with explicit government/supranational guarantees;
- Privately placed, long dated, inflation linked lending transactions;
- Private equity and infrastructure funds;
- Collateralised lending with banks;
- Collateralised loan obligations;
- Uncollateralised interest rate and inflation swaps; and
- Other illiquid debt securities, private loans and structured finance transactions.

D.4.3 Justification for use of an alternative valuation approach

The majority of the Company's assets are measured at fair value based on quoted market information or observable active market data. Where quoted market information or observable market data is not available, an alternative valuation method is used. This occurs when either:

- the individual nature of the asset means that there is no quoted price available (for example, investment property); or
- the asset is not actively traded in a market (such as holdings in unlisted private equity funds).

Alternative valuation methods include the use of estimates and assumptions that are not market observable. Where estimates and assumptions are used by the Company in valuing its assets, they are based on a combination of expert judgement, independent third-party evidence and internally developed models, calibrated to market observable data where possible.

D.4.4 Assumptions underlying the valuation approach and assessment of valuation uncertainty

The Company performs an annual exercise to assess valuation uncertainty across its investment portfolio. The main assumptions underlying the valuation approach and assessment of valuation uncertainty for the categories identified in section D.4.2 are described below.

The Company sets property assumptions for our commercial and equity release mortgage assets with reference to available market data and to internal and external expert views. The assumptions for UK commercial and residential property are derived from external market forecasts. No additional loadings above and beyond the market forecasts have been applied.

Commercial mortgages, commercial real estate loans, healthcare and other PFI mortgages (£9,224 million)

The mortgages are valued using a model that calculates a credit risk adjusted value for each mortgage. The credit risk adjusted contractual future cash flows are calculated by stochastically forecasting how the future loan repayments are impacted by a large number of inputs. The key inputs feeding into the credit risk calculation are changes in property value, probability of tenant defaults, expected rental growth and property growth and likelihood of the borrower continuing to service the loan if the tenant defaults. The credit risk adjusted cash flows are then discounted at a risk-free rate plus a liquidity premium calibrated to lending on new loans.

Valuation uncertainty arises from variation in the expected range of the key inputs feeding into the credit risk calculation and the liquidity premium. Valuation uncertainty has been assessed as significant for this asset class.

The future property growth and future rental growth assumptions are based on market forecasts. These forecasts will allow for market views on the impact of climate change. An adjustment based on market advice is also made to long-term future property growth (after the end of the period covered by market forecasts) to allow for additional capex that might be required to address climate issues.

Mortgages secured against student accommodation (£619 million) are valued using a discounted cashflow approach whereby all contractual cashflows on the mortgage are discounted at risk free (gilt) yield plus 'DCF margin'. The 'DCF margin' is the spread available on new mortgages of that type.

A small portion of the commercial real estate loan portfolio is managed by an external asset manager (£271 million). These mortgages are valued using a discounted cash flow approach, where credit spreads depend on the rating of the mortgage and are inferred from market observations. Valuation uncertainty has been assessed as moderate for these assets.

Equity release Securitised Notes and Mortgages (£7,729 million)

The Company's exposure to equity release mortgages arises primarily through its investment in mortgage-backed securitised notes issued by one of its subsidiaries. The company also has a direct investment in a small block of unsecuritised equity release mortgages, representing the new business written since the previous securitisation took place.

The equity release backed securitised notes consist of senior notes and a subordinated junior note (which represents the equity tranche of the asset proceeds). The overall value of the loan notes represents the underlying value of the securitisation and is equal to the value of the equity release mortgages and cash held in the securitisation, less the present value of future expenses. The junior note is calculated by discounting the modelled junior note cash flows at an appropriate equity discount rate. The senior notes are valued by discounting the contractual cash flows for each note at a risk-free rate, plus a spread (consisting of the appropriate EIOPA financial long-term average spreads plus an additional spread to reflect the specific risks relating to these notes). The additional spread is set to solve the equation of value set out above.

Equity release mortgages are valued using an internal model, with fair value initially being equal to the transaction price. The value of these loans is dependent on the expected term of the mortgage and the forecast property value at the end of the term and is calculated by adjusting future cash flows for credit risk and discounting using a yield curve plus a liquidity premium calibrated to lending on new loans. At 31 December 2022 the illiquidity premium used in the discount rate was 155 bps.

The mortgages have a no negative equity guarantee ("NNEG") such that the cost of any potential shortfall between the value of the loan and the realised value of the property, at the end of the term, is recognised by a deduction to the value of the loan. Property valuations at the reporting date are obtained by taking the most recent valuation for the property and indexing using an internal house price index based on published Land Registry data.

NNEG is calculated using base property growth rates reduced for the cost of potential dilapidations, using a stochastic model. In addition, a cost of capital charge is applied to reflect the variability in these cash flows. The base property growth rate assumption is RPI +0.75% which includes a reduction to the growth rate of 0.5% per annum for the potential impact of climate change actions. The modelled growth rates include an adjustment for the 5-year period 2023-2027 to reflect the market view of short-term growth being lower than long-term growth. The combination of the adjusted rate over the first five years and the base property growth rate equates to a long-term average growth rate of 3.1% per annum at 31 December 2022 over a twenty five year projection. After applying the cost of capital charge, dilapidations and the stochastic distribution, the effective net long-term growth rate equates to 0.4% per annum.

The potential impact of climate change at longer durations has been kept under review; there is an explicit allowance for climate risk in the base assumptions for future house price growth.

Valuation uncertainty has been assessed as moderate for these assets.

Investment property and property partnerships (£6,160 million)

Investment property is valued either quarterly or monthly by external chartered surveyors in accordance with guidance issued by The Royal Institution of Chartered Surveyors ("RICS"). Valuations are performed by surveyors in accordance with methodologies described in the RICS "red book". A property gross value is calculated by dividing the expected rental cash flows by an appropriate rental yield. Future cash flows are calculated based on the surveyor's expectation of rental receipts during and after the current tenancy ends, typically based on an assessment of rents charged on comparable properties.

The extent of uncertainty within the valuation of investment properties has been assessed based on back-testing analysis performed across the Company's portfolio. This back-testing analysis compares sale prices of investment properties against the properties' valuation one year prior to the date of sale, with adjustments made to allow for movements in property markets over the year. The results of this analysis corroborate closely with other research information available in the public domain and suggest that valuation uncertainty is significant for this asset class.

Over the Counter (“OTC”) derivatives (£4,913 million)

Although valued using established and accepted valuation methodologies, OTC derivatives are not quoted in an active market and an element of valuation uncertainty may exist in arriving at a fair value. The extent of valuation uncertainty is assessed by comparing valuations against counterparty statements as well as considering any differences between balance sheet valuations and the level at which contracts could hypothetically be closed out.

Valuation uncertainty has been assessed as moderate for this asset class. Please note this section excludes uncollateralised OTC derivatives with PFI counterparties (see comments below).

PFI and private infrastructure lending (£5,069 million)

PFI and private Infrastructure loans are valued using a discounted cash flow model which add spreads for credit and illiquidity to a risk-free discount rate. Credit spreads are updated quarterly using an internally developed methodology which depends on the credit rating of each loan, the duration of each loan, credit spreads on publicly traded bonds and an adjustment to reflect the estimated recovery rate in the event of the infrastructure loan defaulting.

Valuation uncertainty arises from variation in the expected range of the key inputs feeding into the credit risk calculation and the illiquidity premium. Valuation uncertainty has been assessed as moderate for this asset class.

Privately placed corporate debt securities (£1,560 million)

Privately placed notes are valued using a discounted cash flow model. The discounted cash flow model uses discount factors based on swap curves, plus credit spreads inferred from comparable, publicly traded bonds as well as an incremental spread to reflect the illiquidity of the securities. Valuation uncertainty arises on the private placement portfolio in the choice of spreads for credit and liquidity.

Valuation uncertainty has been assessed as moderate for this asset class.

Privately placed debt securities with explicit sovereign or supranational guarantees (£1,174 million)

The Company holds a number of debt securities supported by explicit sovereign or supranational guarantees, under export credit agency or similar schemes. In these cases, the credit spreads used to value the instruments reflect the security provided by the sovereign guarantee. An additional illiquidity premium is also included in the total spread.

Valuation uncertainty has been assessed as low for these loans.

Private equity and Infrastructure funds (£243 million)

Fair values for unlisted private equity and infrastructure funds are based on net asset value statements provided by fund administrators. The valuation of underlying equities is compliant with guidelines published by the British Venture Capital Association, the European Private Equity and Venture Capital association and other international bodies.

The extent of valuation uncertainty is estimated with reference to back testing analysis which involves comparing sale proceeds for portfolio businesses against lagged valuations adjusted for movements in value to earnings ratios for proxy stock market indices.

Valuation uncertainty has been assessed as significant for this asset class.

Collateralised lending with banks (£1,529 million)

Collateralised lending with banks comprises loans to banking counterparties which have been collateralised with illiquid securities.

For Barclays liquidity swaps the fair values are calculated using valuation models which incorporate a number of assumptions including probability of counterparty default and expected loss in the event of counterparty default. Expected loss in the event of default is driven by assumptions describing the expected liquidation period of the collateral, the volatility of the collateral during this liquidation period and the extent to which we believe there is a correlation between the collateral value and counterparty default probability. Valuation uncertainty arises from variations in the expected range for a number of the key assumptions described above.

There are also some short term (<6 months) reverse repurchase agreements held. Valuation at cost is used and considered to be a materially accurate proxy for fair value.

Valuation uncertainty has been assessed as moderate for this asset class.

Collateralised loan obligations (“CLO”) (£224 million)

The Company holds an illiquid senior note issued by an SPV which is backed by a series of loans to PFI counterparties. The asset is valued using a discounted cash flow methodology incorporating risk free rates, relevant credit and CDS spreads plus an illiquidity premium.

Valuation uncertainty has been assessed as moderate for this asset.

Uncollateralised interest rate and inflation swaps (£160 million)

The Company holds a number of uncollateralised interest rate and inflation swaps with PFI counterparties. These swaps were originally structured between PFI counterparties and banks and involve the PFI counterparty paying a fixed interest rate in return for a floating interest rate. Interest rates have fallen sharply since the swaps were originally executed, causing their fair value to be strongly positive in favour of the bank. The Company subsequently acquired these positions from the originating banks in secondary market transactions during 2017 and 2018.

These swaps are not collateralised, meaning the Company is exposed to counterparty credit risk. The valuation of these swaps therefore includes a credit valuation adjustment (“CVA”) to reflect counterparty default risk. This references likelihood of counterparty default,

recovery in event of default, exposure to counterparty at time of default and an excess spread implied by the most recent structured PFI transactions.

Valuation uncertainty has been assessed as moderate for this asset class.

Illiquid inflation linked notes (£777 million)

The Company holds a number of illiquid, long duration inflation linked notes. Future cash flows are forecast using market-implied CPI/RPI rates then discounted using swap curves, plus credit spreads inferred from the closest comparable publicly traded instruments (with adjustments where necessary) and an illiquidity premium.

Valuation uncertainty has been assessed as moderate for this asset class.

Other illiquid debt securities, private loans and structured finance transactions (£1,663 million)

A range of other illiquid debt securities are valued using discounted cash flow methodologies. Discount factors are constructed using risk free rates, credit and illiquidity spreads appropriate for the security in question.

Valuation uncertainty has been assessed as moderate for this asset class.

D.4.5 Adequacy of the valuation compared to experience

The Company operates Independent price verification (IPV) controls across all assets. For asset types where a secondary source is available (such as OTC derivatives and publicly traded bonds), this involves comparing the primary valuation to a secondary independent source, investigating material differences and making valuation adjustments where the Company believes it is appropriate to do so.

For illiquid debt securities which are marked to model the IPV process includes a review of the valuation methodology, periodic assessment of both observable and judgemental model inputs as well as reviewing any secondary trading activity in the asset to understand whether anything can be learnt regarding the appropriateness of the valuation methodology.

For asset classes where a secondary source is not available and there is no secondary trading activity (such as investment property and private equity), the Company relies on the implementation of accepted valuation standards by parties independent of the Group as described above (e.g. valuation of investment property in line with the methodologies described in the RICS “red book”). To assess the reasonableness of valuations back testing analysis is performed on an annual basis for any assets sold during the year. Results of these back-testing analyses are presented in the Company's Solvency II valuation uncertainty assessments.

D.5 Any other information

The company has no other material information to disclose regarding the valuation of assets and liabilities.

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

E. Capital Management

In this Chapter

| | | |
|-----|--|----|
| E.1 | Own Funds | 55 |
| E.2 | Solvency Capital Requirement ("SCR") and Minimum Capital Requirement ("MCR") | 58 |
| E.3 | Use of duration-based equity risk sub-module in the calculation of the SCR | 59 |
| E.4 | Difference between the Standard Formula and Internal Model | 59 |
| E.5 | Non-compliance with the MCR and non-compliance with the SCR | 62 |
| E.6 | Any other information | 62 |

This section of the report describes the internal operational structures and procedures underlying the Company's capital management process covering structure and quality of Own Funds; SCR and MCR; methodology for calculation of the SCR; differences between Internal Model and Standard Formula and any other material information.

E.1 Own Funds

E.1.1 Management of Own Funds

The primary objective of capital management is to optimise the balance between return and risk, whilst maintaining regulatory capital in accordance with risk appetite. In managing Own Funds, the Company seeks to:

- Match the profile of its assets and liabilities, taking account of the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth and satisfy the requirements of its policyholders and its regulator, the PRA;
- Retain financial flexibility by maintaining sufficient liquidity; and
- Allocate capital efficiently, applying it to support value adding growth and repatriating excess capital to the Group through dividends.

In order to achieve these objectives, Own Funds are monitored via projections over a three-year planning horizon. The Company also uses a number of sensitivity tests to understand the volatility of earnings, the volatility of its capital requirements, and to manage its capital more efficiently. Sensitivities to economic and operating experience are regularly produced on the Company's key financial performance metrics to inform decision making and planning processes, and as part of the framework for identifying and quantifying the risks to which the Company is exposed.

For long-term business in particular, sensitivities of market consistent performance indicators to changes in both economic and non-economic experience are continually used to manage the business and to inform the decision making process.

There have been no material changes to the objectives, policies or processes with respect to the management of Own Funds during the year.

E.1.2 Own Funds by tier

At 31 December 2022, total basic Own Funds equalled the total eligible Own Funds to meet the SCR, with no tiering limit restrictions. Eligible Own Funds were subject to restrictions of £341 million to meet the MCR.

The table below sets out the Company's Own Funds at 31 December 2022:

| 31 December 2022 | Total £m | Tier 1 unrestricted £m | Tier 1 restricted £m | Tier 2 £m | Tier 3 £m |
|---|---------------|------------------------------|----------------------------|--------------|--------------|
| Ordinary share capital | 3 | 3 | — | — | — |
| Surplus funds | 4,451 | 4,451 | — | — | — |
| Preference shares | — | — | — | — | — |
| Reconciliation reserve | 5,272 | 5,272 | — | — | — |
| Subordinated liabilities | — | — | — | — | — |
| An amount equal to the value of net deferred tax assets | 341 | — | — | — | 341 |
| Total Basic Own Funds after adjustment | 10,068 | 9,727 | — | — | 341 |
| Restrictions | — | — | — | — | — |
| Total Eligible Own Funds to meet the SCR | 10,068 | 9,727 | — | — | 341 |
| Restrictions to meet the MCR | (341) | — | — | — | (341) |
| Total Eligible Own Funds to meet the MCR | 9,727 | 9,727 | — | — | — |

| 31 December 2021 | Total £m | Tier 1 unrestricted £m | Tier 1 restricted £m | Tier 2 £m | Tier 3 £m |
|---|---------------|------------------------------|----------------------------|--------------|--------------|
| Ordinary share capital | 343 | 343 | — | — | — |
| Surplus funds | 5,065 | 5,065 | — | — | — |
| Preference shares | 970 | — | 970 | — | — |
| Reconciliation reserve | 4,343 | 4,343 | — | — | — |
| Subordinated liabilities | 697 | — | 191 | 505 | — |
| An amount equal to the value of net deferred tax assets | — | — | — | — | — |
| Total Basic Own Funds after adjustment | 11,417 | 9,751 | 1,161 | 505 | — |
| Restrictions | — | — | — | — | — |
| Total Eligible Own Funds to meet the SCR | 11,417 | 9,751 | 1,161 | 505 | — |
| Restrictions to meet the MCR | (58) | — | — | (58) | — |
| Total Eligible Own Funds to meet the MCR | 11,359 | 9,751 | 1,161 | 447 | — |

Further information on Own Funds by tier is presented in QRT S23.01.01 'Own Funds' within section F.1.

- Tier 1 unrestricted capital

Unrestricted Tier 1 capital of £9,727 million (2021: £9,751 million) represents 97% of the Company's Own Funds. This consists of ordinary share capital, surplus funds and the reconciliation reserve, which reconciles the total excess of assets over liabilities with identifiable Own Funds instruments (refer to section E.1.5). Tier 1 unrestricted capital includes high quality instruments with features such as permanence, subordination, undated, absence of redemption incentives, mandatory costs and encumbrances.

- Tier 1 restricted capital

Restricted Tier 1 capital of £nil (2021: £1,161 million) consists of preference shares and subordinated debt, both qualifying as restricted Tier 1 capital under the transitional provisions. Transitional measures are referred to in section E.1.3. Tier 1 restricted Own Funds are distinguished from Tier 1 unrestricted capital as they are subject to further quantitative restrictions. The preference shares were redeemed during year and all subordinated debt was settled (refer to section E.1.3.2 and E.1.3.3).

- Tier 2 capital

Tier 2 capital of £nil (2021: £505 million) consists of subordinated debt, qualifying as Tier 2 capital under the transitional provisions. The amount of tier 2 capital allowed to meet the MCR is restricted to 20% of the MCR. The MCR is referred to in section E.2.2. The features of Tier 2 capital include subordination, minimum duration of 10 years with no contractual opportunity to redeem within 5 years, absence of redemption incentives, mandatory costs and encumbrances. The subordinated debt was settled during the year (refer to section E.1.3.2)

- Tier 3 capital

Tier 3 capital of £341 million (2021: £nil) consist of deferred tax assets, qualifying as Tier 3 capital under the transitional provisions,

E.1.3 Details of Own Funds items

E.1.3.1 Issued share capital and share premium as at 31 December 2022

As at 31 December 2022 the Company had an aggregate issued and outstanding ordinary share capital of £3 million (2021: £343 million)

The reduction in share capital is due to the following transactions:

- On 27 July 2022, the Company reduced its share capital by cancelling and extinguishing 340,000,000 ordinary shares of £1 each, with the amount from such reduction being credited to a distributable reserve of the Company.
- On 11 August 2022, the Company allotted 469,699,387 ordinary shares of £1 each to UKLH for a consideration of £470m.
- On 14 October 2022, the Company reduced its share capital by cancelling and extinguishing 469,866,387 ordinary shares of £1 each, with £470m from the reduction being credited to a distributable reserve of the Company.

E.1.3.2 Preference shares in issue as at 31 December 2022

The Company's Own Funds include the following preference shares:

| Capital Instrument | Date of next call | Solvency II Tier | Solvency II value 2022 £m | Solvency II value 2021 £m |
|--|--------------------------------------|-------------------|------------------------------|------------------------------|
| Step-up Tier 1 Capital Securities (STICS) RT1 | 1 July 2025 and then five yearly | Tier 1 restricted | — | 500 |
| Restricted Tier 1 Subordinated Notes (RT1 Notes) | 31 May 2028 and then six monthly | Tier 1 restricted | — | 114 |
| Restricted Tier 1 Subordinated Notes (RT1 Notes) | 9 November 2030 and then six monthly | Tier 1 restricted | — | 356 |
| Total preference shares | | | — | 970 |

The Step-up Tier 1 Insurance Capital Securities ("STICS") were transferred to the Company following the Part VII transfer of assets and liabilities from Friends Life Limited ("FLL") during 2017. The STICS are intra-group debt instruments that were originally issued by FLL to Friends Life Holdings plc ("FLH").

In December 2021 the £500 million STICS issued by UKLAP were transferred to Aviva Group Holdings Limited ("AGH").

On 2 August 2022, the Company received a capital contribution of £500 million from UKLH, with which the Company repaid the £500 million STICS issued to AGH.

The £114 million Restricted Tier 1 Subordinated Notes ("RT1 Notes") were issued on 31 May 2018 and £356m RT1 Notes were issued on 9 November 2020. The RT1 Notes were perpetual securities and were not redeemable at the option of the holders at any time. The Company had the right, at its sole option, to redeem all (but not part) of the RT1 Notes, providing that the solvency conditions are met, and the relevant regulatory approvals have been obtained.

The fixed interest on the RT1 Notes was due and payable only at the sole and absolute discretion of the Company. The Company was not permitted to pay the interest if the solvency conditions were not satisfied. Unpaid interest is assumed to be cancelled and shall not become due or accumulate. No interest was accrued until the payment was declared.

On 11 August 2022, the Company redeemed the £470m RT1 Notes held by Aviva Group Holdings Limited (AGH).

E.1.3.3 Subordinated liabilities in issue as at 31 December 2022

Under IFRS, subordinated debt is valued on an amortised cost basis. Under Solvency II, subordinated debt is valued on a fair value basis, with changes in own credit standing removed for subsequent measurement. A discounted cash flow approach has been used to assess the fair value and, for the purpose of valuation, it is assumed that the option to redeem at the first call date will be exercised.

| Capital Instrument, including nominal, coupon and extent of subordination | Callable at par at option of the Company from | Solvency II Tier | Solvency II value 2022 £m | Solvency II value 2021 £m |
|---|---|-------------------|------------------------------|------------------------------|
| 8.25% £500m subordinated debt | At maturity on 22 April 2022 | Tier 2 | — | 505 |
| 1.7102% £200m subordinated notes | Callable since December 2014 | Tier 1 restricted | — | 191 |
| Total subordinated debt | | | — | 696 |

Transitional measures (unaudited)

The transitional measures prescribed under Solvency II allow the subordinated debt concerned to count towards a firm's available Own Funds, subject to tiering limits, for a period of up to ten years after 1 January 2016. The Company's subordinated notes do not qualify directly as Solvency II Own Funds, but all met the Solvency I requirements without reliance on waivers and are all therefore eligible for Solvency II transitional treatment. The debt is grandfathered either as Tier 1 if it is perpetual or Tier 2 if it is dated.

Movement in the year

On 21 April 2022, the Company received a capital contribution of £500 million from UKLH, with which the Company repaid £500 million subordinated debt to FLH.

On 3 August 2022, the Company received a capital contribution of £200 million from UKLH, with which the Company repaid £200 million of subordinated debt to UKLH.

E.1.4 Surplus funds

The Company has recognised £4,451 million of surplus funds which meet the criteria for classification as Tier 1 Own Funds. These are With-profits funds, where accumulated profits have not yet been made available for policyholders or beneficiaries. The surplus Own Funds in excess of notional SCR within a With-profits fund is restricted via an adjustment to the reconciliation reserve shown in section E.1.5 below (Adjustment for restricted Own Fund items in respect of RFFs).

E.1.5 Reconciliation reserve

The table below sets out the constituents of the reconciliation reserve:

| | 2022 £m | 2021 £m |
|---|---------------|------------|
| Solvency II excess of assets over liabilities | 11,675 | 11,748 |
| Other Basic Own Funds items | (4,795) | (6,377) |
| Adjustment for restricted Own Fund items in respect of RFFs (unaudited) | (1,607) | (1,027) |
| Reconciliation reserve | 5,272 | 4,343 |

The reconciliation reserve equals the total excess of Solvency II assets over liabilities reduced by the following:

- Other Basic Own Funds items that have been separately identified on the Own Funds QRT being share capital, preference shares and surplus funds.
- The surplus Own Funds over notional SCR held within RFFs (refer to section E.1.7).

E.1.6 Differences between IFRS net assets and the excess of assets over liabilities as calculated for Solvency II

The table below lists the material differences between equity as shown in the financial statements of the Company and the excess of assets over liabilities as calculated under Solvency II.

| | 2022 £m | 2021 £m |
|--|---------------|------------|
| Total Company equity on an IFRS basis | 6,439 | 6,542 |
| Elimination of intangible assets, deferred acquisition costs and deferred income reserve | (1,108) | (1,355) |
| Technical provision valuation differences (net of transitional deductions) | 7,415 | 8,279 |
| Inclusion of risk margin (net of transitional deductions) | (500) | (835) |
| Reinsurance recoverable valuation differences | (1,905) | (2,389) |
| Elimination of UDS from liabilities | 1,849 | 1,826 |
| Net deferred tax adjustments | (550) | (479) |
| Revaluation of participations | 82 | 117 |
| Other adjustments onto Solvency II basis (including fair value adjustments) | (48) | 43 |
| Solvency II excess of assets over liabilities | 11,675 | 11,748 |

The excess of assets over liabilities is £5,236 million higher (2021: £5,206 million higher) on a Solvency II basis than the value under IFRS, with the difference primarily driven by the different approaches used to value technical provisions:

- The elimination of intangible assets, deferred acquisition costs and deferred income reserve are described in sections D.1.1, D.1.2 and D.3.6 respectively.
- Technical provision valuation differences and the inclusion of the risk margin are described in section D.2.4.
- Reinsurance recoverable valuation differences are described in section D.1.9.
- The elimination of UDS from liabilities is described in section D.3.6.
- Net deferred tax adjustments are described in section D.3.2.
- Revaluation of participations is described in section D.1.5.
- Other adjustments onto a Solvency II basis primarily consist of fair value adjustments on loans (described in section D.1.8) and adjustments in respect of financial reinsurance liabilities (described in section D.3.4).

E.1.7 Restricted Own Funds items in respect of RFFs and MA portfolios (unaudited)

As at 31 December 2022, the total of excess of assets over liabilities within RFFs and MA portfolios amounted to £5,667 million, of which £1,607 million is restricted from the Company's Own Funds.

- Where a RFF exists, the Own Funds in excess of notional SCR of the RFF are restricted and deducted from the Company's Own Funds. This is reflected as an adjustment to the reconciliation reserve. The With-profits funds in the Company are treated as RFFs.
- In applying Article 80 of the Solvency II Delegated Acts to the Reattributed Inherited Estate External Support Account ("RIEESA"), the surplus of Own Funds over the notional capital requirement, where the capital requirement includes a buffer in addition to the notional SCR, is not restricted. The objective of this buffer is to ensure the policyholders of the New With-Profits Sub-Fund ("NWPSF") are not exposed to unacceptable risk of failing to meet statutory capital requirements. The headroom test is considered an appropriate indication of the levels of assets in the RIEESA which are available to absorb losses elsewhere in the business and are not part of the RFF.
- The Company's MA portfolios do not have a surplus in excess of SCR and, as a consequence, no restriction to Own Funds has been applied.

There are no other restrictions on Own Fund items.

E.2 SCR and MCR

E.2.1 SCR (unaudited)

The Company SCR at 31 December 2022 is £5,619 million (2021: £7,820 million).

The Company SCR includes the results of the following sub-funds:

- UKLAP NP - Non-profit business written in the Non-profit sub-fund, including a matching adjustment portfolio
- NWPSF - primarily includes With-profits business
- OWPSF - primarily includes With-profits business
- WPSF - primarily includes With-profits business
- PMSF - primarily includes With-profits business
- FP WPSF - as well as With-profits business, it also includes a unit-linked portfolio (units held by UKLAP NP)
- FPLAL WPSF - primarily includes With-profits business
- FLAS WPSF - includes significant portfolios of Non-profit and unit-linked business (units held by UKLAP NP) as well as With-profits business
- FLC WPSF - primarily includes With-profits business and is the new fund consisting of ex-FLC NWPSF and ex-FLC OWPSF merged on 1st July 2022.
- WL WPSF - includes a significant portfolio of unit-linked business (units held by UKLAP NP) as well as With-profits business
- SGF - a With-profits fund that is an investment option for unitised contracts

The contribution of the above sub-funds to the Company SCR is calculated using an Internal Model with the exception of the ALPI DAC subsidiary (within the UKLAP NP sub-fund) which is valued using a Standard Formula calculation and aggregated using the Partial Internal Model methodology. This is a simple case since ALPI DAC is a strategic equity holding of UKLAP it only contributes to the equity risk module.

The table below shows the results of the Company SCR as at 31 December 2022 split by sub-fund:

| SCR split by sub-fund | £m |
|-----------------------|--------------|
| UKLAP NP | 4,001 |
| NWPSF | 301 |
| OWPSF | 105 |
| WPSF | 344 |
| PMSF | 71 |
| FP WPSF | 272 |
| FPLAL WPSF | 14 |
| FLAS WPSF | 156 |
| FLC WPSF | 285 |
| WL WPSF | 3 |
| SGF | 66 |
| Company SCR | 5,619 |

A more detailed breakdown of the Company SCR by risk module is shown in the following table, including the split of each module between Internal Model and Standard Formula. Each risk module includes the impact of diversification within that module, and the diversification line includes diversification between risk modules and Partial Internal Model diversification. 'Other risks and adjustments' include other adjustments from the S.25.02 QRT and the loss absorbing capacity of deferred tax.

| SCR by risk module (£m) | Total | Internal Model | Standard Formula |
|------------------------------------|--------------|----------------|------------------|
| Market risk | 4,771 | 4,542 | 228 |
| Counterparty default risk | 127 | 127 | — |
| Life underwriting risk | 3,237 | 3,237 | — |
| Operational risk | 1,583 | 1,583 | — |
| Other risks and adjustments | (1,225) | (1,225) | — |
| Total undiversified modules | 8,493 | 8,265 | 228 |
| Diversification | (2,874) | | |
| SCR excluding capital add-on | 5,619 | | |
| SCR | 5,619 | | |

The following table shows the results of the Company SCR as at 31 December 2022, compared to 31 December 2021:

| Company SCR | Total £m |
|-------------------------|----------------|
| 31 December 2022 | 5,619 |
| 31 December 2021 | 7,820 |
| Decrease | (2,201) |

The Company's SCR at 31 December 2022 is lower than the SCR as at 31 December 2021. The SCR has decreased primarily due to economic changes (in particular a rise in interest rates) and the run-off of existing business, partly offset by increased capital requirements from the writing of new business and high inflation in 2022.

E.2.2 MCR

The MCR represents the minimum level below which the amount of financial resources of a firm should not fall.

The MCR is calculated using a linear formula that applies prescribed factors to capital-at-risk and the best estimate liability (net of reinsurance). The factors applied to the best estimate liability vary by type (With-profits guaranteed benefits, With-profits discretionary benefits, index/unit-linked and other). The MCR is subject to a floor, equal to 25% of the SCR, and a cap, equal to 45% of the SCR. There is an absolute floor of €3.7 million.

The MCR for the Company at 31 December 2022 is £1,663 million.

The following table shows the results of the Company MCR as at 31 December 2022, compared with the MCR as at 31 December 2021:

| Company MCR | Total £m |
|-------------------------|--------------|
| 31 December 2022 | 1,663 |
| 31 December 2021 | 2,236 |
| Decrease | (573) |

The Company's MCR at 31 December 2022 is lower than the MCR as at 31 December 2021. The change from prior year is principally due to the reduction in technical provisions driven by the rise in interest rates during 2022.

E.2.3 Standard Formula simplifications (unaudited)

Where the SCR is calculated using the Standard Formula, the Solvency II regulations specify 23 simplified calculations that may be used across all of the Standard Formula risk modules except operational risk. The use of these simplifications is disclosed in QRT S.25.02.21, where applicable. The Company has not used any of these simplified calculations to calculate the SCR at 31 December 2022.

E.2.4 Standard Formula undertaking specific parameters ("USPs") (unaudited)

Where the SCR is calculated using the Standard Formula, Solvency II regulations specify certain USPs that may be used in place of the standard parameters, subject to regulatory approval. These are available for life and health revision risks, and non-life (including some health) premium and reserve risks. The use of these USPs must be disclosed in QRT S.25.02.21, where applicable. The Company has not used any USPs to calculate the SCR at 31 December 2022.

E.2.5 Transitional measures, disclosure of capital add-ons and USPs (unaudited)

Regulators have the power to impose capital add-ons to the SCR or to require the use of certain USPs in the Standard Formula, where there are significant deficiencies in a firm's Internal Model or Partial Internal Model, or where a Standard Formula firm's risk profile deviates significantly from the assumptions underlying the Standard Formula. The SCR of the Company at 31 December 2022 does not include an add-on imposed by the regulators.

E.3 Use of the duration-based equity risk sub-module in the calculation of the SCR (unaudited)

Insurance firms that have particular types of retirement provision business managed on a ring-fenced basis, for which the SCR is calculated using the Standard Formula, are entitled to calculate the equity risk capital requirement using a specified duration-based approach. The Company does not use the duration-based equity risk sub-module in the calculation of the SCR.

E.4 Differences between the Standard Formula and Internal Model (unaudited)

E.4.1 Use of the Internal Model in the Company's business

The Internal Model provides input to a number of key business processes and activities. Therefore, the outputs from the Internal Model are used in day-to-day risk management and business decisions across the Company. "Use" does not imply that the Internal Model is used to directly run the business, but rather that the outputs of the Internal Model and the Internal Model itself are used to support decision-making, whilst acknowledging its limitations and balancing against other elements of the RMF.

The primary purpose of the Internal Model is to calculate the capital metrics required for regulatory reporting under Solvency II. The outputs of the Internal Model are used internally and externally in risk based performance reporting and risk and financial strength reporting to senior management and to the Board.

The granular metrics produced by the Internal Model are also used to set strategy and support a series of other activities, including:

- Strategy and business planning: allocating capital between business areas to measure risk-adjusted return and set risk appetites as part of the business planning cycle;

- Pricing: improving pricing and product design by assessing the level of capital required to support different types of products and their inherent risks;
- Transactions: assessing the appropriateness of potential business investments through the impact on surplus capital;
- Reinsurance: identifying the need for targeted reinsurance contracts to mitigate undesirable risk exposures, through modelling potential adverse scenarios; and
- Asset and liability management: measuring the impact of market changes on assets and liabilities to drive investment and hedging strategy.

Further details on how the Internal Model is fully integrated into the Company's risk management system are given in section B.3.3.

E.4.2 Undertakings in scope of the Internal Model

The Group is a large multinational insurance organisation operating across a variety of business lines; this drives the risk profile and, by extension, the design and structure of the Internal Model. The Group uses a Partial Internal Model. The Company, as part of the Group, makes use of the Group Partial Internal Model.

The Group Partial Internal Model has been designed to allow each legal entity within the Group to run the business with a focus on risk. This means that the Internal Model has been designed to produce capital figures at a range of levels and granularities, from legal entity to fund level (and in some cases to a product or asset level), allowing for diversification between risk types at each of those levels. Producing and understanding the capital requirements at different levels of granularity is crucial to ensure that the model outputs can be effectively used in the day-to-day running of the business.


The funds and subsidiaries of the Company included in the Internal Model scope are listed in section E.2.1.

E.4.3 Calculation of the Internal Model

E.4.3.1 Methods used

The purpose of the Internal Model is to identify the risks to which the Group is exposed, model these risks using suitably calibrated inputs and aggregate them to compute the SCR. The Internal Model produces an aggregate distribution of the change in basic Own Funds over a one-year time horizon from which the SCR can be directly derived (i.e. the SCR is the 99.5th percentile) in line with Article 101 of the Solvency II Delegated Regulations.

An overview of the Company's approach is shown below.



Overview of the Company's modelling approach

The Company's Internal Model allows flexibility in determining which statistical distributions to use to represent risk factors (such as mortality, interest rates or credit risk) including those with heavy tails and empirical distributions. The model is not limited to assuming risks follow normal (or similar) distributions, as is implicit in the Standard Formula. This flexibility is important to ensure that management accurately model the behaviour of the most important risks to the Company.

For the majority of risk factors, standard statistical distributions fitted via the standard risk factor calibration process are used. However, for some risk types, such as credit risk or operational risk, distributions are derived from further modelling processes. This approach is appropriate given both the materiality of the risk types and the desire to ensure the risk's behaviour is accurately reflected.

A wide range of testing and review processes are used to ensure that the calibrations are appropriate and the Internal Model outputs are reasonable. These range from bottom-up reviews of the material assumptions used in the modelling process and testing of the calibrations and loss functions (i.e. the mathematical formulae used as a proxy for the calculations in the asset and liability management models for the valuation of the assets and liabilities on the balance sheet), to top-down stress and scenario testing, as well as profit and loss attribution exercises.

Aviva has chosen to implement a Partial Internal Model Group wide, defined as using a combination of Internal Model and Standard Formula approaches to calculate SCRs for different components of the business. Within the Company, these components are distinct blocks of business, rather than risks. In order to integrate the Internal Model capital calculations with the Standard Formula calculations the Partial Internal Model technique 2 as described in Annex XVIII of Directive 2009/138/EC is used.

E.4.3.2 Data used in the Internal Model

The key data used in the Company's Internal Model is listed below:

- Accounting data (IFRS) – this is used in the valuation of certain liabilities;
- Policy data – this includes claims as well as policies in force and past policies;
- Operational risk data – an external database of information with regards to industry operational risk losses is used. This is provided by the Operational Risk Insurance Consortium;
- Financial market data – the calibration process for market and credit risks often uses external financial market asset data (e.g. FTSE index returns);
- Internal asset data – the valuation of the base Solvency II Balance Sheet relies on the market valuation of assets, as well as mark to model valuations of certain non-traded assets. The data used is largely taken from the accounting process and, therefore, most data will be included under the heading 'accounting data'; and
- Other data – data that does not fall under the above five categories.

The Solvency II Data Governance Group Business Standard establishes the control environment and the criteria to be used to assess the quality of the data in terms of appropriateness, completeness, accuracy, and consistency before using it for the SCR calculation.

E.4.3.3 Integration of the Standard Formula into the Partial Internal Model

As described in section E.4.3.1 the Company has chosen to implement a Partial Internal Model using integration technique 2 to combine results of the Internal Model and Standard Formula as described in Annex XVIII of the Delegated Regulations.

This technique requires an upper and lower bound to be specified for correlations between the entire Internal Model block and each of the Standard Formula risk modules. A correlation matrix is then constructed with correlations between Standard Formula and Internal Model risk modules within these bounds. The correlations are chosen so that the SCR aggregated using this correlation matrix is maximised. The only business using the Standard Formula approach is the ALPI DAC subsidiary within the UKLAP NP sub-fund.

E.4.4 Differences between Standard Formula and Internal Model methodologies and underlying assumptions

The main difference between the Standard Formula and Internal Model approach is that the methodology and assumptions used in the Internal Model are tailored to the Company's risk profile, whereas the Standard Formula uses a standardised approach.

The Standard Formula prescribes formulae to calculate the capital required driven by exposure to various risks; for the Internal Model the Company calibrates a distribution of losses for each risk and use these, along with a set of correlations between these risks, to derive a joint distribution of losses for the business. The capital requirement is derived from this joint distribution, to ensure the Company holds sufficient capital with 99.5% confidence. Calibrating risks for the Internal Model therefore requires detailed data analysis and use of statistical models to derive the most appropriate distribution.

The two bases also use a different treatment for the loss absorbing capacity of technical provisions. Under the Internal Model, loss functions net of the loss absorbing capacity of technical provisions are used, whereas in the Standard Formula an adjustment is made to the gross SCR for this loss absorbing capacity of technical provisions. The calculation of loss absorbing capacity of deferred tax also differs between the two approaches as this is specified by the Standard Formula calculation.

Another key difference is in the modelling approach used to aggregate the results. For the Internal Model, the Company determines an aggregate distribution of losses by combining marginal risk distributions for each risk using a Gaussian Copula and applying loss functions. The Standard Formula uses a hierarchical correlations approach, where explicit correlation matrices are used to combine sub-module losses within each risk module, and then to combine the calculated losses of the different risk modules.

A key feature of the Company's approach compared to the Standard Formula is that fat tailed risks are captured (i.e. risks where the probability of extreme values is higher than using the normal distribution) and non-linear loss profiles. In addition, the Company is able to model diversification more granularly and, in particular, capture important features such as geographical diversification. Another key difference is that the Internal Model reflects all material quantifiable risks to which the Company is exposed, whereas the Standard Formula only considers a subset of risks. These are detailed below.

Market risks module

- The Internal Model considers changes in market volatility, which are not explicitly modelled in the Standard Formula. Interest rate and equity volatility risks are particularly important for modelling business with guarantees.
- The Internal Model includes credit risk on sovereign bonds, which is not currently modelled under Standard Formula. The Internal Model also explicitly considers default migration and spread risks including some allowance for diversification between various credit exposures.
- Interest rates are modelled using three principal components, not just the change in the level of interest rates as under the Standard Formula.

- The Internal Model explicitly models inflation risk which is not included in the Standard Formula.
- For equity risk, only exposure to asset price falls is reflected in the Standard Formula, whereas the Internal Model allows for the full distribution of equity returns which allows exposure to equity values rising or falling to be captured.

Counterparty default module

- The Standard Formula considers all counterparty default risk under one module, whereas the Internal Model allows for the type of the counterparty and the nature of the exposure.

Life Insurance module

- The Standard Formula assumes standard portfolios, whereas the Internal Model calibrations are tailored to the Company's specific portfolios.

Operational Risk

- The Internal Model models operational risks using a scenario based approach. The Standard Formula uses a formulaic approach.

E.5 Non-compliance with the MCR and non-compliance with the SCR (unaudited)

The Company complied with the MCR and SCR at all times during 2022.

E.6 Any other information

The table below shows the Operating Capital Generated by the Company (unaudited). These figures reflect the regulatory TMTP position.:

| | 2022 £m |
|---------------------------------------|--------------|
| New business | (71) |
| Existing business | 656 |
| Other | 446 |
| Operating capital generation | 1,031 |
| Non-operating capital generation | 422 |
| Total capital generation | 1,453 |
| Dividends | (601) |
| Total change in excess capital | 852 |

Aviva Life & Pensions UK Limited

Solvency and Financial Condition Report

2022

F. Appendices

In this Chapter

| | | |
|-----|------------------------------|----|
| F.0 | Cautionary statement | 64 |
| F.1 | Public disclosure templates | 65 |
| F.2 | Glossary | 74 |
| F.3 | Approvals and determinations | 74 |
| F.4 | Directors' statement | 75 |
| F.5 | Audit opinion | 76 |

F.0 Cautionary statement

This document should be read in conjunction with the documents distributed by Aviva plc (the 'Company' or 'Aviva') through The Regulatory News Service (RNS). This announcement contains, and we may make other verbal or written 'forward-looking statements' with respect to certain of Aviva's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives (including, without limitation, climate-related plans and goals). Statements containing the words 'believes', 'intends', 'expects', 'projects', 'plans', 'will', 'seeks', 'aims', 'may', 'could', 'outlook', 'likely', 'target', 'goal', 'guidance', 'trends', 'future', 'estimates', 'potential', 'objective', 'predicts', 'ambition' and 'anticipates', and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the announcement include, but are not limited to: the impact of ongoing uncertain conditions in the global financial markets and the national and international political and economic situation generally (including those arising from the Russia-Ukraine conflict); market developments and government actions (including those arising from the evolving relationship between the UK and the EU); the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; reduce the value or yield of our investment portfolio and impact our asset and liability matching; the impact of changes in short or long-term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events (including the longer-term impact of COVID-19) on our business activities and results of operations; the transitional, litigation and physical risks associated with climate change; failure to understand and respond effectively to the risks associated with environmental, social or governance ('ESG') factors; our reliance on information and technology and third-party service providers for our operations and systems; the impact of the Group's risk mitigation strategies proving less effective than anticipated, including the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; poor investment performance of the Group's asset management business; the withdrawal by customer's at short notice of assets under the Group's management; failure to manage risks in operating securities lending of Group and third-party client assets; increased competition in the UK and in other countries where we have significant operations; regulatory approval of changes to the Group's internal model for calculation of regulatory capital under the UK's version of Solvency II rules; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs (DAC) and acquired value of in-force business (AVIF); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events and malicious acts (including cyber attack and theft, loss or misuse of customer data); risks associated with arrangements with third parties, including joint ventures; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in tax laws and interpretation of existing tax laws in jurisdictions where we conduct business; changes to International Financial Reporting Standards relevant to insurance companies and their interpretation (for example, IFRS 17); the inability to protect our intellectual property; the effect of undisclosed liabilities, separation issues and other risks associated with our business disposals; and other uncertainties, such as diversion of management attention and other resources, relating to future acquisitions, combinations or disposals within relevant industries; the policies, decisions and actions of government or regulatory authorities in the UK, the EU, the US, Canada or elsewhere, including changes to and the implementation of key legislation and regulation (for example, FCA Consumer Duty and Solvency II). Please see Aviva's most recent Annual Report for further details of risks, uncertainties and other factors relevant to the business and its securities.

Aviva undertakes no obligation to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this report are current only as of the date on which such statements are made. The climate metrics used in this document should be treated with special caution, as they are more uncertain than, for example, historical financial information and given the wider uncertainty around the evolution and impact of climate change. Climate metrics include estimates of historical emissions and historical climate change and forward-looking climate metrics (such as ambitions, targets, climate scenarios and climate projections and forecasts). Our understanding of climate change and its impact continue to evolve. Accordingly, both historical and forward-looking climate metrics are inherently uncertain and, therefore, less decision-useful than metrics based on historical financial statements.

Aviva plc is a company registered in England No. 2468686.

Registered office St Helen's 1 Undershaft London EC3P 3DQ

F.1 Public disclosure quantitative reporting templates

The following pages contain the Company's public disclosure templates, as listed below:

- S.02.01.02 Balance Sheet
- S.05.01.02 Premiums, claims and expenses by line of business
- S.12.01.02 Life and health SLT technical provisions
- S.22.01.21 Impact of long-term guarantees and transitional measures
- S.23.01.01 Own Funds
- S.25.02.21 Solvency Capital Requirement – For undertakings using the standard formula and partial internal model
- S.28.01.01 Minimum Capital Requirement – Only life or only non-life insurance or re-insurance activity

Annex I

S.02.01.02

Balance Sheet

| Amount in £'000s | | Solvency II Value |
|---|--------------|--------------------|
| Assets | | C0010 |
| Intangible assets | R0030 | — |
| Deferred tax assets | R0040 | 341,162 |
| Pension benefit surplus | R0050 | — |
| Property, plant & equipment held for own use | R0060 | 45,381 |
| Investments (other than assets held for index-linked and unit-linked contracts) | R0070 | 82,233,780 |
| Property (other than for own use) | R0080 | 1,276,827 |
| Holdings in related undertakings, including participations | R0090 | 27,746,451 |
| Equities | R0100 | 2,163,965 |
| - Equities - Listed | R0110 | 2,158,607 |
| - Equities - Unlisted | R0120 | 5,358 |
| Bonds | R0130 | 44,956,538 |
| - Government Bonds | R0140 | 15,715,204 |
| - Corporate Bonds | R0150 | 21,082,494 |
| - Structured Notes | R0160 | 62,540 |
| - Collateralised securities | R0170 | 8,096,300 |
| Collective Investments Undertakings | R0180 | 456,714 |
| Derivatives | R0190 | 3,103,603 |
| Deposits other than cash equivalents | R0200 | 2,529,682 |
| Other investments | R0210 | — |
| Assets held for index-linked and unit-linked contracts | R0220 | 138,745,283 |
| Loans & mortgages | R0230 | 17,261,197 |
| - Loans on policies | R0240 | 12,502 |
| - Loans & mortgages to individuals | R0250 | 353,226 |
| - Other loans & mortgages | R0260 | 16,895,469 |
| Reinsurance recoverables from: | R0270 | 64,718,983 |
| - Reinsurance recoverables - Non-life and health similar to non-life | R0280 | — |
| - Reinsurance recoverables - Non-life excluding health | R0290 | — |
| - Reinsurance recoverables - Health similar to non-life | R0300 | — |
| - Reinsurance recoverables - Life and health similar to life, excluding health and index-linked and unit-linked | R0310 | 18,838,802 |
| - Reinsurance recoverables - Health similar to life | R0320 | 330,540 |
| - Reinsurance recoverables - Life excluding health and index-linked and unit-linked | R0330 | 18,508,262 |
| - Reinsurance recoverables - Life index-linked and unit-linked | R0340 | 45,880,181 |
| Deposits to cedants | R0350 | — |
| Insurance & intermediaries receivables | R0360 | 342,405 |
| Reinsurance receivables | R0370 | 307,400 |
| Receivables (trade, not insurance) | R0380 | 1,204,708 |
| Own Shares (held directly) | R0390 | — |
| Amounts due in respect of own fund items or initial fund called up but not yet paid in | R0400 | — |
| Cash and cash equivalents | R0410 | 1,010,096 |
| Any other assets, not elsewhere shown | R0420 | 34,384 |
| Total assets | R0500 | 306,244,779 |
| Liabilities | | |
| Technical provisions - Non-life | R0510 | — |
| - Technical provisions - Non-life (excluding health) | R0520 | — |
| - TP calculated as a whole - Non-life (excluding health) | R0530 | — |
| - Best Estimate - Non-life (excluding health) | R0540 | — |
| - Risk margin - Non-life (excluding health) | R0550 | — |
| - Technical provisions - Health (similar to non-life) | R0560 | — |
| - TP calculated as a whole - Health (similar to non-life) | R0570 | — |
| - Best Estimate - Health (similar to non-life) | R0580 | — |
| - Risk margin - Health (similar to non-life) | R0590 | — |
| Technical provisions - Life (excluding index-linked and unit linked) | R0600 | 81,663,896 |
| - Technical provisions - Health (similar to life) | R0610 | 624,195 |
| - TP calculated as a whole - Health (similar to life) | R0620 | — |
| - Best Estimate - Health (similar to life) | R0630 | 624,193 |
| - Risk margin - Health (similar to life) | R0640 | 2 |
| - Technical provisions - Life (excluding health and index-linked and unit-linked) | R0650 | 81,039,702 |
| - TP calculated as a whole - Life (excl health, index-linked and unit-linked) | R0660 | — |
| - Best Estimate - Life (excl health, index-linked and unit-linked) | R0670 | 80,706,474 |
| - Risk margin - Life (excl health, index-linked and unit-linked) | R0680 | 333,228 |
| Technical provisions - Index-linked and unit-linked | R0690 | 140,799,359 |
| - TP calculated as a whole - Index-linked and unit-linked | R0700 | — |
| - Best Estimate - Index-linked and unit-linked | R0710 | 140,632,833 |
| - Risk margin - Index-linked and unit-linked | R0720 | 166,525 |
| Contingent liabilities | R0740 | — |
| Provisions other than technical provisions | R0750 | 150,299 |
| Pension benefit obligations | R0760 | 408 |
| Deposits from reinsurers | R0770 | 57,588,009 |
| Deferred tax liabilities | R0780 | 651,940 |
| Derivatives | R0790 | 7,806,642 |
| Debts owed to credit institutions | R0800 | 204,312 |
| Financial liabilities other than debts owed to credit institutions | R0810 | 2,794,950 |
| Insurance & intermediaries payables | R0820 | 2,042,279 |
| Reinsurance payables | R0830 | 102,053 |
| Payables (trade, not insurance) | R0840 | 760,071 |
| Subordinated liabilities | R0850 | — |
| - Subordinated liabilities not in BOF | R0860 | — |
| - Subordinated liabilities in BOF | R0870 | — |
| Any other liabilities, not elsewhere shown | R0880 | 5,485 |
| Total liabilities | R0900 | 294,569,703 |
| Excess of assets over liabilities | R1000 | 11,675,076 |

Annex I

S.05.01.02

Premiums, claims and expenses by line of business

Amounts in £'000s

| | | Line of Business for: life e insurance obligation | | | | | | Life reinsurance obligations | | Total |
|--|-------|---|-------------------------------------|---------------------------------------|----------------------|---|--|------------------------------|------------------|------------|
| | | Health [accepted non-proportional reinsurance] | Insurance with profit participation | Unit-linked or index-linked insurance | Other life insurance | Annuities stemming from non-life insurance contracts and relating to health insurance obligations | Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations | Health reinsurance | Life reinsurance | |
| | | C0210 | C0220 | C0230 | C0240 | C0250 | C0260 | C0270 | C0280 | C0300 |
| Premiums written | | | | | | | | | | |
| Gross - Direct Business | R1410 | 418,886 | 61,824 | 12,556,606 | 7,287,454 | 0 | 0 | 0 | 54,439 | 20,379,210 |
| Reinsurers' share | R1420 | 146,255 | 7,485 | 4,309,587 | 3,140,770 | 0 | 0 | 0 | (8) | 7,604,090 |
| Net | R1500 | 272,631 | 54,339 | 8,247,019 | 4,146,684 | 0 | 0 | 0 | 54,447 | 12,775,120 |
| Premiums earned | | | | | | | | | | |
| Gross - Direct Business | R1510 | 418,886 | 61,824 | 12,556,606 | 7,287,454 | 0 | 0 | 0 | 54,439 | 20,379,210 |
| Reinsurers' share | R1520 | 146,255 | 7,485 | 4,309,587 | 3,140,770 | 0 | 0 | 0 | (8) | 7,604,090 |
| Net | R1600 | 272,631 | 54,339 | 8,247,019 | 4,146,684 | 0 | 0 | 0 | 54,447 | 12,775,120 |
| Claims incurred | | | | | | | | | | |
| Gross - Direct Business | R1610 | 181,168 | 3,102,646 | 10,201,664 | 5,376,292 | 0 | 0 | 0 | 86,622 | 18,948,391 |
| Reinsurers' share | R1620 | 76,178 | 3,999 | 3,037,099 | 3,056,260 | 0 | 0 | 0 | 3,198 | 6,176,734 |
| Net | R1700 | 104,990 | 3,098,647 | 7,164,564 | 2,320,032 | 0 | 0 | 0 | 83,424 | 12,771,657 |
| Changes in other technical provisions | | | | | | | | | | |
| Gross - Direct Business | R1710 | 391,765 | 7,154,067 | 11,295,005 | 17,868,312 | 0 | 50,315 | 5,011 | 469,146 | 37,233,621 |
| Reinsurers' share | R1720 | 207,585 | (13,239) | 3,261,893 | 6,534,635 | 0 | 15,094 | 1,503 | 118,738 | 10,126,210 |
| Net | R1800 | 184,181 | 7,167,306 | 8,033,112 | 11,333,677 | 0 | 35,220 | 3,508 | 350,407 | 27,107,410 |
| Expenses incurred | R1900 | 180,356 | 160,196 | 658,131 | 1,500,014 | 0 | 0 | 0 | 398 | 2,499,095 |
| Other expenses | R2500 | | | | | | | | | (341,012) |
| Total expenses | R2600 | | | | | | | | | 2,158,083 |

Annex I

S.12.01.02

Life and Health SLT Technical Provisions

Amounts in £'000s

Technical provisions calculated as a whole

Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole

| | Insurance with profit participation | Unit-linked or index-linked insurance | | Other life insurance | | | Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance | Accepted reinsurance | Total (Life other than health insurance, incl. Unit-Linked) | |
|-------|-------------------------------------|--|--------------------------------------|--|--------------------------------------|-------|--|----------------------|---|-------|
| | | Contracts without options and guarantees | Contracts with options or guarantees | Contracts without options and guarantees | Contracts with options or guarantees | | | | | |
| | C0020 | C0030 | C0040 | C0050 | C0060 | C0070 | C0080 | C0090 | C0100 | C0150 |
| R0010 | 0 | 0 | | | 0 | | | 0 | 0 | 0 |
| R0020 | 0 | 0 | | | 0 | | | 0 | 0 | 0 |

Technical provisions calculated as a sum of BE and RM

Best Estimate

Gross Best Estimate

Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default

Best estimate minus recoverables from reinsurance and SPV - Total

Risk Margin

Amount of the transitional on Technical Provisions

Technical Provisions calculated as a whole

Best estimate

Risk margin

Technical provisions - Total

| | | | | | | | | | | |
|-------|------------|-------------|-------------|--------|------------|------------|---------|---------|-----------|-------------|
| R0030 | 26,888,268 | | 139,801,072 | 57,413 | | 53,248,829 | 112,308 | 76,399 | 1,752,503 | 221,936,792 |
| R0080 | 45,085 | | 45,649,071 | 17,224 | | 18,246,831 | 7,623 | 23,822 | 398,788 | 64,388,443 |
| R0090 | 26,843,182 | | 94,152,001 | 40,189 | | 35,001,998 | 104,685 | 52,577 | 1,353,715 | 157,548,349 |
| R0100 | 337,612 | 605,428 | | | 969,092 | | | 6,455 | 20,681 | 1,939,268 |
| R0110 | 0 | 0 | | | 0 | | | 0 | 0 | 0 |
| R0120 | (54,456) | | (1,783) | 0 | | -526,479 | 0 | (799) | (13,967) | (597,484) |
| R0130 | (82,980) | (438,902) | | | (892,126) | | | (6,455) | (19,051) | (1,439,515) |
| R0200 | 27,088,444 | 140,023,227 | | | 52,911,623 | | | 75,600 | 1,740,166 | 221,839,060 |

Technical provisions calculated as a whole

Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole

| | Health [accepted non-proportional reinsurance] | | Annuities stemming from non-life insurance contracts and relating to health insurance obligations | Health reinsurance | Total (Health similar to life insurance) | |
|-------|--|--------------------------------------|---|--------------------|--|-------|
| | Contracts without options and guarantees | Contracts with options or guarantees | | | | |
| | C0160 | C0170 | C0180 | C0190 | C0200 | C0210 |
| R0010 | 0 | | | 0 | 0 | 0 |
| R0020 | 0 | | | 0 | 0 | 0 |

Technical provisions calculated as a sum of BE and RM**Best Estimate****Gross Best Estimate**

Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default

Best estimate minus recoverables from reinsurance and SPV - Total

Risk Margin**Amount of the transitional on Technical Provisions**

Technical Provisions calculated as a whole

Best estimate

Risk margin

Technical provisions - Total

| | | | | | | |
|-------|----------|---------|-----|---|-------|----------|
| R0030 | | 620,742 | 922 | 0 | 2,528 | 624,193 |
| R0080 | | 329,505 | 277 | 0 | 758 | 330,540 |
| R0090 | | 291,238 | 646 | 0 | 1,770 | 293,653 |
| R0100 | 30,485 | | | 0 | 0 | 30,485 |
| R0110 | — | | | 0 | 0 | 0 |
| R0120 | | 0 | 0 | 0 | 0 | 0 |
| R0130 | (30,483) | | | 0 | 0 | (30,483) |
| R0200 | 621,666 | | | 0 | 2,528 | 624,195 |

Annex I

S.22.01.21

Impact of long-term guarantees and transitional measures

Amounts in £'000s

| | | Amount with LG measures and transitionals | Impact of transitional on technical provisions | Impact of transitional on interest rate | Impact of volatility adjustment set to zero | Impact of matching adjustment set to zero |
|---|--------|---|--|---|---|---|
| | | C0010 | C0030 | C0050 | C0070 | C0090 |
| Technical Provisions | R0010 | 222,463,255 | 2,067,482 | 0 | 332,801 | 3,600,865 |
| Basic Own Funds | R0020 | 10,067,701 | (1,565,258) | 0 | (2,645) | (3,512,935) |
| Eligible own funds to meet Solvency Capital Requirement | R0050 | 10,067,701 | (1,565,258) | 0 | (2,645) | (3,512,935) |
| Solvency Capital Requirement | R0090 | 5,619,072 | 502,225 | 0 | 133,538 | 3,232,166 |
| Eligible own funds to meet Minimum Capital Requirement | R01 00 | 9,726,539 | (1,565,258) | 0 | (2,645) | (3,512,935) |
| Minimum Capital Requirement | R0110 | 1,663,444 | 6,321 | 0 | 2,822 | 699,164 |

Annex I**S.23.01.01****Own Funds****Amounts in £'000s****Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35**

Ordinary share capital (gross of own shares)

Share premium account related to ordinary share capital

Initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual-type undertakings

Subordinated mutual member accounts

Surplus funds

Preference shares

Share premium account related to preference shares

Reconciliation reserve

Subordinated liabilities

An amount equal to the value of net deferred tax assets

Other own fund items approved by the supervisory authority as basic own funds not specified above

Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds

Deductions

Deductions for participations in financial and credit institutions

Total basic own funds after deductions**Ancillary own funds**

Unpaid and uncalled ordinary share capital callable on demand

Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual-type undertakings, callable on demand

Unpaid and uncalled preference shares callable on demand

A legally binding commitment to subscribe and pay for subordinated liabilities on demand

Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC

Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC

Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC

Supplementary members calls other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC

Other ancillary own funds

Total ancillary own funds - Solo**Available and eligible own funds**

Total available own funds to meet the SCR

Total available own funds to meet the MCR

Total eligible own funds to meet the SCR

Total eligible own funds to meet the MCR

SCR**MCR****Ratio of eligible own funds to SCR****Ratio of eligible own funds to MCR****Reconciliation Reserve**

Excess of assets over liabilities

Own shares (held directly and indirectly)

Foreseeable dividends, distributions and charges

Other basic own fund items

Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds

Reconciliation reserve**Expected profits**

Expected profits included in future premiums (EPIFP) - Life business

Expected profits included in future premiums (EPIFP) - Non-life business

Total expected profits included in future premiums (EPIFP)

| Total | Tier 1 Unrestricted | Tier 1 Restricted | Tier 2 | Tier 3 |
|-------|------------------------|----------------------|--------|--------|
| C0010 | C0020 | C0030 | C0040 | C0050 |

| | | | | | |
|-------|-----------|-----------|---|---|---------|
| R0010 | 2,732 | 2,732 | | 0 | |
| R0030 | 0 | 0 | | 0 | |
| R0040 | 0 | 0 | | 0 | |
| R0050 | 0 | 0 | 0 | 0 | 0 |
| R0070 | 4,451,310 | 4,451,310 | | | |
| R0090 | 0 | 0 | 0 | 0 | 0 |
| R0110 | 0 | 0 | 0 | 0 | 0 |
| R0130 | 5,272,497 | 5,272,497 | | | |
| R0140 | 0 | 0 | 0 | 0 | 0 |
| R0160 | 341,162 | | | | 341,162 |
| R0180 | 0 | 0 | 0 | 0 | 0 |

| | | | | | |
|-------|---|--|--|--|--|
| R0220 | 0 | | | | |
|-------|---|--|--|--|--|

| | | | | | |
|-------|------------|-----------|---|---|---------|
| R0230 | 0 | 0 | 0 | 0 | 0 |
| R0290 | 10,067,701 | 9,726,539 | 0 | 0 | 341,162 |

| | | | | | |
|-------|---|--|--|---|---|
| R0300 | 0 | | | 0 | |
| R0310 | 0 | | | 0 | |
| R0320 | 0 | | | 0 | 0 |
| R0330 | 0 | | | 0 | 0 |
| R0340 | 0 | | | 0 | |
| R0350 | 0 | | | 0 | 0 |
| R0360 | 0 | | | 0 | |
| R0370 | 0 | | | 0 | 0 |
| R0390 | 0 | | | 0 | 0 |
| R0400 | 0 | | | 0 | 0 |

| | | | | | |
|-------|------------|-----------|---|---|---------|
| R0500 | 10,067,701 | 9,726,539 | 0 | 0 | 341,162 |
| R0510 | 9,726,539 | 9,726,539 | 0 | 0 | |
| R0540 | 10,067,701 | 9,726,539 | 0 | 0 | 341,162 |
| R0550 | 9,726,539 | 9,726,539 | 0 | 0 | |
| R0580 | 5,619,072 | | | | |
| R0600 | 1,663,444 | | | | |
| R0620 | 1.79 | | | | |
| R0640 | 5.85 | | | | |

C0060

| | |
|-------|------------|
| R0700 | 11,675,076 |
| R0710 | 0 |
| R0720 | 0 |
| R0730 | 4,795,204 |
| R0740 | 1,607,375 |
| R0760 | 5,272,497 |

| | |
|-------|-----------|
| R0770 | 1,593,920 |
| R0780 | 0 |
| R0790 | 1,593,920 |

Annex I

S.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Amounts in £'000s

Linear formula component for non-life insurance and reinsurance obligations

MCRNL Result

R0010 C0010
0

| Net (of reinsurance/ SPV) best estimate and TP calculated as a whole | Net (of reinsurance) written premiums in the last 12 months |
|---|---|
|---|---|

Medical expense insurance and proportional reinsurance
Income protection insurance and proportional reinsurance
Workers' compensation insurance and proportional reinsurance
Motor vehicle liability insurance and proportional reinsurance
Other motor insurance and proportional reinsurance
Marine, aviation and transport insurance and proportional reinsurance
Fire and other damage to property insurance and proportional reinsurance
General liability insurance and proportional reinsurance
Credit and suretyship insurance and proportional reinsurance
Legal expenses insurance and proportional reinsurance
Assistance and proportional reinsurance
Miscellaneous financial loss insurance and proportional reinsurance
Non-proportional health reinsurance
Non-proportional casualty reinsurance
Non-proportional marine, aviation and transport reinsurance
Non-proportional property reinsurance

| | C0020 | C0030 |
|-------|-------|-------|
| R0020 | — | — |
| R0030 | — | — |
| R0040 | — | — |
| R0050 | — | — |
| R0060 | — | — |
| R0070 | — | — |
| R0080 | — | — |
| R0090 | — | — |
| R0100 | — | — |
| R0110 | — | — |
| R0120 | — | — |
| R0130 | — | — |
| R0140 | — | — |
| R0150 | — | — |
| R0160 | — | — |
| R0170 | — | — |

Linear formula component for life insurance and reinsurance obligations

MCRL Result

R0200 C0040
1,663,444

| Net (of reinsurance/ SPV) best estimate and TP calculated as a whole | Net (of reinsurance/ SPV) total capital at risk |
|---|---|
|---|---|

Obligations with profit participation - Guaranteed benefits
Obligations with profit participation - Future discretionary benefits
Index-linked and unit-linked insurance obligations
Other life (re)insurance and health (re)insurance obligations
Total capital at risk for all life (re)insurance obligations

| | C0050 | C0060 |
|-------|------------|-------------|
| R0210 | 16,581,181 | |
| R0220 | 10,784,289 | |
| R0230 | 94,752,652 | |
| R0240 | 35,126,395 | |
| R0250 | | 299,715,495 |

Overall MCR calculation

Linear MCR
SCR
MCR cap
MCR floor
Combined MCR
Absolute floor of the MCR

| | C0070 |
|-------|-----------|
| R0300 | 1,663,444 |
| R0310 | 5,619,072 |
| R0320 | 2,528,582 |
| R0330 | 1,404,768 |
| R0340 | 1,663,444 |
| R0350 | 3,186 |

Minimum Capital Requirement

| | C0070 |
|-------|-----------|
| R0400 | 1,663,444 |

F.2 Glossary of abbreviations and definitions

A glossary explaining the key terms used in this report is available on www.aviva.com/glossary.

F.3 Approvals and determinations

The following approvals, determinations and modifications apply for the Company at 31 December 2022:

F.3.1 Approvals

| Approval | Further Information | PRA Reference |
|--|--|---------------|
| Matching adjustment in the calculation of technical provisions | 4 November 2021: approval to apply a matching adjustment to the risk-free interest rate term structure (replaces previous 00001365 Approval) | 00003456 |
| Volatility adjustment in the calculation of technical provisions | | 4658257 |
| Transitional measures on technical provisions | 7 October 2022: permission to recalculate its transitional deduction to its technical provisions as at 30 June 2022 | 00005442 |
| | 10 December 2021: permission to recalculate its transitional deduction to its technical provisions as at 31 December 2021 | 00003602 |
| | 26 June 2020: approval to recalculate transitional deduction as at 1 January 2020 to reflect change in risk profile due to Mixer phase 4 | 00001373 |
| | 31 December 2019 Reset | 5418763 |
| | Friends Life Part VII transfer | 4657753 |
| | 31 December 2017 reset | 4850459 |
| Partial internal model in the calculation of the SCR | 5 December 2015: original approval | 2243186 |
| | 1 March 2016: amendments and extensions to the internal model | 2429705 |
| | 23 March 2017: amendments and extensions to the internal model | 4105641 |
| | 21 December 2017: amendments and extensions to the internal model | 4800491 |
| | 10 December 2018: amendments and extensions to the internal model | 5090845 |
| | 25 October 2019: amendments and extensions to the internal model | 5276051 |
| | 9 December 2020: amendments and extensions to the Internal model | 00002047 |
| | 15 December 2022: amendments and extensions to the internal model | 00005732 |
| Own funds items not on the list | 4 April 2018: approval to classify equity accounted subordinated liabilities as restricted Tier 1 capital | 4906578 |
| | 5 October 2020: approval to classify as restricted Tier 1 capital, up to £356,136,387, issued to Aviva Group Holdings Ltd | 00001758 |

The Company has none of the following: ancillary Own Funds, 'non-standard' items in Own Funds, use of transitional measure on the risk-free interest rate, application of the duration-based equity risk sub-module for standard formula operations or application of undertaking specific parameters for standard formula operations.

F.3.2 Determinations

The Company has a letter 20 July 2015 from the PRA on the application of the ring fenced fund restriction to the NWPSF and RIEESA as required by Article 80 of the Solvency II Delegated Acts.

F.3.3 Modifications

There are no modifications. No permission has been sought for non-disclosure of information in the SFCR.

F.4 Directors' statement

We acknowledge our responsibility for preparing the Solvency and Financial Condition Report of Aviva Life & Pensions UK Limited at 31 December 2022 in all material respects in accordance with the PRA Rules and the Solvency II Regulations.

The Board is satisfied that to the best of its knowledge and belief:

- a) throughout the financial year to 31 December 2022, the Company has complied in all material respects with the requirements of the PRA Rules and the Solvency II Regulations as applicable to the Company; and
- b) it is reasonable to believe that in respect of the period from 31 December 2022 to the date of the publication of the SFCR, the Company has continued so to comply and that it will continue so to comply in the future.

Iain Pearce
Director
27 March 2023

F.5 Audit opinion

Report of the external independent auditors to the Directors of Aviva Life & Pensions UK Limited ('the Company') pursuant to Rule 4.1 (2) of the External Audit Part of the PRA Rulebook applicable to Solvency II firms

Report on the Audit of the relevant elements of the Solvency and Financial Condition Report

Opinion

Except as stated below, we have audited the following documents prepared by the Company as at 31 December 2022:

- The 'Valuation for solvency purposes' and 'Capital Management' sections of the Solvency and Financial Condition Report of the Company as at 31 December 2022, (**the Narrative Disclosures subject to audit**); and
- Company templates S.02.01.02, S.12.01.02, S.22.01.21, S.23.01.01 and S.28.01.01 (**the Templates subject to audit**).

The Narrative Disclosures subject to audit and the Templates subject to audit are collectively referred to as the '**relevant elements of the Solvency and Financial Condition Report**'.

We are not required to audit, nor have we audited, and as a consequence do not express an opinion on the Other Information which comprises:

- Information contained within the relevant elements of the Solvency and Financial Condition Report set out above which is, or derives from the Solvency Capital Requirement, as identified in the Appendix to this report;
- The 'Summary', 'Business and performance', 'System of governance' and 'Risk profile' elements of the Solvency and Financial Condition Report;
- Company templates S.05.01.02 and S.25.02.21;
- Information calculated in accordance with the previous regime used in the calculation of the transitional measure on technical provisions, and as a consequence all information relating to the transitional measure on technical provisions as set out in the Appendix to this report;
- The written acknowledgement by management of their responsibilities, including for the preparation of the Solvency and Financial Condition Report (**the Responsibility Statement**).

To the extent the information subject to audit in the relevant elements of the Solvency and Financial Condition Report includes amounts that are totals, sub-totals or calculations derived from the Other Information, we have relied without verification on the Other Information.

In our opinion, the information subject to audit in the relevant elements of the Solvency and Financial Condition Report of the Company as at 31 December 2022 is prepared, in all material respects, in accordance with the financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based, as modified by relevant supervisory modifications, and as supplemented by supervisory approvals and determinations.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) including ISA (UK) 800 and ISA (UK) 805, and applicable law. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the Solvency and Financial Condition Report in the UK, including the FRC's Ethical Standard as applied to public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

Our evaluation of the directors' assessment of the Company's ability to continue to adopt the going concern basis of accounting included:

- Obtained the directors' Going Concern assessment and challenged the rationale for the downside scenarios adopted and material assumptions made using our knowledge of the Company's business performance, review of regulatory correspondence and obtaining further corroborating evidence;
- Considered management's assessment of the regulatory Solvency coverage and liquidity position in the forward-looking scenarios considered which have been driven from the Company's Own Risk and Solvency Assessment ("ORSA");
- Considered information obtained during the course of the audit and publicly available market information to identify any evidence that would contradict management's assessment of going concern; and
- Enquired and understood the actions taken by the directors to mitigate the impacts arising from economic uncertainty, including review of Board minutes and attendance at all Audit and Risk Committee meetings.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date on which the Solvency and Financial Condition Report is authorised for issue.

In auditing the Solvency and Financial Condition Report, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the Solvency and Financial Condition Report is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the Company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

Emphasis of Matter - Basis of Accounting

We draw attention to the 'Valuation for solvency purposes' and 'Capital Management' sections of the Solvency and Financial Condition Report, which describe the basis of accounting. The Solvency and Financial Condition Report is prepared in compliance with the financial reporting provisions of the PRA Rules and Solvency II regulations, and therefore in accordance with a special purpose financial reporting framework. The Solvency and Financial Condition Report is required to be published, and intended users include but are not limited to the Prudential Regulation Authority. As a result, the Solvency and Financial Condition Report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Other Information

The Directors are responsible for the Other Information.

Our opinion on the relevant elements of the Solvency and Financial Condition Report does not cover the Other Information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the Solvency and Financial Condition Report, our responsibility is to read the Other Information and, in doing so, consider whether the Other Information is materially inconsistent with the relevant elements of the Solvency and Financial Condition Report, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the relevant elements of the Solvency and Financial Condition Report or a material misstatement of the Other Information. If, based on the work we have performed, we conclude that there is a material misstatement of this Other Information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Directors for the Solvency and Financial Condition Report

The Directors are responsible for the preparation of the Solvency and Financial Condition Report in accordance with the financial reporting provisions of the PRA rules and Solvency II regulations which have been modified by the modifications, and supplemented by the approvals and determinations made by the PRA under section 138A of FSMA, the PRA Rules and Solvency II regulations on which they are based, as detailed in Appendix F3.

The Directors are also responsible for such internal control as they determine is necessary to enable the preparation of a Solvency and Financial Condition Report that is free from material misstatement, whether due to fraud or error.

Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report

It is our responsibility to form an independent opinion as to whether the information subject to audit in the relevant elements of the Solvency and Financial Condition Report is prepared, in all material respects, in accordance with financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based.

Our objectives are to obtain reasonable assurance about whether the relevant elements of the Solvency and Financial Condition Report are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decision making or the judgement of the users taken on the basis of the Solvency and Financial Condition Report.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the Company and industry, we identified that the principal risks of non-compliance with laws and regulations related to UK and EU principles, such as those governed by the Prudential Regulation Authority ("PRA") and the Financial Conduct Authority ("FCA"), and we considered the extent to which non-compliance might have a material effect on the Solvency and Financial Condition Report. We also considered those laws and regulations that have a direct impact on the Solvency and Financial Condition Report such as the Solvency II regulations (2015). We evaluated management's incentives and opportunities for fraudulent manipulation of the Solvency and Financial Condition Report (including the risk of override of controls), and determined that the principal risks were related to management bias in accounting estimates and judgemental areas of the Solvency and Financial Condition Report and the posting of inappropriate journals. Audit procedures performed included:

- Discussions with the Audit Committee, Internal Audit and senior management involved in the Risk and Compliance functions and the company's legal function, including consideration of known or suspected instances of non-compliance with laws and regulation and fraud;
- Evaluation and testing of the operating effectiveness of management's controls designed to prevent and detect irregularities;
- Assessment of matters reported on the Aviva Group's whistleblowing helpline and fraud register and the results of management's investigation of such matters;
- Reading key correspondence with the PRA and the FCA, including those in relation to compliance with laws and regulations;
- Reviewing relevant meeting minutes including those of the Board and With-Profits Committee and attendance at all Audit and Risk Committee meetings;
- Identifying and testing journal entries based on risk criteria;
- Designing audit procedures to incorporate unpredictability around the nature, timing or extent of our testing; and
- Reviewing the Company's register of litigation and claims, Internal Audit reports, and Compliance reports in so far as they related to non compliance with laws and regulations and fraud.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the Solvency and Financial Condition Report. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinion, has been prepared for the Board of Directors of the Company in accordance with External Audit rule 2.1 of the Solvency II firms Sector of the PRA Rulebook and for no other purpose. We do not, in providing this report, accept or assume responsibility for any other purpose or to any other party save where expressly agreed by our prior consent in writing.

Other Matter

The Company has authority to calculate its Solvency Capital Requirement using a [partial] internal model ("the Model") approved by the Prudential Regulation Authority in accordance with the Solvency II Regulations. In forming our opinion (and in accordance with PRA Rules), we are not required to audit the inputs to, design of, operating effectiveness of and outputs from the Model, or whether the Model is being applied in accordance with the Company's application or approval order.

Report on Other Legal and Regulatory Requirements

In accordance with Rule 4.1 (3) of the External Audit Part of the PRA Rulebook for Solvency II firms we are also required to consider whether the Other Information is materially inconsistent with our knowledge obtained in the audit of the Company's statutory financial statements. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

The engagement partner on the audit resulting in this independent auditors' report is Joanne Leeson.

PricewaterhouseCoopers LLP
Chartered Accountants
7 More London Riverside
London
SE1 2RT
27 March 2023

Appendix – relevant elements of the Solvency and Financial Condition Report that are not subject to audit

The relevant elements of the Solvency and Financial Condition Report that are not subject to audit comprise:

- The following elements of template S.02.01.02:
 - Row R0550: Technical provisions - non-life (excluding health) - risk margin
 - Row R0590: Technical provisions - health (similar to non-life) - risk margin
 - Row R0640: Technical provisions - health (similar to life) - risk margin
 - Row R0680: Technical provisions - life (excluding health and index-linked and unit-linked) - risk margin
 - Row R0720: Technical provisions - Index-linked and unit-linked - risk margin
- The following elements of template S.12.01.02
 - Row R0100: Technical provisions calculated as a sum of BE and RM - Risk margin
 - Rows R0110 to R0130 – Amount of transitional measure on technical provisions
- The following elements of template S.22.01.21
 - Column C0030 – Impact of transitional on technical provisions
 - Row R0010 – Technical provisions
 - Row R0090 – Solvency Capital Requirement
- The following elements of template S.23.01.01
 - Row R0580: SCR
 - Row R0740: Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
- The following elements of Company template S.28.01.01
 - Row R0310: SCR
- Elements of the Narrative Disclosures subject to audit identified as ‘unaudited’.